https://www.hirudotherapysociety.org/en/research/capecchi-2018-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/capecchi-2018-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/capecchi-2018-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/capecchi-2018-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scarlatescu-2017-anticoagulant-therapy-sepsis-importance-timing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scarlatescu-2017-anticoagulant-therapy-sepsis-importance-timing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scarlatescu-2017-anticoagulant-therapy-sepsis-importance-timing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scarlatescu-2017-anticoagulant-therapy-sepsis-importance-timing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tillman-2018-plasma-contact-factors-therapeutic-targets 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tillman-2018-plasma-contact-factors-therapeutic-targets 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tillman-2018-plasma-contact-factors-therapeutic-targets 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tillman-2018-plasma-contact-factors-therapeutic-targets 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/compton-2019-pifa-pluss-p4-assay-screening 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/compton-2019-pifa-pluss-p4-assay-screening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/compton-2019-pifa-pluss-p4-assay-screening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/compton-2019-pifa-pluss-p4-assay-screening 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/durda-2018-state-art-factor-xiii-laboratory 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/durda-2018-state-art-factor-xiii-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/durda-2018-state-art-factor-xiii-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/durda-2018-state-art-factor-xiii-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hanjaya-putra-2018-platelet-targeted-dual-pathway-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hanjaya-putra-2018-platelet-targeted-dual-pathway-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hanjaya-putra-2018-platelet-targeted-dual-pathway-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hanjaya-putra-2018-platelet-targeted-dual-pathway-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/spagnolello-2019-dabigatran-reversal-idarucizumab-emergency-lumbar 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/spagnolello-2019-dabigatran-reversal-idarucizumab-emergency-lumbar 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/spagnolello-2019-dabigatran-reversal-idarucizumab-emergency-lumbar 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/spagnolello-2019-dabigatran-reversal-idarucizumab-emergency-lumbar 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elkind-2018-atrial-cardiopathy-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elkind-2018-atrial-cardiopathy-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elkind-2018-atrial-cardiopathy-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elkind-2018-atrial-cardiopathy-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tubaro-2018-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tubaro-2018-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tubaro-2018-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tubaro-2018-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/badreldin-2019-direct-thrombin-inhibitor-utilization-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/badreldin-2019-direct-thrombin-inhibitor-utilization-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/badreldin-2019-direct-thrombin-inhibitor-utilization-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/badreldin-2019-direct-thrombin-inhibitor-utilization-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kornblith-2019-trauma-induced-coagulopathy-past-present 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kornblith-2019-trauma-induced-coagulopathy-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kornblith-2019-trauma-induced-coagulopathy-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kornblith-2019-trauma-induced-coagulopathy-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/handal-orefice-2019-pulmonary-embolism-management-critical-care 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/handal-orefice-2019-pulmonary-embolism-management-critical-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/handal-orefice-2019-pulmonary-embolism-management-critical-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/handal-orefice-2019-pulmonary-embolism-management-critical-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brennan-2019-acquired-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brennan-2019-acquired-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brennan-2019-acquired-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brennan-2019-acquired-platelet-function-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2019-diagnosis-sepsis-induced-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2019-diagnosis-sepsis-induced-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2019-diagnosis-sepsis-induced-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2019-diagnosis-sepsis-induced-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/singh-2020-real-world-outcomes-associated-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/singh-2020-real-world-outcomes-associated-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/singh-2020-real-world-outcomes-associated-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/singh-2020-real-world-outcomes-associated-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gibler-2019-management-severe-bleeding-treated-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gibler-2019-management-severe-bleeding-treated-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gibler-2019-management-severe-bleeding-treated-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gibler-2019-management-severe-bleeding-treated-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mtwesi-2019-stroke-prevention-atrial-fibrillation-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mtwesi-2019-stroke-prevention-atrial-fibrillation-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mtwesi-2019-stroke-prevention-atrial-fibrillation-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mtwesi-2019-stroke-prevention-atrial-fibrillation-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2019-diagnosis-management-sepsis-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2019-diagnosis-management-sepsis-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2019-diagnosis-management-sepsis-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2019-diagnosis-management-sepsis-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2019-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2019-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2019-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2019-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moia-2019-reversal-agents-oral-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moia-2019-reversal-agents-oral-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moia-2019-reversal-agents-oral-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moia-2019-reversal-agents-oral-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vranckx-2019-edoxaban-based-versus-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vranckx-2019-edoxaban-based-versus-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vranckx-2019-edoxaban-based-versus-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vranckx-2019-edoxaban-based-versus-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schafer-1985-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schafer-1985-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schafer-1985-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schafer-1985-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laterre-2019-should-continue-test-soluble-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laterre-2019-should-continue-test-soluble-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laterre-2019-should-continue-test-soluble-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laterre-2019-should-continue-test-soluble-thrombomodulin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/subramanian-2019-thromboelastography-guided-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/subramanian-2019-thromboelastography-guided-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/subramanian-2019-thromboelastography-guided-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/subramanian-2019-thromboelastography-guided-resuscitation-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/peacock-2019-idarucizumab-reversal-dabigatran-early-emergency 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/peacock-2019-idarucizumab-reversal-dabigatran-early-emergency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/peacock-2019-idarucizumab-reversal-dabigatran-early-emergency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/peacock-2019-idarucizumab-reversal-dabigatran-early-emergency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rios-2019-comparative-effectiveness-safety-pharmacological-non 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rios-2019-comparative-effectiveness-safety-pharmacological-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rios-2019-comparative-effectiveness-safety-pharmacological-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rios-2019-comparative-effectiveness-safety-pharmacological-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/damiana-2019-citrullination-fibrinogen-peptidylarginine-deiminase-2 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/damiana-2019-citrullination-fibrinogen-peptidylarginine-deiminase-2 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/damiana-2019-citrullination-fibrinogen-peptidylarginine-deiminase-2 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/damiana-2019-citrullination-fibrinogen-peptidylarginine-deiminase-2 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lopes-2019-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lopes-2019-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lopes-2019-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lopes-2019-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/briggs-2019-confidence-attitudes-toward-osteoarthritis-care 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/briggs-2019-confidence-attitudes-toward-osteoarthritis-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/briggs-2019-confidence-attitudes-toward-osteoarthritis-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/briggs-2019-confidence-attitudes-toward-osteoarthritis-care 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ding-2019-repeated-mechanical-thrombectomy-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ding-2019-repeated-mechanical-thrombectomy-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ding-2019-repeated-mechanical-thrombectomy-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ding-2019-repeated-mechanical-thrombectomy-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tucker-2020-protein-c-activator-ab002-rapidly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tucker-2020-protein-c-activator-ab002-rapidly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tucker-2020-protein-c-activator-ab002-rapidly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tucker-2020-protein-c-activator-ab002-rapidly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yasaka-2020-idarucizumab-emergency-reversal-anticoagulant-effects 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yasaka-2020-idarucizumab-emergency-reversal-anticoagulant-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yasaka-2020-idarucizumab-emergency-reversal-anticoagulant-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yasaka-2020-idarucizumab-emergency-reversal-anticoagulant-effects 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dingman-2020-argatroban-dosing-requirements-extracorporeal-life 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dingman-2020-argatroban-dosing-requirements-extracorporeal-life 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dingman-2020-argatroban-dosing-requirements-extracorporeal-life 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dingman-2020-argatroban-dosing-requirements-extracorporeal-life 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2020-medical-management-secondary-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2020-medical-management-secondary-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2020-medical-management-secondary-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2020-medical-management-secondary-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rowe-2020-anticoagulation-reversal-survey-ares 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rowe-2020-anticoagulation-reversal-survey-ares 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rowe-2020-anticoagulation-reversal-survey-ares 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rowe-2020-anticoagulation-reversal-survey-ares 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuno-2021-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuno-2021-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuno-2021-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuno-2021-antithrombotic-therapy-atrial-fibrillation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/juang-2020-coagulation-factor-xii-contributes-hemostasis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/juang-2020-coagulation-factor-xii-contributes-hemostasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/juang-2020-coagulation-factor-xii-contributes-hemostasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/juang-2020-coagulation-factor-xii-contributes-hemostasis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sherwood-2020-outcomes-cardiac-catheterization-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sherwood-2020-outcomes-cardiac-catheterization-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sherwood-2020-outcomes-cardiac-catheterization-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sherwood-2020-outcomes-cardiac-catheterization-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/luzak-2020-fibrinogen-glycation-presence-glucose-impair 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/luzak-2020-fibrinogen-glycation-presence-glucose-impair 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/luzak-2020-fibrinogen-glycation-presence-glucose-impair 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/luzak-2020-fibrinogen-glycation-presence-glucose-impair 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaido-2020-comparison-molecular-structure-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaido-2020-comparison-molecular-structure-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaido-2020-comparison-molecular-structure-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaido-2020-comparison-molecular-structure-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rivera-caravaca-2020-treatment-strategies-atrial-fibrillation-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rivera-caravaca-2020-treatment-strategies-atrial-fibrillation-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rivera-caravaca-2020-treatment-strategies-atrial-fibrillation-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rivera-caravaca-2020-treatment-strategies-atrial-fibrillation-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hohnloser-2020-anticoagulation-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hohnloser-2020-anticoagulation-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hohnloser-2020-anticoagulation-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hohnloser-2020-anticoagulation-stroke-prevention-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/darius-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/darius-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/darius-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/darius-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weisblat-1988-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weisblat-1988-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weisblat-1988-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weisblat-1988-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2021-increased-intracranial-hemorrhage-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2021-increased-intracranial-hemorrhage-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2021-increased-intracranial-hemorrhage-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2021-increased-intracranial-hemorrhage-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/spasiano-2020-early-thromboelastography-acute-traumatic-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/spasiano-2020-early-thromboelastography-acute-traumatic-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/spasiano-2020-early-thromboelastography-acute-traumatic-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/spasiano-2020-early-thromboelastography-acute-traumatic-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bugaev-2020-thromboelastography-rotational-thromboelastometry-bleeding-coagulopa 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bugaev-2020-thromboelastography-rotational-thromboelastometry-bleeding-coagulopa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bugaev-2020-thromboelastography-rotational-thromboelastometry-bleeding-coagulopa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bugaev-2020-thromboelastography-rotational-thromboelastometry-bleeding-coagulopa 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shankaranarayanan-2020-anticoagulation-strategies-filter-life-covid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shankaranarayanan-2020-anticoagulation-strategies-filter-life-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shankaranarayanan-2020-anticoagulation-strategies-filter-life-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shankaranarayanan-2020-anticoagulation-strategies-filter-life-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baksaas-aasen-2020-viscoelastic-haemostatic-assay-augmented-protocols 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baksaas-aasen-2020-viscoelastic-haemostatic-assay-augmented-protocols 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baksaas-aasen-2020-viscoelastic-haemostatic-assay-augmented-protocols 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baksaas-aasen-2020-viscoelastic-haemostatic-assay-augmented-protocols 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meneses-2020-massive-transfusion-protocol-adult-trauma 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meneses-2020-massive-transfusion-protocol-adult-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meneses-2020-massive-transfusion-protocol-adult-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meneses-2020-massive-transfusion-protocol-adult-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nowak-2020-mechanical-thrombectomy-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nowak-2020-mechanical-thrombectomy-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nowak-2020-mechanical-thrombectomy-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nowak-2020-mechanical-thrombectomy-acute-ischaemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/haastrup-2020-real-world-experience-reversal-dabigatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/haastrup-2020-real-world-experience-reversal-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/haastrup-2020-real-world-experience-reversal-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/haastrup-2020-real-world-experience-reversal-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wada-2020-covid-19-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wada-2020-covid-19-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wada-2020-covid-19-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wada-2020-covid-19-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/muraca-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/muraca-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/muraca-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/muraca-2020-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/litvinov-2021-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/litvinov-2021-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/litvinov-2021-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/litvinov-2021-fibrinogen-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gendron-2020-dabigatran-level-reversal-can-predict 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gendron-2020-dabigatran-level-reversal-can-predict 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gendron-2020-dabigatran-level-reversal-can-predict 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gendron-2020-dabigatran-level-reversal-can-predict 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mori-2021-diagnosis-treatment-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mori-2021-diagnosis-treatment-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mori-2021-diagnosis-treatment-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mori-2021-diagnosis-treatment-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/adelborg-2021-disseminated-intravascular-coagulation-epidemiology-biomarkers 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/adelborg-2021-disseminated-intravascular-coagulation-epidemiology-biomarkers 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/adelborg-2021-disseminated-intravascular-coagulation-epidemiology-biomarkers 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/adelborg-2021-disseminated-intravascular-coagulation-epidemiology-biomarkers 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mendelson-2021-diagnosis-management-transient-ischemic-attack 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mendelson-2021-diagnosis-management-transient-ischemic-attack 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mendelson-2021-diagnosis-management-transient-ischemic-attack 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mendelson-2021-diagnosis-management-transient-ischemic-attack 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brill-2021-teg-rotem-damage-control-resuscitation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brill-2021-teg-rotem-damage-control-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brill-2021-teg-rotem-damage-control-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brill-2021-teg-rotem-damage-control-resuscitation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kawata-2021-splanchnic-vein-thrombosis-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kawata-2021-splanchnic-vein-thrombosis-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kawata-2021-splanchnic-vein-thrombosis-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kawata-2021-splanchnic-vein-thrombosis-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ten-cate-2021-management-disseminated-intravascular-coagulation-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ten-cate-2021-management-disseminated-intravascular-coagulation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ten-cate-2021-management-disseminated-intravascular-coagulation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ten-cate-2021-management-disseminated-intravascular-coagulation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brazhnik-2021-risk-stratification-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brazhnik-2021-risk-stratification-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brazhnik-2021-risk-stratification-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brazhnik-2021-risk-stratification-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ropper-2021-cerebral-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ropper-2021-cerebral-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ropper-2021-cerebral-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ropper-2021-cerebral-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/galante-2021-portal-vein-thrombosis-overview-current 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/galante-2021-portal-vein-thrombosis-overview-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/galante-2021-portal-vein-thrombosis-overview-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/galante-2021-portal-vein-thrombosis-overview-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/giustozzi-2021-coagulopathy-sepsis-pathophysiology-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/giustozzi-2021-coagulopathy-sepsis-pathophysiology-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/giustozzi-2021-coagulopathy-sepsis-pathophysiology-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/giustozzi-2021-coagulopathy-sepsis-pathophysiology-clinical-manifestations 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arora-2021-p-selectin-expression-assay-repeatedly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arora-2021-p-selectin-expression-assay-repeatedly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arora-2021-p-selectin-expression-assay-repeatedly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arora-2021-p-selectin-expression-assay-repeatedly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/devreese-2021-covid-19-related-laboratory-coagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/devreese-2021-covid-19-related-laboratory-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/devreese-2021-covid-19-related-laboratory-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/devreese-2021-covid-19-related-laboratory-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ham-2021-rechargeable-anti-thrombotic-coating-blood 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ham-2021-rechargeable-anti-thrombotic-coating-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ham-2021-rechargeable-anti-thrombotic-coating-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ham-2021-rechargeable-anti-thrombotic-coating-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zaaqoq-2021-heparin-induced-thrombocytopenia-extra-corporeal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zaaqoq-2021-heparin-induced-thrombocytopenia-extra-corporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zaaqoq-2021-heparin-induced-thrombocytopenia-extra-corporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zaaqoq-2021-heparin-induced-thrombocytopenia-extra-corporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rodrigues-2021-pediatric-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rodrigues-2021-pediatric-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rodrigues-2021-pediatric-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rodrigues-2021-pediatric-cerebral-sinus-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nobleza-2021-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nobleza-2021-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nobleza-2021-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nobleza-2021-intracerebral-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/raina-2021-anticoagulation-acute-kidney-injury-undergoing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/raina-2021-anticoagulation-acute-kidney-injury-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/raina-2021-anticoagulation-acute-kidney-injury-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/raina-2021-anticoagulation-acute-kidney-injury-undergoing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/debette-2021-eso-guideline-management-extracranial-intracranial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/debette-2021-eso-guideline-management-extracranial-intracranial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/debette-2021-eso-guideline-management-extracranial-intracranial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/debette-2021-eso-guideline-management-extracranial-intracranial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stone-2021-retrospective-effectiveness-reduced-dose-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stone-2021-retrospective-effectiveness-reduced-dose-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stone-2021-retrospective-effectiveness-reduced-dose-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stone-2021-retrospective-effectiveness-reduced-dose-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xu-2021-endovascular-therapy-versus-anticoagulation-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xu-2021-endovascular-therapy-versus-anticoagulation-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xu-2021-endovascular-therapy-versus-anticoagulation-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xu-2021-endovascular-therapy-versus-anticoagulation-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/medved-2021-story-fibrin-ogen-x3b1-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/medved-2021-story-fibrin-ogen-x3b1-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/medved-2021-story-fibrin-ogen-x3b1-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/medved-2021-story-fibrin-ogen-x3b1-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weller-2022-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weller-2022-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weller-2022-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weller-2022-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/best-2022-optimal-timing-anticoagulation-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/best-2022-optimal-timing-anticoagulation-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/best-2022-optimal-timing-anticoagulation-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/best-2022-optimal-timing-anticoagulation-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/khayat-2022-impact-fibrinogen-infusion-thrombin-generation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/khayat-2022-impact-fibrinogen-infusion-thrombin-generation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/khayat-2022-impact-fibrinogen-infusion-thrombin-generation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/khayat-2022-impact-fibrinogen-infusion-thrombin-generation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-franchis-2021-baveno-vii-renewing-consensus-portal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-franchis-2021-baveno-vii-renewing-consensus-portal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-franchis-2021-baveno-vii-renewing-consensus-portal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-franchis-2021-baveno-vii-renewing-consensus-portal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/do-2022-sensitivity-activated-partial-thromboplastin-time 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/do-2022-sensitivity-activated-partial-thromboplastin-time 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/do-2022-sensitivity-activated-partial-thromboplastin-time 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/do-2022-sensitivity-activated-partial-thromboplastin-time 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cabalar-2022-how-does-antiplatelet-anticoagulants-affect 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cabalar-2022-how-does-antiplatelet-anticoagulants-affect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cabalar-2022-how-does-antiplatelet-anticoagulants-affect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cabalar-2022-how-does-antiplatelet-anticoagulants-affect 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fruchtman-1986-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fruchtman-1986-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fruchtman-1986-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fruchtman-1986-disseminated-intravascular-coagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/christensen-2022-cerebral-venous-sinus-thrombosis-preterm 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/christensen-2022-cerebral-venous-sinus-thrombosis-preterm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/christensen-2022-cerebral-venous-sinus-thrombosis-preterm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/christensen-2022-cerebral-venous-sinus-thrombosis-preterm 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/szanto-2022-platelet-function-testing-current-practice 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/szanto-2022-platelet-function-testing-current-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/szanto-2022-platelet-function-testing-current-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/szanto-2022-platelet-function-testing-current-practice 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shukla-2021-portal-vein-thrombosis-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shukla-2021-portal-vein-thrombosis-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shukla-2021-portal-vein-thrombosis-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shukla-2021-portal-vein-thrombosis-cirrhosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/favaloro-2022-harmonizing-factor-assay-related-testing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/favaloro-2022-harmonizing-factor-assay-related-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/favaloro-2022-harmonizing-factor-assay-related-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/favaloro-2022-harmonizing-factor-assay-related-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2022-disseminated-intravascular-coagulation-past-present 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2022-disseminated-intravascular-coagulation-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2022-disseminated-intravascular-coagulation-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2022-disseminated-intravascular-coagulation-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/larsen-2022-platelet-function-testing-update-future 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/larsen-2022-platelet-function-testing-update-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/larsen-2022-platelet-function-testing-update-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/larsen-2022-platelet-function-testing-update-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qi-2023-effect-anticoagulant-versus-non-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qi-2023-effect-anticoagulant-versus-non-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qi-2023-effect-anticoagulant-versus-non-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qi-2023-effect-anticoagulant-versus-non-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kiladjian-2023-myeloproliferative-neoplasms-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kiladjian-2023-myeloproliferative-neoplasms-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kiladjian-2023-myeloproliferative-neoplasms-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kiladjian-2023-myeloproliferative-neoplasms-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nelson-2023-towards-understanding-effect-fibrinogen-interactions 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nelson-2023-towards-understanding-effect-fibrinogen-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nelson-2023-towards-understanding-effect-fibrinogen-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nelson-2023-towards-understanding-effect-fibrinogen-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elkrief-2023-management-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elkrief-2023-management-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elkrief-2023-management-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elkrief-2023-management-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-den-helm-2023-platelet-function-neonates-children 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-den-helm-2023-platelet-function-neonates-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-den-helm-2023-platelet-function-neonates-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-den-helm-2023-platelet-function-neonates-children 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tucker-2024-optimization-laboratory-diagnosis-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tucker-2024-optimization-laboratory-diagnosis-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tucker-2024-optimization-laboratory-diagnosis-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tucker-2024-optimization-laboratory-diagnosis-heparin-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sarkar-2023-assessment-platelet-function-automated-light 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sarkar-2023-assessment-platelet-function-automated-light 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sarkar-2023-assessment-platelet-function-automated-light 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sarkar-2023-assessment-platelet-function-automated-light 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chan-2023-assessment-platelet-function-high-throughput 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chan-2023-assessment-platelet-function-high-throughput 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chan-2023-assessment-platelet-function-high-throughput 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chan-2023-assessment-platelet-function-high-throughput 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2023-pathophysiology-diagnosis-management-sepsis-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2023-pathophysiology-diagnosis-management-sepsis-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2023-pathophysiology-diagnosis-management-sepsis-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2023-pathophysiology-diagnosis-management-sepsis-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2023-effects-coagulation-factors-risk-endometriosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2023-effects-coagulation-factors-risk-endometriosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2023-effects-coagulation-factors-risk-endometriosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2023-effects-coagulation-factors-risk-endometriosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dai-2023-effectiveness-safety-dabigatran-reversal-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dai-2023-effectiveness-safety-dabigatran-reversal-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dai-2023-effectiveness-safety-dabigatran-reversal-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dai-2023-effectiveness-safety-dabigatran-reversal-idarucizumab 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cai-2023-sepsis-induced-coagulopathy-subphenotype-identification 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cai-2023-sepsis-induced-coagulopathy-subphenotype-identification 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cai-2023-sepsis-induced-coagulopathy-subphenotype-identification 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cai-2023-sepsis-induced-coagulopathy-subphenotype-identification 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/refaai-2023-retrospective-real-world-utilization-4 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/refaai-2023-retrospective-real-world-utilization-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/refaai-2023-retrospective-real-world-utilization-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/refaai-2023-retrospective-real-world-utilization-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nam-2023-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nam-2023-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nam-2023-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nam-2023-sepsis-induced-coagulopathy-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ramazanoglu-2023-warfarin-vs-doac-comparative-outcomes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ramazanoglu-2023-warfarin-vs-doac-comparative-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ramazanoglu-2023-warfarin-vs-doac-comparative-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ramazanoglu-2023-warfarin-vs-doac-comparative-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuklik-2023-outcome-intracranial-hemorrhage-under-dabigatran 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuklik-2023-outcome-intracranial-hemorrhage-under-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuklik-2023-outcome-intracranial-hemorrhage-under-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuklik-2023-outcome-intracranial-hemorrhage-under-dabigatran 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2023-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2023-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2023-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2023-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/umemura-2023-anticoagulant-therapies-against-sepsis-induced 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/umemura-2023-anticoagulant-therapies-against-sepsis-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/umemura-2023-anticoagulant-therapies-against-sepsis-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/umemura-2023-anticoagulant-therapies-against-sepsis-induced 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2023-mechanisms-management-coagulopathy-trauma-sepsis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2023-mechanisms-management-coagulopathy-trauma-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2023-mechanisms-management-coagulopathy-trauma-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2023-mechanisms-management-coagulopathy-trauma-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bick-1978-disseminated-intravascular-coagulation-related-syndromes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bick-1978-disseminated-intravascular-coagulation-related-syndromes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bick-1978-disseminated-intravascular-coagulation-related-syndromes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bick-1978-disseminated-intravascular-coagulation-related-syndromes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/franchini-2024-how-manage-high-d-dimer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/franchini-2024-how-manage-high-d-dimer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/franchini-2024-how-manage-high-d-dimer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/franchini-2024-how-manage-high-d-dimer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pipe-2023-global-comparative-field-evaluate-factor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pipe-2023-global-comparative-field-evaluate-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pipe-2023-global-comparative-field-evaluate-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pipe-2023-global-comparative-field-evaluate-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/liu-2024-narrative-acute-pancreatitis-induced-splanchnic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/liu-2024-narrative-acute-pancreatitis-induced-splanchnic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/liu-2024-narrative-acute-pancreatitis-induced-splanchnic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/liu-2024-narrative-acute-pancreatitis-induced-splanchnic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barouqa-2024-performance-evaluation-heparin-induced-platelet 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barouqa-2024-performance-evaluation-heparin-induced-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barouqa-2024-performance-evaluation-heparin-induced-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barouqa-2024-performance-evaluation-heparin-induced-platelet 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mcintyre-2023-direct-oral-anticoagulants-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mcintyre-2023-direct-oral-anticoagulants-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mcintyre-2023-direct-oral-anticoagulants-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mcintyre-2023-direct-oral-anticoagulants-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carll-2023-viscoelastic-testing-methods 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carll-2023-viscoelastic-testing-methods 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carll-2023-viscoelastic-testing-methods 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carll-2023-viscoelastic-testing-methods 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2024-mechanical-thrombectomy-anticoagulated-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2024-mechanical-thrombectomy-anticoagulated-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2024-mechanical-thrombectomy-anticoagulated-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2024-mechanical-thrombectomy-anticoagulated-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/platton-2023-diagnosis-laboratory-monitoring-acquired-hemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/platton-2023-diagnosis-laboratory-monitoring-acquired-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/platton-2023-diagnosis-laboratory-monitoring-acquired-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/platton-2023-diagnosis-laboratory-monitoring-acquired-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kankaria-2023-platelet-function-testing-clinical-outcomes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kankaria-2023-platelet-function-testing-clinical-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kankaria-2023-platelet-function-testing-clinical-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kankaria-2023-platelet-function-testing-clinical-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/landi-2024-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/landi-2024-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/landi-2024-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/landi-2024-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cohen-2024-cancer-associated-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cohen-2024-cancer-associated-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cohen-2024-cancer-associated-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cohen-2024-cancer-associated-splanchnic-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hussein-2024-immune-stealth-vp28-conjugated-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hussein-2024-immune-stealth-vp28-conjugated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hussein-2024-immune-stealth-vp28-conjugated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hussein-2024-immune-stealth-vp28-conjugated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/williams-2024-sepsis-induced-coagulopathy-comprehensive-narrative 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/williams-2024-sepsis-induced-coagulopathy-comprehensive-narrative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/williams-2024-sepsis-induced-coagulopathy-comprehensive-narrative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/williams-2024-sepsis-induced-coagulopathy-comprehensive-narrative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-2024-reversal-resumption-anticoagulants-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-2024-reversal-resumption-anticoagulants-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-2024-reversal-resumption-anticoagulants-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-2024-reversal-resumption-anticoagulants-anticoagulant-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/housley-2024-cavernous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/housley-2024-cavernous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/housley-2024-cavernous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/housley-2024-cavernous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nguyen-2024-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nguyen-2024-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nguyen-2024-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nguyen-2024-cerebral-venous-sinus-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arshad-2024-tackling-deadly-global-phenomenon-sepsis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arshad-2024-tackling-deadly-global-phenomenon-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arshad-2024-tackling-deadly-global-phenomenon-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arshad-2024-tackling-deadly-global-phenomenon-sepsis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vasquez-2024-contemporary-outcomes-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vasquez-2024-contemporary-outcomes-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vasquez-2024-contemporary-outcomes-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vasquez-2024-contemporary-outcomes-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/attah-2024-anti-pf4-elisa-negative-sra 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/attah-2024-anti-pf4-elisa-negative-sra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/attah-2024-anti-pf4-elisa-negative-sra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/attah-2024-anti-pf4-elisa-negative-sra 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frol-2024-idarucizumab-dabigatran-treated-acute-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frol-2024-idarucizumab-dabigatran-treated-acute-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frol-2024-idarucizumab-dabigatran-treated-acute-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frol-2024-idarucizumab-dabigatran-treated-acute-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valgimigli-2024-demystifying-contemporary-12-month-dual 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valgimigli-2024-demystifying-contemporary-12-month-dual 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valgimigli-2024-demystifying-contemporary-12-month-dual 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valgimigli-2024-demystifying-contemporary-12-month-dual 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sainbayar-2024-dual-vs-triple-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sainbayar-2024-dual-vs-triple-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sainbayar-2024-dual-vs-triple-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sainbayar-2024-dual-vs-triple-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lindsay-2024-correction-trauma-induced-coagulopathy-goal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lindsay-2024-correction-trauma-induced-coagulopathy-goal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lindsay-2024-correction-trauma-induced-coagulopathy-goal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lindsay-2024-correction-trauma-induced-coagulopathy-goal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dix-2024-changing-face-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dix-2024-changing-face-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dix-2024-changing-face-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dix-2024-changing-face-cerebral-venous-sinus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhao-2024-integrated-microfluidic-multiple-electrode-aggregometry 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhao-2024-integrated-microfluidic-multiple-electrode-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhao-2024-integrated-microfluidic-multiple-electrode-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhao-2024-integrated-microfluidic-multiple-electrode-aggregometry 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iba-2024-sepsis-induced-coagulopathy-sic-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iba-2024-sepsis-induced-coagulopathy-sic-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iba-2024-sepsis-induced-coagulopathy-sic-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iba-2024-sepsis-induced-coagulopathy-sic-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/johnson-bishop-2024-cerebral-sinus-venous-thrombosis-pediatric 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/johnson-bishop-2024-cerebral-sinus-venous-thrombosis-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/johnson-bishop-2024-cerebral-sinus-venous-thrombosis-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/johnson-bishop-2024-cerebral-sinus-venous-thrombosis-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jazayeri-2024-reevaluating-heparin-mechanical-thrombectomy-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jazayeri-2024-reevaluating-heparin-mechanical-thrombectomy-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jazayeri-2024-reevaluating-heparin-mechanical-thrombectomy-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jazayeri-2024-reevaluating-heparin-mechanical-thrombectomy-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/miraclin-t-2024-cerebral-venous-sinus-thrombosis-current 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/miraclin-t-2024-cerebral-venous-sinus-thrombosis-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/miraclin-t-2024-cerebral-venous-sinus-thrombosis-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/miraclin-t-2024-cerebral-venous-sinus-thrombosis-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kan-2024-evolution-advances-endovascular-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kan-2024-evolution-advances-endovascular-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kan-2024-evolution-advances-endovascular-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kan-2024-evolution-advances-endovascular-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnum-2024-splanchnic-vein-thrombosis-management-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnum-2024-splanchnic-vein-thrombosis-management-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnum-2024-splanchnic-vein-thrombosis-management-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnum-2024-splanchnic-vein-thrombosis-management-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/stepanian-2024-light-transmission-aggregometry-platelet-function 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/stepanian-2024-light-transmission-aggregometry-platelet-function 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/stepanian-2024-light-transmission-aggregometry-platelet-function 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/stepanian-2024-light-transmission-aggregometry-platelet-function 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/araiza-garaygordobil-2024-randomized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/araiza-garaygordobil-2024-randomized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/araiza-garaygordobil-2024-randomized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/araiza-garaygordobil-2024-randomized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yamakawa-2024-clinical-practice-guidelines-management-disseminated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yamakawa-2024-clinical-practice-guidelines-management-disseminated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yamakawa-2024-clinical-practice-guidelines-management-disseminated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yamakawa-2024-clinical-practice-guidelines-management-disseminated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kristoffersen-2024-intravenous-thrombolysis-xa0-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kristoffersen-2024-intravenous-thrombolysis-xa0-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kristoffersen-2024-intravenous-thrombolysis-xa0-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kristoffersen-2024-intravenous-thrombolysis-xa0-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/korompoki-2024-prevention-stroke-intracerebral-haemorrhage-survivors 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/korompoki-2024-prevention-stroke-intracerebral-haemorrhage-survivors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/korompoki-2024-prevention-stroke-intracerebral-haemorrhage-survivors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/korompoki-2024-prevention-stroke-intracerebral-haemorrhage-survivors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scott-2024-management-splanchnic-vein-thrombosis-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scott-2024-management-splanchnic-vein-thrombosis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scott-2024-management-splanchnic-vein-thrombosis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scott-2024-management-splanchnic-vein-thrombosis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bendapudi-2025-how-i-diagnose-treat-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bendapudi-2025-how-i-diagnose-treat-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bendapudi-2025-how-i-diagnose-treat-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bendapudi-2025-how-i-diagnose-treat-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/curtiaud-2025-biomarkers-sepsis-induced-coagulopathy-diagnostic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/curtiaud-2025-biomarkers-sepsis-induced-coagulopathy-diagnostic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/curtiaud-2025-biomarkers-sepsis-induced-coagulopathy-diagnostic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/curtiaud-2025-biomarkers-sepsis-induced-coagulopathy-diagnostic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/panyukov-2024-scaling-theory-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/panyukov-2024-scaling-theory-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/panyukov-2024-scaling-theory-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/panyukov-2024-scaling-theory-fibrin-polymerization 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/maire-2025-splanchnic-vein-thrombosis-pancreatitis-outcome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/maire-2025-splanchnic-vein-thrombosis-pancreatitis-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/maire-2025-splanchnic-vein-thrombosis-pancreatitis-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/maire-2025-splanchnic-vein-thrombosis-pancreatitis-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cardi-2025-splanchnic-vein-thrombosis-2003-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cardi-2025-splanchnic-vein-thrombosis-2003-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cardi-2025-splanchnic-vein-thrombosis-2003-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cardi-2025-splanchnic-vein-thrombosis-2003-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/passey-2025-comparison-safety-efficacy-ultrasound-accelerated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/passey-2025-comparison-safety-efficacy-ultrasound-accelerated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/passey-2025-comparison-safety-efficacy-ultrasound-accelerated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/passey-2025-comparison-safety-efficacy-ultrasound-accelerated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/umemura-2025-mortality-diagnosis-etiology-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/umemura-2025-mortality-diagnosis-etiology-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/umemura-2025-mortality-diagnosis-etiology-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/umemura-2025-mortality-diagnosis-etiology-disseminated-intravascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mohsenian-2025-genetic-spectrum-rare-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mohsenian-2025-genetic-spectrum-rare-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mohsenian-2025-genetic-spectrum-rare-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mohsenian-2025-genetic-spectrum-rare-bleeding-disorders 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abdeldayem-2025-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abdeldayem-2025-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abdeldayem-2025-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abdeldayem-2025-antithrombotic-therapy-acute-coronary-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dehbi-2025-collaboration-optimal-timing-anticoagulation-ischaemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dehbi-2025-collaboration-optimal-timing-anticoagulation-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dehbi-2025-collaboration-optimal-timing-anticoagulation-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dehbi-2025-collaboration-optimal-timing-anticoagulation-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/d-anna-2025-oral-anticoagulation-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/d-anna-2025-oral-anticoagulation-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/d-anna-2025-oral-anticoagulation-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/d-anna-2025-oral-anticoagulation-versus-no-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kaisaier-2025-left-atrial-appendage-closure-vs 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kaisaier-2025-left-atrial-appendage-closure-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kaisaier-2025-left-atrial-appendage-closure-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kaisaier-2025-left-atrial-appendage-closure-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/guo-2025-vascular-endothelial-cell-targeted-mrna 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/guo-2025-vascular-endothelial-cell-targeted-mrna 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/guo-2025-vascular-endothelial-cell-targeted-mrna 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/guo-2025-vascular-endothelial-cell-targeted-mrna 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/landmesser-2025-catheter-based-left-atrial-appendage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/landmesser-2025-catheter-based-left-atrial-appendage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/landmesser-2025-catheter-based-left-atrial-appendage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/landmesser-2025-catheter-based-left-atrial-appendage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/longacre-2025-teg-rotem-technology-clinical-applications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/longacre-2025-teg-rotem-technology-clinical-applications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/longacre-2025-teg-rotem-technology-clinical-applications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/longacre-2025-teg-rotem-technology-clinical-applications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anon-2025-easl-clinical-practice-guidelines-vascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anon-2025-easl-clinical-practice-guidelines-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anon-2025-easl-clinical-practice-guidelines-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anon-2025-easl-clinical-practice-guidelines-vascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anon-2025-uk-wide-2265-receiving-reversal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anon-2025-uk-wide-2265-receiving-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anon-2025-uk-wide-2265-receiving-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anon-2025-uk-wide-2265-receiving-reversal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/savonitto-2026-non-st-segment-elevation-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/savonitto-2026-non-st-segment-elevation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/savonitto-2026-non-st-segment-elevation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/savonitto-2026-non-st-segment-elevation-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tantry-2026-individualized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tantry-2026-individualized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tantry-2026-individualized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tantry-2026-individualized-antithrombotic-therapy-acute-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jeong-2026-notch-signaling-leech-neurogenesis-expression 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jeong-2026-notch-signaling-leech-neurogenesis-expression 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jeong-2026-notch-signaling-leech-neurogenesis-expression 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jeong-2026-notch-signaling-leech-neurogenesis-expression 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/spurgeon-2026-markers-platelet-function-testing-flow 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/spurgeon-2026-markers-platelet-function-testing-flow 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/spurgeon-2026-markers-platelet-function-testing-flow 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/spurgeon-2026-markers-platelet-function-testing-flow 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/smock-2026-quality-assurance-platelet-function-testing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/smock-2026-quality-assurance-platelet-function-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/smock-2026-quality-assurance-platelet-function-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/smock-2026-quality-assurance-platelet-function-testing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zackson-1982-cell-clones-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zackson-1982-cell-clones-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zackson-1982-cell-clones-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zackson-1982-cell-clones-segmentation-leech-development 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gibbs-1995-conversion-thrombin-anticoagulant-protein-engineering 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gibbs-1995-conversion-thrombin-anticoagulant-protein-engineering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gibbs-1995-conversion-thrombin-anticoagulant-protein-engineering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gibbs-1995-conversion-thrombin-anticoagulant-protein-engineering 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hopkins-1995-development-novel-recombinant-serpin-potential 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hopkins-1995-development-novel-recombinant-serpin-potential 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hopkins-1995-development-novel-recombinant-serpin-potential 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hopkins-1995-development-novel-recombinant-serpin-potential 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warkentin-1995-hemostasis-atherosclerosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warkentin-1995-hemostasis-atherosclerosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warkentin-1995-hemostasis-atherosclerosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warkentin-1995-hemostasis-atherosclerosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/blomback-1994-fibrinogen-structure-activation-polymerization-fibrin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/blomback-1994-fibrinogen-structure-activation-polymerization-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/blomback-1994-fibrinogen-structure-activation-polymerization-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/blomback-1994-fibrinogen-structure-activation-polymerization-fibrin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cote-1997-functional-characterization-recombinant-human-meizothrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cote-1997-functional-characterization-recombinant-human-meizothrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cote-1997-functional-characterization-recombinant-human-meizothrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cote-1997-functional-characterization-recombinant-human-meizothrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kelley-1997-soluble-tissue-factor-mutant-selective 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kelley-1997-soluble-tissue-factor-mutant-selective 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kelley-1997-soluble-tissue-factor-mutant-selective 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kelley-1997-soluble-tissue-factor-mutant-selective 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/russo-1997-stable-expression-purification-secreted-human 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/russo-1997-stable-expression-purification-secreted-human 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/russo-1997-stable-expression-purification-secreted-human 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/russo-1997-stable-expression-purification-secreted-human 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martinez-1997-congenital-dysfibrinogenemia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martinez-1997-congenital-dysfibrinogenemia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martinez-1997-congenital-dysfibrinogenemia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martinez-1997-congenital-dysfibrinogenemia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mosesson-1998-fibrinogen-structure-fibrin-clot-assembly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mosesson-1998-fibrinogen-structure-fibrin-clot-assembly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mosesson-1998-fibrinogen-structure-fibrin-clot-assembly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mosesson-1998-fibrinogen-structure-fibrin-clot-assembly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lakkireddy-2014-feasibility-safety-uninterrupted-rivaroxaban 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lakkireddy-2014-feasibility-safety-uninterrupted-rivaroxaban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lakkireddy-2014-feasibility-safety-uninterrupted-rivaroxaban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lakkireddy-2014-feasibility-safety-uninterrupted-rivaroxaban 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dillier-2014-safety-continuous-periprocedural-rivaroxaban-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dillier-2014-safety-continuous-periprocedural-rivaroxaban-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dillier-2014-safety-continuous-periprocedural-rivaroxaban-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dillier-2014-safety-continuous-periprocedural-rivaroxaban-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cappato-2015-uninterrupted-rivaroxaban-vs-uninterrupted-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cappato-2015-uninterrupted-rivaroxaban-vs-uninterrupted-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cappato-2015-uninterrupted-rivaroxaban-vs-uninterrupted-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cappato-2015-uninterrupted-rivaroxaban-vs-uninterrupted-vitamin-k 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/calkins-2017-uninterrupted-dabigatran-versus-warfarin-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/calkins-2017-uninterrupted-dabigatran-versus-warfarin-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/calkins-2017-uninterrupted-dabigatran-versus-warfarin-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/calkins-2017-uninterrupted-dabigatran-versus-warfarin-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cardoso-2017-updated-meta-oral-anticoagulants-versus-vitamin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cardoso-2017-updated-meta-oral-anticoagulants-versus-vitamin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cardoso-2017-updated-meta-oral-anticoagulants-versus-vitamin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cardoso-2017-updated-meta-oral-anticoagulants-versus-vitamin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cardoso-2018-uninterrupted-anticoagulation-non-vitamin-k-antagonist 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cardoso-2018-uninterrupted-anticoagulation-non-vitamin-k-antagonist 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cardoso-2018-uninterrupted-anticoagulation-non-vitamin-k-antagonist 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cardoso-2018-uninterrupted-anticoagulation-non-vitamin-k-antagonist 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/di-2020-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/di-2020-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/di-2020-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/di-2020-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/silva-2020-safety-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/silva-2020-safety-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/silva-2020-safety-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/silva-2020-safety-catheter-ablation-atrial-fibrillation-uninterrupted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/brockmeyer-2020-uninterrupted-anticoagulation-catheter-ablation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/brockmeyer-2020-uninterrupted-anticoagulation-catheter-ablation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/brockmeyer-2020-uninterrupted-anticoagulation-catheter-ablation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/brockmeyer-2020-uninterrupted-anticoagulation-catheter-ablation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cardoso-2020-uninterrupted-direct-oral-anticoagulants-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cardoso-2020-uninterrupted-direct-oral-anticoagulants-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cardoso-2020-uninterrupted-direct-oral-anticoagulants-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cardoso-2020-uninterrupted-direct-oral-anticoagulants-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/asad-2021-uninterrupted-versus-interrupted-direct-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/asad-2021-uninterrupted-versus-interrupted-direct-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/asad-2021-uninterrupted-versus-interrupted-direct-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/asad-2021-uninterrupted-versus-interrupted-direct-oral-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kondo-2022-insights-uninterrupted-anticoagulation-left-atrial-catheter 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kondo-2022-insights-uninterrupted-anticoagulation-left-atrial-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kondo-2022-insights-uninterrupted-anticoagulation-left-atrial-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kondo-2022-insights-uninterrupted-anticoagulation-left-atrial-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hardy-2022-uninterrupted-doacs-approach-catheter-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hardy-2022-uninterrupted-doacs-approach-catheter-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hardy-2022-uninterrupted-doacs-approach-catheter-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hardy-2022-uninterrupted-doacs-approach-catheter-ablation-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jamil-2022-comparison-interrupted-uninterrupted-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jamil-2022-comparison-interrupted-uninterrupted-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jamil-2022-comparison-interrupted-uninterrupted-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jamil-2022-comparison-interrupted-uninterrupted-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arachchillage-2016-rivaroxaban-limits-complement-activation-compared 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arachchillage-2016-rivaroxaban-limits-complement-activation-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arachchillage-2016-rivaroxaban-limits-complement-activation-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arachchillage-2016-rivaroxaban-limits-complement-activation-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cohen-2016-rivaroxaban-versus-warfarin-treat-patients-thrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cohen-2016-rivaroxaban-versus-warfarin-treat-patients-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cohen-2016-rivaroxaban-versus-warfarin-treat-patients-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cohen-2016-rivaroxaban-versus-warfarin-treat-patients-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crowley-2017-catastrophic-antiphospholipid-syndrome-switching 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crowley-2017-catastrophic-antiphospholipid-syndrome-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crowley-2017-catastrophic-antiphospholipid-syndrome-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crowley-2017-catastrophic-antiphospholipid-syndrome-switching 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ciampa-2018-oral-anticoagulation-cost-primary-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ciampa-2018-oral-anticoagulation-cost-primary-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ciampa-2018-oral-anticoagulation-cost-primary-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ciampa-2018-oral-anticoagulation-cost-primary-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/winter-2017-coagulation-testing-core-laboratory 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/winter-2017-coagulation-testing-core-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/winter-2017-coagulation-testing-core-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/winter-2017-coagulation-testing-core-laboratory 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pengo-2018-rivaroxaban-vs-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pengo-2018-rivaroxaban-vs-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pengo-2018-rivaroxaban-vs-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pengo-2018-rivaroxaban-vs-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hadjiski-2019-rivaroxaban-versus-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hadjiski-2019-rivaroxaban-versus-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hadjiski-2019-rivaroxaban-versus-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hadjiski-2019-rivaroxaban-versus-warfarin-high-risk-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ordi-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ordi-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ordi-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ordi-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anon-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anon-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anon-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anon-2019-rivaroxaban-versus-vitamin-k-antagonist-antiphospholipid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arachchillage-2020-what-appropriate-anticoagulation-strategy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arachchillage-2020-what-appropriate-anticoagulation-strategy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arachchillage-2020-what-appropriate-anticoagulation-strategy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arachchillage-2020-what-appropriate-anticoagulation-strategy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/khodashahi-2019-comparison-therapeutic-effects-rivaroxaban-versus 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/khodashahi-2019-comparison-therapeutic-effects-rivaroxaban-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/khodashahi-2019-comparison-therapeutic-effects-rivaroxaban-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/khodashahi-2019-comparison-therapeutic-effects-rivaroxaban-versus 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pengo-2020-rivaroxaban-antiphospholipid-syndrome-traps-two-year 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pengo-2020-rivaroxaban-antiphospholipid-syndrome-traps-two-year 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pengo-2020-rivaroxaban-antiphospholipid-syndrome-traps-two-year 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pengo-2020-rivaroxaban-antiphospholipid-syndrome-traps-two-year 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/williams-2021-direct-oral-anticoagulants-versus-warfarin-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/williams-2021-direct-oral-anticoagulants-versus-warfarin-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/williams-2021-direct-oral-anticoagulants-versus-warfarin-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/williams-2021-direct-oral-anticoagulants-versus-warfarin-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arora-2021-direct-oral-anticoagulation-agents-thromboprophylaxis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arora-2021-direct-oral-anticoagulation-agents-thromboprophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arora-2021-direct-oral-anticoagulation-agents-thromboprophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arora-2021-direct-oral-anticoagulation-agents-thromboprophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mittal-2024-rivaroxaban-stroke-patients-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mittal-2024-rivaroxaban-stroke-patients-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mittal-2024-rivaroxaban-stroke-patients-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mittal-2024-rivaroxaban-stroke-patients-antiphospholipid-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kondo-2001-argatroban-prevention-treatment-thromboembolism-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kondo-2001-argatroban-prevention-treatment-thromboembolism-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kondo-2001-argatroban-prevention-treatment-thromboembolism-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kondo-2001-argatroban-prevention-treatment-thromboembolism-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/verme-2003-argatroban-dosing-patients-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/verme-2003-argatroban-dosing-patients-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/verme-2003-argatroban-dosing-patients-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/verme-2003-argatroban-dosing-patients-heparin-induced-thrombocytopenia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elalamy-2019-argatroban-heparin-induced-thrombocytopenia-survey 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elalamy-2019-argatroban-heparin-induced-thrombocytopenia-survey 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elalamy-2019-argatroban-heparin-induced-thrombocytopenia-survey 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elalamy-2019-argatroban-heparin-induced-thrombocytopenia-survey 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sulakshana-2022-heparin-induced-thrombocytopenia-covid-19-systematic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sulakshana-2022-heparin-induced-thrombocytopenia-covid-19-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sulakshana-2022-heparin-induced-thrombocytopenia-covid-19-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sulakshana-2022-heparin-induced-thrombocytopenia-covid-19-systematic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/francis-2025-evaluation-standardized-electronic-argatroban-dosing 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/francis-2025-evaluation-standardized-electronic-argatroban-dosing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/francis-2025-evaluation-standardized-electronic-argatroban-dosing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/francis-2025-evaluation-standardized-electronic-argatroban-dosing 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mahmoud-2015-bivalirudin-percutaneous-coronary-intervention-it 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mahmoud-2015-bivalirudin-percutaneous-coronary-intervention-it 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mahmoud-2015-bivalirudin-percutaneous-coronary-intervention-it 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mahmoud-2015-bivalirudin-percutaneous-coronary-intervention-it 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2017-bivalirudin-percutaneous-coronary-intervention-chronic-total 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2017-bivalirudin-percutaneous-coronary-intervention-chronic-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2017-bivalirudin-percutaneous-coronary-intervention-chronic-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2017-bivalirudin-percutaneous-coronary-intervention-chronic-total 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hu-2021-bivalirudin-patients-undergoing-percutaneous-coronary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hu-2021-bivalirudin-patients-undergoing-percutaneous-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hu-2021-bivalirudin-patients-undergoing-percutaneous-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hu-2021-bivalirudin-patients-undergoing-percutaneous-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wu-2022-safety-profile-bivalirudin-chinese-female-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wu-2022-safety-profile-bivalirudin-chinese-female-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wu-2022-safety-profile-bivalirudin-chinese-female-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wu-2022-safety-profile-bivalirudin-chinese-female-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/al-2023-bivalirudin-versus-unfractionated-heparin-patients-myocardial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/al-2023-bivalirudin-versus-unfractionated-heparin-patients-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/al-2023-bivalirudin-versus-unfractionated-heparin-patients-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/al-2023-bivalirudin-versus-unfractionated-heparin-patients-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moruf-2012-peri-procedural-bridging-low-molecular-weight 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moruf-2012-peri-procedural-bridging-low-molecular-weight 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moruf-2012-peri-procedural-bridging-low-molecular-weight 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moruf-2012-peri-procedural-bridging-low-molecular-weight 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ghanbari-2012-meta-safety-efficacy-uninterrupted-warfarin-compared 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ghanbari-2012-meta-safety-efficacy-uninterrupted-warfarin-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ghanbari-2012-meta-safety-efficacy-uninterrupted-warfarin-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ghanbari-2012-meta-safety-efficacy-uninterrupted-warfarin-compared 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schulman-2014-reduced-dose-warfarin-interrupted-warfarin-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schulman-2014-reduced-dose-warfarin-interrupted-warfarin-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schulman-2014-reduced-dose-warfarin-interrupted-warfarin-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schulman-2014-reduced-dose-warfarin-interrupted-warfarin-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nikolakopoulos-2019-heparin-bridging-therapy-patients-chronic-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nikolakopoulos-2019-heparin-bridging-therapy-patients-chronic-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nikolakopoulos-2019-heparin-bridging-therapy-patients-chronic-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nikolakopoulos-2019-heparin-bridging-therapy-patients-chronic-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ng-2015-tranexamic-acid-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ng-2015-tranexamic-acid-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ng-2015-tranexamic-acid-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ng-2015-tranexamic-acid-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ghadimi-2016-perioperative-management-bleeding-patient 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ghadimi-2016-perioperative-management-bleeding-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ghadimi-2016-perioperative-management-bleeding-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ghadimi-2016-perioperative-management-bleeding-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/habbab-2019-topical-tranexamic-acid-cardiac-surgery-meta 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/habbab-2019-topical-tranexamic-acid-cardiac-surgery-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/habbab-2019-topical-tranexamic-acid-cardiac-surgery-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/habbab-2019-topical-tranexamic-acid-cardiac-surgery-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alaifan-2019-tranexamic-acid-cardiac-surgery-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alaifan-2019-tranexamic-acid-cardiac-surgery-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alaifan-2019-tranexamic-acid-cardiac-surgery-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alaifan-2019-tranexamic-acid-cardiac-surgery-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zufferey-2021-exposure-response-relationship-tranexamic-acid-cardiac 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zufferey-2021-exposure-response-relationship-tranexamic-acid-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zufferey-2021-exposure-response-relationship-tranexamic-acid-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zufferey-2021-exposure-response-relationship-tranexamic-acid-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dionne-2022-tranexamic-acid-gastrointestinal-bleeding-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dionne-2022-tranexamic-acid-gastrointestinal-bleeding-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dionne-2022-tranexamic-acid-gastrointestinal-bleeding-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dionne-2022-tranexamic-acid-gastrointestinal-bleeding-systematic-meta 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pe-2021-tranexamic-acid-cardiac-surgery-low-doses 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pe-2021-tranexamic-acid-cardiac-surgery-low-doses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pe-2021-tranexamic-acid-cardiac-surgery-low-doses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pe-2021-tranexamic-acid-cardiac-surgery-low-doses 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shi-2022-effect-high-vs-low-dose-tranexamic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shi-2022-effect-high-vs-low-dose-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shi-2022-effect-high-vs-low-dose-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shi-2022-effect-high-vs-low-dose-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/patel-2022-update-applications-limitations-perioperative-tranexamic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/patel-2022-update-applications-limitations-perioperative-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/patel-2022-update-applications-limitations-perioperative-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/patel-2022-update-applications-limitations-perioperative-tranexamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsan-2023-prophylactic-intravenous-tranexamic-acid-thromboembolism-non 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsan-2023-prophylactic-intravenous-tranexamic-acid-thromboembolism-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsan-2023-prophylactic-intravenous-tranexamic-acid-thromboembolism-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsan-2023-prophylactic-intravenous-tranexamic-acid-thromboembolism-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lamy-2024-topical-versus-intravenous-tranexamic-acid-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lamy-2024-topical-versus-intravenous-tranexamic-acid-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lamy-2024-topical-versus-intravenous-tranexamic-acid-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lamy-2024-topical-versus-intravenous-tranexamic-acid-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/houston-2024-hospital-policy-tranexamic-acid-reduce-transfusion 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/houston-2024-hospital-policy-tranexamic-acid-reduce-transfusion 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/houston-2024-hospital-policy-tranexamic-acid-reduce-transfusion 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/houston-2024-hospital-policy-tranexamic-acid-reduce-transfusion 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhang-2023-intravenous-tranexamic-acid-reduces-post-operative 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhang-2023-intravenous-tranexamic-acid-reduces-post-operative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhang-2023-intravenous-tranexamic-acid-reduces-post-operative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhang-2023-intravenous-tranexamic-acid-reduces-post-operative 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yadav-2024-contemporary-blood-transfusion-critically-ill-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yadav-2024-contemporary-blood-transfusion-critically-ill-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yadav-2024-contemporary-blood-transfusion-critically-ill-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yadav-2024-contemporary-blood-transfusion-critically-ill-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/la-2025-optimizing-tranexamic-acid-adult-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/la-2025-optimizing-tranexamic-acid-adult-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/la-2025-optimizing-tranexamic-acid-adult-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/la-2025-optimizing-tranexamic-acid-adult-cardiac-surgery 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ay-2019-treatment-cancer-associated-venous-thromboembolism-age 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ay-2019-treatment-cancer-associated-venous-thromboembolism-age 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ay-2019-treatment-cancer-associated-venous-thromboembolism-age 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ay-2019-treatment-cancer-associated-venous-thromboembolism-age 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-2019-efficacy-safety-direct-oral-anticoagulants-secondary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-2019-efficacy-safety-direct-oral-anticoagulants-secondary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-2019-efficacy-safety-direct-oral-anticoagulants-secondary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-2019-efficacy-safety-direct-oral-anticoagulants-secondary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/agnelli-2020-apixaban-treatment-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/agnelli-2020-apixaban-treatment-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/agnelli-2020-apixaban-treatment-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/agnelli-2020-apixaban-treatment-venous-thromboembolism-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ageno-2020-bleeding-apixaban-dalteparin-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ageno-2020-bleeding-apixaban-dalteparin-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ageno-2020-bleeding-apixaban-dalteparin-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ageno-2020-bleeding-apixaban-dalteparin-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/verso-2021-effects-concomitant-administration-anticancer-agents 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/verso-2021-effects-concomitant-administration-anticancer-agents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/verso-2021-effects-concomitant-administration-anticancer-agents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/verso-2021-effects-concomitant-administration-anticancer-agents 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bravo-2021-apixaban-low-weight-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bravo-2021-apixaban-low-weight-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bravo-2021-apixaban-low-weight-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bravo-2021-apixaban-low-weight-patients-cancer-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/riaz-2021-direct-oral-anticoagulants-compared-dalteparin-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/riaz-2021-direct-oral-anticoagulants-compared-dalteparin-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/riaz-2021-direct-oral-anticoagulants-compared-dalteparin-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/riaz-2021-direct-oral-anticoagulants-compared-dalteparin-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/becattini-2022-renal-function-clinical-outcome-patients-cancer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/becattini-2022-renal-function-clinical-outcome-patients-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/becattini-2022-renal-function-clinical-outcome-patients-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/becattini-2022-renal-function-clinical-outcome-patients-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/agnelli-2021-apixaban-dalteparin-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/agnelli-2021-apixaban-dalteparin-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/agnelli-2021-apixaban-dalteparin-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/agnelli-2021-apixaban-dalteparin-treatment-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sanchez-2022-treatment-cancer-associated-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sanchez-2022-treatment-cancer-associated-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sanchez-2022-treatment-cancer-associated-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sanchez-2022-treatment-cancer-associated-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shin-2022-cost-utility-comparing-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shin-2022-cost-utility-comparing-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shin-2022-cost-utility-comparing-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shin-2022-cost-utility-comparing-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cohen-2024-early-time-courses-recurrent-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cohen-2024-early-time-courses-recurrent-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cohen-2024-early-time-courses-recurrent-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cohen-2024-early-time-courses-recurrent-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fioretti-2023-abelacimab-cancer-associated-thrombosis-right-drug 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fioretti-2023-abelacimab-cancer-associated-thrombosis-right-drug 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fioretti-2023-abelacimab-cancer-associated-thrombosis-right-drug 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fioretti-2023-abelacimab-cancer-associated-thrombosis-right-drug 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chung-2025-real-world-evaluation-therapeutic-anticoagulation-cancer 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chung-2025-real-world-evaluation-therapeutic-anticoagulation-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chung-2025-real-world-evaluation-therapeutic-anticoagulation-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chung-2025-real-world-evaluation-therapeutic-anticoagulation-cancer 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/enden-2011-long-term-outcome-additional-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/enden-2011-long-term-outcome-additional-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/enden-2011-long-term-outcome-additional-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/enden-2011-long-term-outcome-additional-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/strijkers-2012-catheter-directed-thrombolysis-iliofemoral-deep-vein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/strijkers-2012-catheter-directed-thrombolysis-iliofemoral-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/strijkers-2012-catheter-directed-thrombolysis-iliofemoral-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/strijkers-2012-catheter-directed-thrombolysis-iliofemoral-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/liew-2015-catheter-directed-thrombolysis-extensive-iliofemoral-deep 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/liew-2015-catheter-directed-thrombolysis-extensive-iliofemoral-deep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/liew-2015-catheter-directed-thrombolysis-extensive-iliofemoral-deep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/liew-2015-catheter-directed-thrombolysis-extensive-iliofemoral-deep 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lu-2017-catheter-directed-thrombolysis-versus-standard-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lu-2017-catheter-directed-thrombolysis-versus-standard-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lu-2017-catheter-directed-thrombolysis-versus-standard-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lu-2017-catheter-directed-thrombolysis-versus-standard-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tang-2019-pharmacomechanical-thrombectomy-versus-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tang-2019-pharmacomechanical-thrombectomy-versus-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tang-2019-pharmacomechanical-thrombectomy-versus-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tang-2019-pharmacomechanical-thrombectomy-versus-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2021-endovascular-treatment-lower-extremity-deep-vein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2021-endovascular-treatment-lower-extremity-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2021-endovascular-treatment-lower-extremity-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2021-endovascular-treatment-lower-extremity-deep-vein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2021-angiojet-thrombectomy-versus-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2021-angiojet-thrombectomy-versus-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2021-angiojet-thrombectomy-versus-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2021-angiojet-thrombectomy-versus-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/farrokhi-2021-comparison-ultrasound-accelerated-versus-conventional 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/farrokhi-2021-comparison-ultrasound-accelerated-versus-conventional 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/farrokhi-2021-comparison-ultrasound-accelerated-versus-conventional 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/farrokhi-2021-comparison-ultrasound-accelerated-versus-conventional 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goldhaber-2021-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goldhaber-2021-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goldhaber-2021-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goldhaber-2021-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/khalid-2022-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/khalid-2022-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/khalid-2022-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/khalid-2022-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2023-effectiveness-safety-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2023-effectiveness-safety-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2023-effectiveness-safety-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2023-effectiveness-safety-catheter-directed-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/duarte-2023-catheter-directed-thrombolysis-protocols-deep-venous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/duarte-2023-catheter-directed-thrombolysis-protocols-deep-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/duarte-2023-catheter-directed-thrombolysis-protocols-deep-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/duarte-2023-catheter-directed-thrombolysis-protocols-deep-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnes-2023-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnes-2023-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnes-2023-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnes-2023-catheter-directed-thrombolysis-deep-vein-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/abramowitz-2024-comparison-anticoagulation-vs-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/abramowitz-2024-comparison-anticoagulation-vs-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/abramowitz-2024-comparison-anticoagulation-vs-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/abramowitz-2024-comparison-anticoagulation-vs-mechanical-thrombectomy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schlager-2025-2025-esvm-guidelines-interventional-treatment-venous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schlager-2025-2025-esvm-guidelines-interventional-treatment-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schlager-2025-2025-esvm-guidelines-interventional-treatment-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schlager-2025-2025-esvm-guidelines-interventional-treatment-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ghofrani-2013-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ghofrani-2013-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ghofrani-2013-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ghofrani-2013-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hoeper-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hoeper-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hoeper-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hoeper-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bishop-2014-riociguat-pulmonary-arterial-hypertension-chronic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bishop-2014-riociguat-pulmonary-arterial-hypertension-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bishop-2014-riociguat-pulmonary-arterial-hypertension-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bishop-2014-riociguat-pulmonary-arterial-hypertension-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/olsson-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/olsson-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/olsson-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/olsson-2014-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2015-chronic-thromboembolic-pulmonary-hypertension-evolving 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2015-chronic-thromboembolic-pulmonary-hypertension-evolving 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2015-chronic-thromboembolic-pulmonary-hypertension-evolving 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2015-chronic-thromboembolic-pulmonary-hypertension-evolving 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/o-2015-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/o-2015-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/o-2015-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/o-2015-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kim-2019-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kim-2019-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kim-2019-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kim-2019-chronic-thromboembolic-pulmonary-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mandras-2020-pulmonary-hypertension-brief-guide-clinicians 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mandras-2020-pulmonary-hypertension-brief-guide-clinicians 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mandras-2020-pulmonary-hypertension-brief-guide-clinicians 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mandras-2020-pulmonary-hypertension-brief-guide-clinicians 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/donaldson-2020-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/donaldson-2020-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/donaldson-2020-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/donaldson-2020-riociguat-treatment-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/logue-2021-chronic-thromboembolic-pulmonary-hypertension-medical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/logue-2021-chronic-thromboembolic-pulmonary-hypertension-medical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/logue-2021-chronic-thromboembolic-pulmonary-hypertension-medical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/logue-2021-chronic-thromboembolic-pulmonary-hypertension-medical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kawakami-2022-balloon-pulmonary-angioplasty-versus-riociguat 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kawakami-2022-balloon-pulmonary-angioplasty-versus-riociguat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kawakami-2022-balloon-pulmonary-angioplasty-versus-riociguat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kawakami-2022-balloon-pulmonary-angioplasty-versus-riociguat 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/benza-2022-riociguat-right-ventricle-pulmonary-arterial-hypertension 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/benza-2022-riociguat-right-ventricle-pulmonary-arterial-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/benza-2022-riociguat-right-ventricle-pulmonary-arterial-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/benza-2022-riociguat-right-ventricle-pulmonary-arterial-hypertension 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-2023-evaluation-management-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-2023-evaluation-management-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-2023-evaluation-management-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-2023-evaluation-management-chronic-thromboembolic-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ageno-2012-oral-anticoagulant-therapy-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ageno-2012-oral-anticoagulant-therapy-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ageno-2012-oral-anticoagulant-therapy-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ageno-2012-oral-anticoagulant-therapy-antithrombotic-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mueck-2014-clinical-pharmacokinetic-pharmacodynamic-profile 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mueck-2014-clinical-pharmacokinetic-pharmacodynamic-profile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mueck-2014-clinical-pharmacokinetic-pharmacodynamic-profile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mueck-2014-clinical-pharmacokinetic-pharmacodynamic-profile 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/di-2017-old-oral-anticoagulants-food-herbal-medicines 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/di-2017-old-oral-anticoagulants-food-herbal-medicines 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/di-2017-old-oral-anticoagulants-food-herbal-medicines 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/di-2017-old-oral-anticoagulants-food-herbal-medicines 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/byon-2019-apixaban-clinical-pharmacokinetic-pharmacodynamic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/byon-2019-apixaban-clinical-pharmacokinetic-pharmacodynamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/byon-2019-apixaban-clinical-pharmacokinetic-pharmacodynamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/byon-2019-apixaban-clinical-pharmacokinetic-pharmacodynamic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chen-2020-direct-oral-anticoagulant-practical-guide-common 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chen-2020-direct-oral-anticoagulant-practical-guide-common 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chen-2020-direct-oral-anticoagulant-practical-guide-common 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chen-2020-direct-oral-anticoagulant-practical-guide-common 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/grze-2021-clinical-significance-drug-food-interactions-direct 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/grze-2021-clinical-significance-drug-food-interactions-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/grze-2021-clinical-significance-drug-food-interactions-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/grze-2021-clinical-significance-drug-food-interactions-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/macdougall-2022-systematic-drug-drug-interactions-rifamycins 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/macdougall-2022-systematic-drug-drug-interactions-rifamycins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/macdougall-2022-systematic-drug-drug-interactions-rifamycins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/macdougall-2022-systematic-drug-drug-interactions-rifamycins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ferri-2022-drug-drug-interactions-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ferri-2022-drug-drug-interactions-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ferri-2022-drug-drug-interactions-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ferri-2022-drug-drug-interactions-direct-oral-anticoagulants 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thompson-2022-personalizing-direct-oral-anticoagulant-therapy-diverse 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thompson-2022-personalizing-direct-oral-anticoagulant-therapy-diverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thompson-2022-personalizing-direct-oral-anticoagulant-therapy-diverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thompson-2022-personalizing-direct-oral-anticoagulant-therapy-diverse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goldstein-2023-interactions-direct-oral-anticoagulants-doacs 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goldstein-2023-interactions-direct-oral-anticoagulants-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goldstein-2023-interactions-direct-oral-anticoagulants-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goldstein-2023-interactions-direct-oral-anticoagulants-doacs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/al-2024-management-direct-oral-anticoagulant-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/al-2024-management-direct-oral-anticoagulant-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/al-2024-management-direct-oral-anticoagulant-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/al-2024-management-direct-oral-anticoagulant-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/decaix-2024-pharmacokinetics-pharmacodynamics-drug-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/decaix-2024-pharmacokinetics-pharmacodynamics-drug-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/decaix-2024-pharmacokinetics-pharmacodynamics-drug-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/decaix-2024-pharmacokinetics-pharmacodynamics-drug-drug-interactions 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yang-2024-evaluation-drug-drug-interactions-clarithromycin-direct 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yang-2024-evaluation-drug-drug-interactions-clarithromycin-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yang-2024-evaluation-drug-drug-interactions-clarithromycin-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yang-2024-evaluation-drug-drug-interactions-clarithromycin-direct 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kamdar-2018-anticoagulation-neonatal-ecmo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kamdar-2018-anticoagulation-neonatal-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kamdar-2018-anticoagulation-neonatal-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kamdar-2018-anticoagulation-neonatal-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ecoffey-2022-practice-advisory-prevention-management-complications 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ecoffey-2022-practice-advisory-prevention-management-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ecoffey-2022-practice-advisory-prevention-management-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ecoffey-2022-practice-advisory-prevention-management-complications 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/neyra-2020-how-prescribe-troubleshoot-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/neyra-2020-how-prescribe-troubleshoot-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/neyra-2020-how-prescribe-troubleshoot-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/neyra-2020-how-prescribe-troubleshoot-continuous-renal-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-2022-anticoagulation-management-high-bleeding-risk-ecmo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-2022-anticoagulation-management-high-bleeding-risk-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-2022-anticoagulation-management-high-bleeding-risk-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-2022-anticoagulation-management-high-bleeding-risk-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prokupets-2023-management-anticoagulation-therapy-ecmo-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prokupets-2023-management-anticoagulation-therapy-ecmo-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prokupets-2023-management-anticoagulation-therapy-ecmo-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prokupets-2023-management-anticoagulation-therapy-ecmo-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wheeler-2023-extracorporeal-membrane-oxygenation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wheeler-2023-extracorporeal-membrane-oxygenation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wheeler-2023-extracorporeal-membrane-oxygenation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wheeler-2023-extracorporeal-membrane-oxygenation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martucci-2024-anticoagulation-bleeding-veno-venous-extracorporeal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martucci-2024-anticoagulation-bleeding-veno-venous-extracorporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martucci-2024-anticoagulation-bleeding-veno-venous-extracorporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martucci-2024-anticoagulation-bleeding-veno-venous-extracorporeal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rodrigues-2024-anticoagulation-management-v-v-ecmo-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rodrigues-2024-anticoagulation-management-v-v-ecmo-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rodrigues-2024-anticoagulation-management-v-v-ecmo-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rodrigues-2024-anticoagulation-management-v-v-ecmo-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/buchtele-2024-rock-hard-place-anticoagulation-management-ecmo 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/buchtele-2024-rock-hard-place-anticoagulation-management-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/buchtele-2024-rock-hard-place-anticoagulation-management-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/buchtele-2024-rock-hard-place-anticoagulation-management-ecmo 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rintoul-2024-management-bleeding-thrombotic-complications-pediatric 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rintoul-2024-management-bleeding-thrombotic-complications-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rintoul-2024-management-bleeding-thrombotic-complications-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rintoul-2024-management-bleeding-thrombotic-complications-pediatric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schiavoni-2024-anticoagulation-management-veno-venous-ecmo-covid 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schiavoni-2024-anticoagulation-management-veno-venous-ecmo-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schiavoni-2024-anticoagulation-management-veno-venous-ecmo-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schiavoni-2024-anticoagulation-management-veno-venous-ecmo-covid 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kuzmin-2024-anticoagulation-management-veno-venous-ecmo-support 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kuzmin-2024-anticoagulation-management-veno-venous-ecmo-support 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kuzmin-2024-anticoagulation-management-veno-venous-ecmo-support 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kuzmin-2024-anticoagulation-management-veno-venous-ecmo-support 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sellers-2011-atrial-fibrillation-anticoagulation-fall-risk-outcomes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sellers-2011-atrial-fibrillation-anticoagulation-fall-risk-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sellers-2011-atrial-fibrillation-anticoagulation-fall-risk-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sellers-2011-atrial-fibrillation-anticoagulation-fall-risk-outcomes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zarraga-2012-oral-anticoagulation-elderly-adults-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zarraga-2012-oral-anticoagulation-elderly-adults-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zarraga-2012-oral-anticoagulation-elderly-adults-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zarraga-2012-oral-anticoagulation-elderly-adults-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/inui-2014-mortality-ground-level-fall-elderly-patient 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/inui-2014-mortality-ground-level-fall-elderly-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/inui-2014-mortality-ground-level-fall-elderly-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/inui-2014-mortality-ground-level-fall-elderly-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wong-2016-anticoagulation-stroke-prevention-elderly-patients-non 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wong-2016-anticoagulation-stroke-prevention-elderly-patients-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wong-2016-anticoagulation-stroke-prevention-elderly-patients-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wong-2016-anticoagulation-stroke-prevention-elderly-patients-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hagerty-2017-fall-risk-anticoagulation-atrial-fibrillation-elderly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hagerty-2017-fall-risk-anticoagulation-atrial-fibrillation-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hagerty-2017-fall-risk-anticoagulation-atrial-fibrillation-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hagerty-2017-fall-risk-anticoagulation-atrial-fibrillation-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/petidier-2018-oral-anticoagulation-therapy-elderly-population-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/petidier-2018-oral-anticoagulation-therapy-elderly-population-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/petidier-2018-oral-anticoagulation-therapy-elderly-population-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/petidier-2018-oral-anticoagulation-therapy-elderly-population-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/coutaz-2020-anticoagulation-vulnerable-elderly-patients-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/coutaz-2020-anticoagulation-vulnerable-elderly-patients-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/coutaz-2020-anticoagulation-vulnerable-elderly-patients-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/coutaz-2020-anticoagulation-vulnerable-elderly-patients-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/obi-2021-examination-anticoagulation-prescription-among-elderly 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/obi-2021-examination-anticoagulation-prescription-among-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/obi-2021-examination-anticoagulation-prescription-among-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/obi-2021-examination-anticoagulation-prescription-among-elderly 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barnett-2021-bleeding-prediction-model-atrial-fibrillation-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barnett-2021-bleeding-prediction-model-atrial-fibrillation-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barnett-2021-bleeding-prediction-model-atrial-fibrillation-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barnett-2021-bleeding-prediction-model-atrial-fibrillation-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/carr-2021-chads-vasc-has-bled-scores-do 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/carr-2021-chads-vasc-has-bled-scores-do 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/carr-2021-chads-vasc-has-bled-scores-do 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/carr-2021-chads-vasc-has-bled-scores-do 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/volgman-2022-management-atrial-fibrillation-patients-75-years 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/volgman-2022-management-atrial-fibrillation-patients-75-years 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/volgman-2022-management-atrial-fibrillation-patients-75-years 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/volgman-2022-management-atrial-fibrillation-patients-75-years 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/raposeiras-2022-incidence-predictors-bleeding-patients-cancer-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/raposeiras-2022-incidence-predictors-bleeding-patients-cancer-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/raposeiras-2022-incidence-predictors-bleeding-patients-cancer-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/raposeiras-2022-incidence-predictors-bleeding-patients-cancer-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pelletier-2022-variation-bleeding-risk-estimates-among-online 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pelletier-2022-variation-bleeding-risk-estimates-among-online 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pelletier-2022-variation-bleeding-risk-estimates-among-online 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pelletier-2022-variation-bleeding-risk-estimates-among-online 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/campos-2023-risk-scores-major-bleeding-direct-oral 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/campos-2023-risk-scores-major-bleeding-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/campos-2023-risk-scores-major-bleeding-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/campos-2023-risk-scores-major-bleeding-direct-oral 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/peyvandi-2016-past-future-haemophilia-diagnosis-treatments 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/peyvandi-2016-past-future-haemophilia-diagnosis-treatments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/peyvandi-2016-past-future-haemophilia-diagnosis-treatments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/peyvandi-2016-past-future-haemophilia-diagnosis-treatments 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mahlangu-2018-emicizumab-prophylaxis-patients-who-have-hemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mahlangu-2018-emicizumab-prophylaxis-patients-who-have-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mahlangu-2018-emicizumab-prophylaxis-patients-who-have-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mahlangu-2018-emicizumab-prophylaxis-patients-who-have-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/young-2018-emicizumab-hemophilia-factor-viii-inhibitors 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/young-2018-emicizumab-hemophilia-factor-viii-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/young-2018-emicizumab-hemophilia-factor-viii-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/young-2018-emicizumab-hemophilia-factor-viii-inhibitors 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mahlangu-2018-rfviiifc-hemophilia-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mahlangu-2018-rfviiifc-hemophilia-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mahlangu-2018-rfviiifc-hemophilia-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mahlangu-2018-rfviiifc-hemophilia-prophylaxis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/samuelson-2019-factor-viii-long-established-haemophilia-emerging 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/samuelson-2019-factor-viii-long-established-haemophilia-emerging 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/samuelson-2019-factor-viii-long-established-haemophilia-emerging 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/samuelson-2019-factor-viii-long-established-haemophilia-emerging 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/valentino-2020-prophylaxis-hemophilia-without-inhibitors-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/valentino-2020-prophylaxis-hemophilia-without-inhibitors-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/valentino-2020-prophylaxis-hemophilia-without-inhibitors-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/valentino-2020-prophylaxis-hemophilia-without-inhibitors-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sun-2021-factor-viii-replacement-prophylaxis-patients-hemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sun-2021-factor-viii-replacement-prophylaxis-patients-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sun-2021-factor-viii-replacement-prophylaxis-patients-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sun-2021-factor-viii-replacement-prophylaxis-patients-hemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/p-2021-treatment-haemophilia-replacement-gene-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/p-2021-treatment-haemophilia-replacement-gene-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/p-2021-treatment-haemophilia-replacement-gene-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/p-2021-treatment-haemophilia-replacement-gene-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dargaud-2021-clinical-utility-subcutaneous-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dargaud-2021-clinical-utility-subcutaneous-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dargaud-2021-clinical-utility-subcutaneous-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dargaud-2021-clinical-utility-subcutaneous-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/franchini-2022-more-recent-history-hemophilia-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/franchini-2022-more-recent-history-hemophilia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/franchini-2022-more-recent-history-hemophilia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/franchini-2022-more-recent-history-hemophilia-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/teranishi-2023-bispecific-antibody-nxt007-exerts-hemostatic-activity 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/teranishi-2023-bispecific-antibody-nxt007-exerts-hemostatic-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/teranishi-2023-bispecific-antibody-nxt007-exerts-hemostatic-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/teranishi-2023-bispecific-antibody-nxt007-exerts-hemostatic-activity 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dargaud-2024-efanesoctocog-alfa-renaissance-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dargaud-2024-efanesoctocog-alfa-renaissance-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dargaud-2024-efanesoctocog-alfa-renaissance-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dargaud-2024-efanesoctocog-alfa-renaissance-factor-viii-replacement 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/oldenburg-2024-comparative-effectiveness-valoctocogene-roxaparvovec 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/oldenburg-2024-comparative-effectiveness-valoctocogene-roxaparvovec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/oldenburg-2024-comparative-effectiveness-valoctocogene-roxaparvovec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/oldenburg-2024-comparative-effectiveness-valoctocogene-roxaparvovec 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/srivastava-2024-lentiviral-gene-therapy-cd34-hematopoietic-cells 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/srivastava-2024-lentiviral-gene-therapy-cd34-hematopoietic-cells 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/srivastava-2024-lentiviral-gene-therapy-cd34-hematopoietic-cells 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/srivastava-2024-lentiviral-gene-therapy-cd34-hematopoietic-cells 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chowdary-2025-haemophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chowdary-2025-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chowdary-2025-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chowdary-2025-haemophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/betz-1992-interaction-n-terminal-region-hirudin-active 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/betz-1992-interaction-n-terminal-region-hirudin-active 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/betz-1992-interaction-n-terminal-region-hirudin-active 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/betz-1992-interaction-n-terminal-region-hirudin-active 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baglin-2002-crystal-structures-native-thrombin-complexed-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baglin-2002-crystal-structures-native-thrombin-complexed-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baglin-2002-crystal-structures-native-thrombin-complexed-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baglin-2002-crystal-structures-native-thrombin-complexed-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wirsching-2003-directed-evolution-towards-protease-resistant-hirudin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wirsching-2003-directed-evolution-towards-protease-resistant-hirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wirsching-2003-directed-evolution-towards-protease-resistant-hirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wirsching-2003-directed-evolution-towards-protease-resistant-hirudin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/corral-2011-structural-basis-thrombin-mediated-factor-v 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/corral-2011-structural-basis-thrombin-mediated-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/corral-2011-structural-basis-thrombin-mediated-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/corral-2011-structural-basis-thrombin-mediated-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/renwick-1963-story-leeches 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/renwick-1963-story-leeches 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/renwick-1963-story-leeches 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/renwick-1963-story-leeches 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/synek-1963-leeches-medicine 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/synek-1963-leeches-medicine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/synek-1963-leeches-medicine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/synek-1963-leeches-medicine 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/colovi-2016-treatment-bloodletting-past-present 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/colovi-2016-treatment-bloodletting-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/colovi-2016-treatment-bloodletting-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/colovi-2016-treatment-bloodletting-past-present 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allender-2017-pharmacologic-considerations-management-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allender-2017-pharmacologic-considerations-management-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allender-2017-pharmacologic-considerations-management-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allender-2017-pharmacologic-considerations-management-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/succar-2019-management-anticoagulation-impella-percutaneous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/succar-2019-management-anticoagulation-impella-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/succar-2019-management-anticoagulation-impella-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/succar-2019-management-anticoagulation-impella-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/szymanski-2020-anticoagulation-impella-bivalirudin-purge-solution 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/szymanski-2020-anticoagulation-impella-bivalirudin-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/szymanski-2020-anticoagulation-impella-bivalirudin-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/szymanski-2020-anticoagulation-impella-bivalirudin-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wood-2020-anticoagulation-management-impella-percutaneous-ventricular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wood-2020-anticoagulation-management-impella-percutaneous-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wood-2020-anticoagulation-management-impella-percutaneous-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wood-2020-anticoagulation-management-impella-percutaneous-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beavers-2021-optimizing-anticoagulation-patients-receiving-impella 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beavers-2021-optimizing-anticoagulation-patients-receiving-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beavers-2021-optimizing-anticoagulation-patients-receiving-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beavers-2021-optimizing-anticoagulation-patients-receiving-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/iskaros-2022-antithrombotic-management-impellatemporary-ventricular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/iskaros-2022-antithrombotic-management-impellatemporary-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/iskaros-2022-antithrombotic-management-impellatemporary-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/iskaros-2022-antithrombotic-management-impellatemporary-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bergen-2022-bicarbonate-purge-solution-patients-cardiogenic-shock 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bergen-2022-bicarbonate-purge-solution-patients-cardiogenic-shock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bergen-2022-bicarbonate-purge-solution-patients-cardiogenic-shock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bergen-2022-bicarbonate-purge-solution-patients-cardiogenic-shock 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moretz-2022-comment-bicarbonate-purge-solution-patients-cardiogenic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moretz-2022-comment-bicarbonate-purge-solution-patients-cardiogenic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moretz-2022-comment-bicarbonate-purge-solution-patients-cardiogenic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moretz-2022-comment-bicarbonate-purge-solution-patients-cardiogenic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ammann-2023-sodium-bicarbonate-alters-protein-stability-blood 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ammann-2023-sodium-bicarbonate-alters-protein-stability-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ammann-2023-sodium-bicarbonate-alters-protein-stability-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ammann-2023-sodium-bicarbonate-alters-protein-stability-blood 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2023-switch-bicarbonate-impella-cp-purge-solution 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2023-switch-bicarbonate-impella-cp-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2023-switch-bicarbonate-impella-cp-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2023-switch-bicarbonate-impella-cp-purge-solution 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hisham-2023-anticoagulation-practices-complications-associated 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hisham-2023-anticoagulation-practices-complications-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hisham-2023-anticoagulation-practices-complications-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hisham-2023-anticoagulation-practices-complications-associated 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sigala-2024-series-bicarbonate-purge-solution-administration-impella 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sigala-2024-series-bicarbonate-purge-solution-administration-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sigala-2024-series-bicarbonate-purge-solution-administration-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sigala-2024-series-bicarbonate-purge-solution-administration-impella 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/berman-2023-safety-effectiveness-anti-xa-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/berman-2023-safety-effectiveness-anti-xa-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/berman-2023-safety-effectiveness-anti-xa-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/berman-2023-safety-effectiveness-anti-xa-unfractionated-heparin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/holmes-2014-prospective-randomized-evaluation-watchman-left-atrial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/holmes-2014-prospective-randomized-evaluation-watchman-left-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/holmes-2014-prospective-randomized-evaluation-watchman-left-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/holmes-2014-prospective-randomized-evaluation-watchman-left-atrial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/price-2014-left-atrial-appendage-occlusion-watchman-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/price-2014-left-atrial-appendage-occlusion-watchman-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/price-2014-left-atrial-appendage-occlusion-watchman-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/price-2014-left-atrial-appendage-occlusion-watchman-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bode-2015-left-atrial-appendage-occlusion-prevention-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bode-2015-left-atrial-appendage-occlusion-prevention-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bode-2015-left-atrial-appendage-occlusion-prevention-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bode-2015-left-atrial-appendage-occlusion-prevention-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhou-2015-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhou-2015-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhou-2015-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhou-2015-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chanda-2017-left-atrial-appendage-occlusion-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chanda-2017-left-atrial-appendage-occlusion-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chanda-2017-left-atrial-appendage-occlusion-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chanda-2017-left-atrial-appendage-occlusion-stroke-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vainrib-2017-left-atrial-appendage-occlusion-exclusion-procedural 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vainrib-2017-left-atrial-appendage-occlusion-exclusion-procedural 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vainrib-2017-left-atrial-appendage-occlusion-exclusion-procedural 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vainrib-2017-left-atrial-appendage-occlusion-exclusion-procedural 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/baman-2018-percutaneous-left-atrial-appendage-occlusion-prevention 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/baman-2018-percutaneous-left-atrial-appendage-occlusion-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/baman-2018-percutaneous-left-atrial-appendage-occlusion-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/baman-2018-percutaneous-left-atrial-appendage-occlusion-prevention 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lakkireddy-2021-amplatzer-amulet-left-atrial-appendage-occluder 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lakkireddy-2021-amplatzer-amulet-left-atrial-appendage-occluder 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lakkireddy-2021-amplatzer-amulet-left-atrial-appendage-occluder 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lakkireddy-2021-amplatzer-amulet-left-atrial-appendage-occluder 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tang-2022-left-atrial-appendage-occlusion-practice-makes 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tang-2022-left-atrial-appendage-occlusion-practice-makes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tang-2022-left-atrial-appendage-occlusion-practice-makes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tang-2022-left-atrial-appendage-occlusion-practice-makes 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kapadia-2023-concomitant-left-atrial-appendage-occlusion-transcatheter 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kapadia-2023-concomitant-left-atrial-appendage-occlusion-transcatheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kapadia-2023-concomitant-left-atrial-appendage-occlusion-transcatheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kapadia-2023-concomitant-left-atrial-appendage-occlusion-transcatheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reinhardt-2024-anticoagulation-alone-vs-anticoagulation-plus-aspirin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reinhardt-2024-anticoagulation-alone-vs-anticoagulation-plus-aspirin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reinhardt-2024-anticoagulation-alone-vs-anticoagulation-plus-aspirin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reinhardt-2024-anticoagulation-alone-vs-anticoagulation-plus-aspirin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/katapadi-2024-post-left-atrial-appendage-occlusion-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/katapadi-2024-post-left-atrial-appendage-occlusion-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/katapadi-2024-post-left-atrial-appendage-occlusion-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/katapadi-2024-post-left-atrial-appendage-occlusion-antithrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lakkireddy-2024-5-year-results-amplatzer-amulet-left 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lakkireddy-2024-5-year-results-amplatzer-amulet-left 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lakkireddy-2024-5-year-results-amplatzer-amulet-left 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lakkireddy-2024-5-year-results-amplatzer-amulet-left 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mitsis-2025-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mitsis-2025-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mitsis-2025-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mitsis-2025-left-atrial-appendage-occlusion-atrial-fibrillation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chesebro-2003-direct-thrombin-inhibitor-therapy-cardiovascular-patient 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chesebro-2003-direct-thrombin-inhibitor-therapy-cardiovascular-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chesebro-2003-direct-thrombin-inhibitor-therapy-cardiovascular-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chesebro-2003-direct-thrombin-inhibitor-therapy-cardiovascular-patient 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/deitcher-2003-clinical-utility-subcutaneous-hirudins 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/deitcher-2003-clinical-utility-subcutaneous-hirudins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/deitcher-2003-clinical-utility-subcutaneous-hirudins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/deitcher-2003-clinical-utility-subcutaneous-hirudins 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/toeg-2015-anticoagulation-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/toeg-2015-anticoagulation-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/toeg-2015-anticoagulation-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/toeg-2015-anticoagulation-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hohner-2015-medication-management-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hohner-2015-medication-management-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hohner-2015-medication-management-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hohner-2015-medication-management-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fatullayev-2015-continuous-flow-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fatullayev-2015-continuous-flow-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fatullayev-2015-continuous-flow-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fatullayev-2015-continuous-flow-left-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shah-2017-bleeding-thrombosis-associated-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shah-2017-bleeding-thrombosis-associated-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shah-2017-bleeding-thrombosis-associated-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shah-2017-bleeding-thrombosis-associated-ventricular-assist-device 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aissaoui-2018-understanding-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aissaoui-2018-understanding-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aissaoui-2018-understanding-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aissaoui-2018-understanding-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gurbel-2018-antithrombotic-strategies-device-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gurbel-2018-antithrombotic-strategies-device-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gurbel-2018-antithrombotic-strategies-device-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gurbel-2018-antithrombotic-strategies-device-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goodwin-2018-neurological-complications-associated-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goodwin-2018-neurological-complications-associated-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goodwin-2018-neurological-complications-associated-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goodwin-2018-neurological-complications-associated-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rettenmaier-2020-management-ischemic-stroke-following-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rettenmaier-2020-management-ischemic-stroke-following-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rettenmaier-2020-management-ischemic-stroke-following-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rettenmaier-2020-management-ischemic-stroke-following-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/plecash-2021-stroke-patients-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/plecash-2021-stroke-patients-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/plecash-2021-stroke-patients-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/plecash-2021-stroke-patients-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/malone-2022-advancements-left-ventricular-assist-devices-prevent 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/malone-2022-advancements-left-ventricular-assist-devices-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/malone-2022-advancements-left-ventricular-assist-devices-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/malone-2022-advancements-left-ventricular-assist-devices-prevent 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bhadra-2023-left-ventricular-assist-device-explantation-double 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bhadra-2023-left-ventricular-assist-device-explantation-double 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bhadra-2023-left-ventricular-assist-device-explantation-double 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bhadra-2023-left-ventricular-assist-device-explantation-double 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shah-2024-evaluation-hemocompatibility-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shah-2024-evaluation-hemocompatibility-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shah-2024-evaluation-hemocompatibility-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shah-2024-evaluation-hemocompatibility-direct-oral-anticoagulant 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cikes-2024-antithrombotic-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cikes-2024-antithrombotic-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cikes-2024-antithrombotic-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cikes-2024-antithrombotic-strategies-left-ventricular-assist-devices 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ndakotsu-2025-evolving-anticoagulation-paradigms-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ndakotsu-2025-evolving-anticoagulation-paradigms-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ndakotsu-2025-evolving-anticoagulation-paradigms-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ndakotsu-2025-evolving-anticoagulation-paradigms-left-ventricular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schmold-2012-molluscan-neurons-culture-shedding-light-synapse 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schmold-2012-molluscan-neurons-culture-shedding-light-synapse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schmold-2012-molluscan-neurons-culture-shedding-light-synapse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schmold-2012-molluscan-neurons-culture-shedding-light-synapse 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/le-2013-leech-nervous-system-valuable-model-microglia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/le-2013-leech-nervous-system-valuable-model-microglia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/le-2013-leech-nervous-system-valuable-model-microglia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/le-2013-leech-nervous-system-valuable-model-microglia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harley-2015-compensatory-plasticity-restores-locomotion-chronic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harley-2015-compensatory-plasticity-restores-locomotion-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harley-2015-compensatory-plasticity-restores-locomotion-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harley-2015-compensatory-plasticity-restores-locomotion-chronic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mclintock-2011-obstetric-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mclintock-2011-obstetric-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mclintock-2011-obstetric-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mclintock-2011-obstetric-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gogarten-2011-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gogarten-2011-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gogarten-2011-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gogarten-2011-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/butwick-2013-postpartum-hemorrhage-low-fibrinogen-levels-past 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/butwick-2013-postpartum-hemorrhage-low-fibrinogen-levels-past 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/butwick-2013-postpartum-hemorrhage-low-fibrinogen-levels-past 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/butwick-2013-postpartum-hemorrhage-low-fibrinogen-levels-past 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/butwick-2015-transfusion-coagulation-management-major-obstetric 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/butwick-2015-transfusion-coagulation-management-major-obstetric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/butwick-2015-transfusion-coagulation-management-major-obstetric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/butwick-2015-transfusion-coagulation-management-major-obstetric 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/henriquez-2018-management-postpartum-hemorrhage-how-improve-maternal 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/henriquez-2018-management-postpartum-hemorrhage-how-improve-maternal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/henriquez-2018-management-postpartum-hemorrhage-how-improve-maternal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/henriquez-2018-management-postpartum-hemorrhage-how-improve-maternal 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pacheco-2018-medical-management-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pacheco-2018-medical-management-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pacheco-2018-medical-management-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pacheco-2018-medical-management-postpartum-hemorrhage-update 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phillips-2019-next-generation-medical-management-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phillips-2019-next-generation-medical-management-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phillips-2019-next-generation-medical-management-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phillips-2019-next-generation-medical-management-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kumaraswami-2022-latest-advances-postpartum-hemorrhage-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kumaraswami-2022-latest-advances-postpartum-hemorrhage-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kumaraswami-2022-latest-advances-postpartum-hemorrhage-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kumaraswami-2022-latest-advances-postpartum-hemorrhage-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shah-2022-major-haemorrhage-past-present-future 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shah-2022-major-haemorrhage-past-present-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shah-2022-major-haemorrhage-past-present-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shah-2022-major-haemorrhage-past-present-future 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hofer-2022-haemostatic-support-postpartum-haemorrhage-literature 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hofer-2022-haemostatic-support-postpartum-haemorrhage-literature 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hofer-2022-haemostatic-support-postpartum-haemorrhage-literature 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hofer-2022-haemostatic-support-postpartum-haemorrhage-literature 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/perelman-2022-thromboelastography-versus-standard-coagulation-assays 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/perelman-2022-thromboelastography-versus-standard-coagulation-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/perelman-2022-thromboelastography-versus-standard-coagulation-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/perelman-2022-thromboelastography-versus-standard-coagulation-assays 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rigouzzo-2024-changing-hemostatic-management-post-partum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rigouzzo-2024-changing-hemostatic-management-post-partum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rigouzzo-2024-changing-hemostatic-management-post-partum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rigouzzo-2024-changing-hemostatic-management-post-partum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/katz-2023-viscoelastic-hemostatic-assays-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/katz-2023-viscoelastic-hemostatic-assays-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/katz-2023-viscoelastic-hemostatic-assays-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/katz-2023-viscoelastic-hemostatic-assays-postpartum-hemorrhage 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mootz-2024-postpartum-hemorrhage-assessment-targeted-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mootz-2024-postpartum-hemorrhage-assessment-targeted-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mootz-2024-postpartum-hemorrhage-assessment-targeted-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mootz-2024-postpartum-hemorrhage-assessment-targeted-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sumikura-2025-postpartum-hemorrhage-preventable-maternal-deaths 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sumikura-2025-postpartum-hemorrhage-preventable-maternal-deaths 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sumikura-2025-postpartum-hemorrhage-preventable-maternal-deaths 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sumikura-2025-postpartum-hemorrhage-preventable-maternal-deaths 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sharifi-2012-moderate-pulmonary-embolism-treated-thrombolysis-mopett 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sharifi-2012-moderate-pulmonary-embolism-treated-thrombolysis-mopett 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sharifi-2012-moderate-pulmonary-embolism-treated-thrombolysis-mopett 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sharifi-2012-moderate-pulmonary-embolism-treated-thrombolysis-mopett 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kucher-2013-randomized-controlled-ultrasound-assisted-catheter 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kucher-2013-randomized-controlled-ultrasound-assisted-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kucher-2013-randomized-controlled-ultrasound-assisted-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kucher-2013-randomized-controlled-ultrasound-assisted-catheter 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/engelberger-2014-ultrasound-assisted-thrombolysis-acute-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/engelberger-2014-ultrasound-assisted-thrombolysis-acute-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/engelberger-2014-ultrasound-assisted-thrombolysis-acute-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/engelberger-2014-ultrasound-assisted-thrombolysis-acute-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/konstantinides-2017-impact-thrombolytic-therapy-long-term-outcome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/konstantinides-2017-impact-thrombolytic-therapy-long-term-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/konstantinides-2017-impact-thrombolytic-therapy-long-term-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/konstantinides-2017-impact-thrombolytic-therapy-long-term-outcome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tapson-2018-randomized-optimum-duration-acoustic-pulse-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tapson-2018-randomized-optimum-duration-acoustic-pulse-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tapson-2018-randomized-optimum-duration-acoustic-pulse-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tapson-2018-randomized-optimum-duration-acoustic-pulse-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yilmaz-2021-low-dose-thrombolysis-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yilmaz-2021-low-dose-thrombolysis-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yilmaz-2021-low-dose-thrombolysis-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yilmaz-2021-low-dose-thrombolysis-submassive-pulmonary-embolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/avgerinos-2021-randomized-comparing-standard-versus-ultrasound 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/avgerinos-2021-randomized-comparing-standard-versus-ultrasound 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/avgerinos-2021-randomized-comparing-standard-versus-ultrasound 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/avgerinos-2021-randomized-comparing-standard-versus-ultrasound 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sanchez-2021-reduced-dose-intravenous-thrombolysis-acute-intermediate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sanchez-2021-reduced-dose-intravenous-thrombolysis-acute-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sanchez-2021-reduced-dose-intravenous-thrombolysis-acute-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sanchez-2021-reduced-dose-intravenous-thrombolysis-acute-intermediate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harvey-2022-catheter-directed-therapies-treatment-high-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harvey-2022-catheter-directed-therapies-treatment-high-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harvey-2022-catheter-directed-therapies-treatment-high-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harvey-2022-catheter-directed-therapies-treatment-high-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sadeghipour-2022-catheter-directed-thrombolysis-vs-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sadeghipour-2022-catheter-directed-thrombolysis-vs-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sadeghipour-2022-catheter-directed-thrombolysis-vs-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sadeghipour-2022-catheter-directed-thrombolysis-vs-anticoagulation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2023-comparative-efficacy-safety-thrombolytic-agents-pulmonary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2023-comparative-efficacy-safety-thrombolytic-agents-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2023-comparative-efficacy-safety-thrombolytic-agents-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2023-comparative-efficacy-safety-thrombolytic-agents-pulmonary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/upadhyay-2024-efficacy-safety-systemic-thrombolysis-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/upadhyay-2024-efficacy-safety-systemic-thrombolysis-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/upadhyay-2024-efficacy-safety-systemic-thrombolysis-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/upadhyay-2024-efficacy-safety-systemic-thrombolysis-catheter-directed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kj-2024-randomized-low-dose-thrombolysis-ultrasound-assisted 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kj-2024-randomized-low-dose-thrombolysis-ultrasound-assisted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kj-2024-randomized-low-dose-thrombolysis-ultrasound-assisted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kj-2024-randomized-low-dose-thrombolysis-ultrasound-assisted 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kjaergaard-2026-randomized-low-dose-ultrasound-assisted-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kjaergaard-2026-randomized-low-dose-ultrasound-assisted-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kjaergaard-2026-randomized-low-dose-ultrasound-assisted-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kjaergaard-2026-randomized-low-dose-ultrasound-assisted-thrombolysis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/haley-2017-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/haley-2017-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/haley-2017-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/haley-2017-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/young-2017-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/young-2017-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/young-2017-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/young-2017-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meier-2019-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meier-2019-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meier-2019-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meier-2019-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cunningham-2020-pediatric-trauma-venous-thromboembolism-prediction 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cunningham-2020-pediatric-trauma-venous-thromboembolism-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cunningham-2020-pediatric-trauma-venous-thromboembolism-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cunningham-2020-pediatric-trauma-venous-thromboembolism-prediction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/witmer-2020-treatment-venous-thromboembolism-pediatric-patients 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/witmer-2020-treatment-venous-thromboembolism-pediatric-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/witmer-2020-treatment-venous-thromboembolism-pediatric-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/witmer-2020-treatment-venous-thromboembolism-pediatric-patients 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/makatsariya-2020-neonatal-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/makatsariya-2020-neonatal-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/makatsariya-2020-neonatal-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/makatsariya-2020-neonatal-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/young-2020-rivaroxaban-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/young-2020-rivaroxaban-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/young-2020-rivaroxaban-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/young-2020-rivaroxaban-treatment-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goldenberg-2022-effect-anticoagulant-therapy-6-weeks-vs 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goldenberg-2022-effect-anticoagulant-therapy-6-weeks-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goldenberg-2022-effect-anticoagulant-therapy-6-weeks-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goldenberg-2022-effect-anticoagulant-therapy-6-weeks-vs 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/betensky-2022-recommendations-standardized-definitions-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/betensky-2022-recommendations-standardized-definitions-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/betensky-2022-recommendations-standardized-definitions-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/betensky-2022-recommendations-standardized-definitions-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whitworth-2023-updated-guidance-efficacy-safety-outcomes-clinical 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whitworth-2023-updated-guidance-efficacy-safety-outcomes-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whitworth-2023-updated-guidance-efficacy-safety-outcomes-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whitworth-2023-updated-guidance-efficacy-safety-outcomes-clinical 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bhat-2024-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bhat-2024-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bhat-2024-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bhat-2024-how-i-treat-pediatric-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/van-2024-anticoagulation-pediatric-patients-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/van-2024-anticoagulation-pediatric-patients-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/van-2024-anticoagulation-pediatric-patients-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/van-2024-anticoagulation-pediatric-patients-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beg-2024-short-term-outcome-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beg-2024-short-term-outcome-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beg-2024-short-term-outcome-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beg-2024-short-term-outcome-neonatal-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/shaw-2020-predictors-preprocedural-direct-oral-anticoagulant-levels 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/shaw-2020-predictors-preprocedural-direct-oral-anticoagulant-levels 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/shaw-2020-predictors-preprocedural-direct-oral-anticoagulant-levels 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/shaw-2020-predictors-preprocedural-direct-oral-anticoagulant-levels 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lefran-1990-hereditary-deficiency-antithrombin-iii-protein-c 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lefran-1990-hereditary-deficiency-antithrombin-iii-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lefran-1990-hereditary-deficiency-antithrombin-iii-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lefran-1990-hereditary-deficiency-antithrombin-iii-protein-c 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosenberg-1987-thrombosis-inherited-deficiencies-antithrombin-protein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosenberg-1987-thrombosis-inherited-deficiencies-antithrombin-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosenberg-1987-thrombosis-inherited-deficiencies-antithrombin-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosenberg-1987-thrombosis-inherited-deficiencies-antithrombin-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anderson-2011-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anderson-2011-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anderson-2011-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anderson-2011-hypercoagulable-states 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qi-2013-prevalence-inherited-antithrombin-protein-c-protein 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qi-2013-prevalence-inherited-antithrombin-protein-c-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qi-2013-prevalence-inherited-antithrombin-protein-c-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qi-2013-prevalence-inherited-antithrombin-protein-c-protein 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phillippe-2014-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phillippe-2014-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phillippe-2014-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phillippe-2014-inherited-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/de-2013-protein-c-deficiency 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/de-2013-protein-c-deficiency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/de-2013-protein-c-deficiency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/de-2013-protein-c-deficiency 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/croles-2017-pregnancy-thrombophilia-risk-first-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/croles-2017-pregnancy-thrombophilia-risk-first-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/croles-2017-pregnancy-thrombophilia-risk-first-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/croles-2017-pregnancy-thrombophilia-risk-first-venous-thrombosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/linnemann-2019-laboratory-diagnostics-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/linnemann-2019-laboratory-diagnostics-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/linnemann-2019-laboratory-diagnostics-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/linnemann-2019-laboratory-diagnostics-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vrtel-2022-detection-unknown-rare-pathogenic-variants-antithrombin 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vrtel-2022-detection-unknown-rare-pathogenic-variants-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vrtel-2022-detection-unknown-rare-pathogenic-variants-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vrtel-2022-detection-unknown-rare-pathogenic-variants-antithrombin 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kobayashi-2024-thrombosis-related-characteristics-pregnant-women 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kobayashi-2024-thrombosis-related-characteristics-pregnant-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kobayashi-2024-thrombosis-related-characteristics-pregnant-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kobayashi-2024-thrombosis-related-characteristics-pregnant-women 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/martin-1999-current-clinical-reteplase-thrombolysis-pharmacokinetic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/martin-1999-current-clinical-reteplase-thrombolysis-pharmacokinetic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/martin-1999-current-clinical-reteplase-thrombolysis-pharmacokinetic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/martin-1999-current-clinical-reteplase-thrombolysis-pharmacokinetic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/miller-1999-effectiveness-early-coronary-angioplasty-abciximab-failed 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/miller-1999-effectiveness-early-coronary-angioplasty-abciximab-failed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/miller-1999-effectiveness-early-coronary-angioplasty-abciximab-failed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/miller-1999-effectiveness-early-coronary-angioplasty-abciximab-failed 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zeymer-2000-thrombolysis-percutaneous-transluminal-coronary 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zeymer-2000-thrombolysis-percutaneous-transluminal-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zeymer-2000-thrombolysis-percutaneous-transluminal-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zeymer-2000-thrombolysis-percutaneous-transluminal-coronary 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hoffmeister-2000-fibrin-specificity-procoagulant-effect-related 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hoffmeister-2000-fibrin-specificity-procoagulant-effect-related 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hoffmeister-2000-fibrin-specificity-procoagulant-effect-related 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hoffmeister-2000-fibrin-specificity-procoagulant-effect-related 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antman-2000-combination-reperfusion-therapy-abciximab-reduced-dose 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antman-2000-combination-reperfusion-therapy-abciximab-reduced-dose 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antman-2000-combination-reperfusion-therapy-abciximab-reduced-dose 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antman-2000-combination-reperfusion-therapy-abciximab-reduced-dose 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rosenberg-2002-feasibility-timing-prehospital-administration 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rosenberg-2002-feasibility-timing-prehospital-administration 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rosenberg-2002-feasibility-timing-prehospital-administration 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rosenberg-2002-feasibility-timing-prehospital-administration 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/boland-2003-early-thrombolysis-treatment-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/boland-2003-early-thrombolysis-treatment-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/boland-2003-early-thrombolysis-treatment-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/boland-2003-early-thrombolysis-treatment-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/scheller-2003-beneficial-effects-immediate-stenting-thrombolysis-acute 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/scheller-2003-beneficial-effects-immediate-stenting-thrombolysis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/scheller-2003-beneficial-effects-immediate-stenting-thrombolysis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/scheller-2003-beneficial-effects-immediate-stenting-thrombolysis-acute 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/menon-2004-thrombolysis-adjunctive-therapy-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/menon-2004-thrombolysis-adjunctive-therapy-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/menon-2004-thrombolysis-adjunctive-therapy-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/menon-2004-thrombolysis-adjunctive-therapy-acute-myocardial-infarction 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/di-2004-combined-abciximab-reteplase-stent-acute-myocardial 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/di-2004-combined-abciximab-reteplase-stent-acute-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/di-2004-combined-abciximab-reteplase-stent-acute-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/di-2004-combined-abciximab-reteplase-stent-acute-myocardial 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2022-impact-intracoronary-reteplase-primary-percutaneous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2022-impact-intracoronary-reteplase-primary-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2022-impact-intracoronary-reteplase-primary-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2022-impact-intracoronary-reteplase-primary-percutaneous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mohamed-2025-tenecteplase-vs-reteplase-patients-acute-st 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mohamed-2025-tenecteplase-vs-reteplase-patients-acute-st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mohamed-2025-tenecteplase-vs-reteplase-patients-acute-st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mohamed-2025-tenecteplase-vs-reteplase-patients-acute-st 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/campbell-2018-tenecteplase-versus-alteplase-thrombectomy-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/campbell-2018-tenecteplase-versus-alteplase-thrombectomy-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/campbell-2018-tenecteplase-versus-alteplase-thrombectomy-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/campbell-2018-tenecteplase-versus-alteplase-thrombectomy-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warach-2020-tenecteplase-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warach-2020-tenecteplase-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warach-2020-tenecteplase-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warach-2020-tenecteplase-thrombolysis-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/berge-2021-european-stroke-organisation-eso-guidelines-intravenous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/berge-2021-european-stroke-organisation-eso-guidelines-intravenous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/berge-2021-european-stroke-organisation-eso-guidelines-intravenous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/berge-2021-european-stroke-organisation-eso-guidelines-intravenous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xiong-2022-advances-acute-ischemic-stroke-therapy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xiong-2022-advances-acute-ischemic-stroke-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xiong-2022-advances-acute-ischemic-stroke-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xiong-2022-advances-acute-ischemic-stroke-therapy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/menon-2022-intravenous-tenecteplase-compared-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/menon-2022-intravenous-tenecteplase-compared-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/menon-2022-intravenous-tenecteplase-compared-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/menon-2022-intravenous-tenecteplase-compared-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zhu-2022-alteplase-tenecteplase-thrombolysis-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zhu-2022-alteplase-tenecteplase-thrombolysis-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zhu-2022-alteplase-tenecteplase-thrombolysis-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zhu-2022-alteplase-tenecteplase-thrombolysis-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-2023-tenecteplase-versus-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-2023-tenecteplase-versus-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-2023-tenecteplase-versus-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-2023-tenecteplase-versus-alteplase-acute-ischaemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tsivgoulis-2023-thrombolysis-acute-ischaemic-stroke-current-status 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tsivgoulis-2023-thrombolysis-acute-ischaemic-stroke-current-status 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tsivgoulis-2023-thrombolysis-acute-ischaemic-stroke-current-status 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tsivgoulis-2023-thrombolysis-acute-ischaemic-stroke-current-status 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/claren-2023-evaluation-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/claren-2023-evaluation-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/claren-2023-evaluation-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/claren-2023-evaluation-mechanical-thrombectomy-acute-ischemic-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wang-2024-comprehensive-tenecteplase-thrombolysis-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wang-2024-comprehensive-tenecteplase-thrombolysis-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wang-2024-comprehensive-tenecteplase-thrombolysis-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wang-2024-comprehensive-tenecteplase-thrombolysis-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meng-2024-tenecteplase-vs-alteplase-patients-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meng-2024-tenecteplase-vs-alteplase-patients-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meng-2024-tenecteplase-vs-alteplase-patients-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meng-2024-tenecteplase-vs-alteplase-patients-acute-ischemic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/muir-2024-tenecteplase-versus-alteplase-acute-stroke-4 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/muir-2024-tenecteplase-versus-alteplase-acute-stroke-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/muir-2024-tenecteplase-versus-alteplase-acute-stroke-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/muir-2024-tenecteplase-versus-alteplase-acute-stroke-4 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/huang-2025-intra-arterial-tenecteplase-following-endovascular 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/huang-2025-intra-arterial-tenecteplase-following-endovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/huang-2025-intra-arterial-tenecteplase-following-endovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/huang-2025-intra-arterial-tenecteplase-following-endovascular 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/g-2025-thrombolysis-ischemic-stroke-beyond-4-5 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/g-2025-thrombolysis-ischemic-stroke-beyond-4-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/g-2025-thrombolysis-ischemic-stroke-beyond-4-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/g-2025-thrombolysis-ischemic-stroke-beyond-4-5 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qiu-2025-intravenous-tenecteplase-thrombectomy-stroke 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qiu-2025-intravenous-tenecteplase-thrombectomy-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qiu-2025-intravenous-tenecteplase-thrombectomy-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qiu-2025-intravenous-tenecteplase-thrombectomy-stroke 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/connor-2005-factor-v-leiden-effect-children-cardiac 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/connor-2005-factor-v-leiden-effect-children-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/connor-2005-factor-v-leiden-effect-children-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/connor-2005-factor-v-leiden-effect-children-cardiac 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/franchini-2011-factor-v-leiden-women-thrombotic-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/franchini-2011-factor-v-leiden-women-thrombotic-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/franchini-2011-factor-v-leiden-women-thrombotic-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/franchini-2011-factor-v-leiden-women-thrombotic-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/blanco-2012-oral-contraception-women-mild-thrombophilia-what 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/blanco-2012-oral-contraception-women-mild-thrombophilia-what 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/blanco-2012-oral-contraception-women-mild-thrombophilia-what 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/blanco-2012-oral-contraception-women-mild-thrombophilia-what 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/erickson-2013-factor-v-leiden-thrombophilia-female-collegiate 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/erickson-2013-factor-v-leiden-thrombophilia-female-collegiate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/erickson-2013-factor-v-leiden-thrombophilia-female-collegiate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/erickson-2013-factor-v-leiden-thrombophilia-female-collegiate 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xin-2013-prevalence-factor-v-e666d-mutation-correlation 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xin-2013-prevalence-factor-v-e666d-mutation-correlation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xin-2013-prevalence-factor-v-e666d-mutation-correlation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xin-2013-prevalence-factor-v-e666d-mutation-correlation 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/kovac-2015-factor-v-leiden-mutation-high-fviii 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/kovac-2015-factor-v-leiden-mutation-high-fviii 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/kovac-2015-factor-v-leiden-mutation-high-fviii 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/kovac-2015-factor-v-leiden-mutation-high-fviii 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tzoran-2016-outcome-patients-venous-thromboembolism-factor-v 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tzoran-2016-outcome-patients-venous-thromboembolism-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tzoran-2016-outcome-patients-venous-thromboembolism-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tzoran-2016-outcome-patients-venous-thromboembolism-factor-v 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gupta-2018-pediatric-thrombotic-events-incidence-clinical-risk 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gupta-2018-pediatric-thrombotic-events-incidence-clinical-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gupta-2018-pediatric-thrombotic-events-incidence-clinical-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gupta-2018-pediatric-thrombotic-events-incidence-clinical-risk 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dautaj-2019-hereditary-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dautaj-2019-hereditary-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dautaj-2019-hereditary-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dautaj-2019-hereditary-thrombophilia 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/z-2020-genetic-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/z-2020-genetic-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/z-2020-genetic-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/z-2020-genetic-risk-factors-venous-thromboembolism 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/goljan-2021-40-year-old-man-sarcoidosis-factor 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/goljan-2021-40-year-old-man-sarcoidosis-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/goljan-2021-40-year-old-man-sarcoidosis-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/goljan-2021-40-year-old-man-sarcoidosis-factor 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/xie-2022-clinical-genetic-risk-factors-acute-incident 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/xie-2022-clinical-genetic-risk-factors-acute-incident 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/xie-2022-clinical-genetic-risk-factors-acute-incident 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/xie-2022-clinical-genetic-risk-factors-acute-incident 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/godier-2013-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/godier-2013-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/godier-2013-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/godier-2013-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gonzalez-2014-trauma-induced-coagulopathy-institution-s-35 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gonzalez-2014-trauma-induced-coagulopathy-institution-s-35 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gonzalez-2014-trauma-induced-coagulopathy-institution-s-35 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gonzalez-2014-trauma-induced-coagulopathy-institution-s-35 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/simmons-2014-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/simmons-2014-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/simmons-2014-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/simmons-2014-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phillips-2017-hemostatic-management-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phillips-2017-hemostatic-management-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phillips-2017-hemostatic-management-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phillips-2017-hemostatic-management-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vernon-2019-bad-blood-coagulopathy-associated-trauma-massive 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vernon-2019-bad-blood-coagulopathy-associated-trauma-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vernon-2019-bad-blood-coagulopathy-associated-trauma-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vernon-2019-bad-blood-coagulopathy-associated-trauma-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/maegele-2020-challenges-improving-patient-outcome-following-massive 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/maegele-2020-challenges-improving-patient-outcome-following-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/maegele-2020-challenges-improving-patient-outcome-following-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/maegele-2020-challenges-improving-patient-outcome-following-massive 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gratz-2020-trauma-induced-coagulopathy-massive-bleeding-current 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gratz-2020-trauma-induced-coagulopathy-massive-bleeding-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gratz-2020-trauma-induced-coagulopathy-massive-bleeding-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gratz-2020-trauma-induced-coagulopathy-massive-bleeding-current 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ho-2022-trauma-induced-coagulopathy-mechanisms-clinical-management 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ho-2022-trauma-induced-coagulopathy-mechanisms-clinical-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ho-2022-trauma-induced-coagulopathy-mechanisms-clinical-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ho-2022-trauma-induced-coagulopathy-mechanisms-clinical-management 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/meizoso-2022-fibrinogen-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/meizoso-2022-fibrinogen-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/meizoso-2022-fibrinogen-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/meizoso-2022-fibrinogen-trauma-induced-coagulopathy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lier-2024-massive-transfusion-trauma 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lier-2024-massive-transfusion-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lier-2024-massive-transfusion-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lier-2024-massive-transfusion-trauma 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dhillon-2024-fluid-resuscitation-trauma-what-you-need 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dhillon-2024-fluid-resuscitation-trauma-what-you-need 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dhillon-2024-fluid-resuscitation-trauma-what-you-need 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dhillon-2024-fluid-resuscitation-trauma-what-you-need 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hutspardol-2025-comparison-conventional-coagulation-tests-rotem 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hutspardol-2025-comparison-conventional-coagulation-tests-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hutspardol-2025-comparison-conventional-coagulation-tests-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hutspardol-2025-comparison-conventional-coagulation-tests-rotem 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schleimer-2016-treatment-post-thrombotic-syndrome 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schleimer-2016-treatment-post-thrombotic-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schleimer-2016-treatment-post-thrombotic-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schleimer-2016-treatment-post-thrombotic-syndrome 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/milinis-2018-antithrombotic-therapy-following-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/milinis-2018-antithrombotic-therapy-following-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/milinis-2018-antithrombotic-therapy-following-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/milinis-2018-antithrombotic-therapy-following-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/qiu-2018-systematic-meta-iliofemoral-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/qiu-2018-systematic-meta-iliofemoral-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/qiu-2018-systematic-meta-iliofemoral-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/qiu-2018-systematic-meta-iliofemoral-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/moini-2019-venoplasty-stenting-post-thrombotic-syndrome-non 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/moini-2019-venoplasty-stenting-post-thrombotic-syndrome-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/moini-2019-venoplasty-stenting-post-thrombotic-syndrome-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/moini-2019-venoplasty-stenting-post-thrombotic-syndrome-non 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/yap-2020-anticoagulation-therapy-post-deep-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/yap-2020-anticoagulation-therapy-post-deep-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/yap-2020-anticoagulation-therapy-post-deep-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/yap-2020-anticoagulation-therapy-post-deep-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ferreira-2021-mid-term-patency-iliac-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ferreira-2021-mid-term-patency-iliac-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ferreira-2021-mid-term-patency-iliac-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ferreira-2021-mid-term-patency-iliac-venous-stenting 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/schlager-2022-closure-post-thrombotic-iliac-arteriovenous-fistulas 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/schlager-2022-closure-post-thrombotic-iliac-arteriovenous-fistulas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/schlager-2022-closure-post-thrombotic-iliac-arteriovenous-fistulas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/schlager-2022-closure-post-thrombotic-iliac-arteriovenous-fistulas 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/villalba-2023-iliac-vein-stenting-pregnancy 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/villalba-2023-iliac-vein-stenting-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/villalba-2023-iliac-vein-stenting-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/villalba-2023-iliac-vein-stenting-pregnancy 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bakas-2023-quality-life-venous-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bakas-2023-quality-life-venous-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bakas-2023-quality-life-venous-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bakas-2023-quality-life-venous-stenting-post-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sebastian-2024-topos 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sebastian-2024-topos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sebastian-2024-topos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sebastian-2024-topos 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barbati-2024-interventional-treatment-post-thrombotic-chronic-venous 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barbati-2024-interventional-treatment-post-thrombotic-chronic-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barbati-2024-interventional-treatment-post-thrombotic-chronic-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barbati-2024-interventional-treatment-post-thrombotic-chronic-venous 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/barco-2025-aspirin-plus-rivaroxaban-versus-rivaroxaban-alone 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/barco-2025-aspirin-plus-rivaroxaban-versus-rivaroxaban-alone 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/barco-2025-aspirin-plus-rivaroxaban-versus-rivaroxaban-alone 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/barco-2025-aspirin-plus-rivaroxaban-versus-rivaroxaban-alone 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/li-2025-iliac-vein-stenting-outcomes-non-thrombotic 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/li-2025-iliac-vein-stenting-outcomes-non-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/li-2025-iliac-vein-stenting-outcomes-non-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/li-2025-iliac-vein-stenting-outcomes-non-thrombotic 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/perry-1990-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/perry-1990-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/perry-1990-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/perry-1990-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/zimmerman-1987-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/zimmerman-1987-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/zimmerman-1987-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/zimmerman-1987-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/james-2011-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/james-2011-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/james-2011-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/james-2011-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cooper-2014-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cooper-2014-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cooper-2014-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cooper-2014-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/leebeek-2016-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/leebeek-2016-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/leebeek-2016-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/leebeek-2016-von-willebrand-s-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/castaman-2017-diagnosis-treatment-von-willebrand-disease-rare 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/castaman-2017-diagnosis-treatment-von-willebrand-disease-rare 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/castaman-2017-diagnosis-treatment-von-willebrand-disease-rare 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/castaman-2017-diagnosis-treatment-von-willebrand-disease-rare 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/calmette-2018-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/calmette-2018-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/calmette-2018-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/calmette-2018-von-willebrand-disease 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laffan-2020-von-willebrand-disease-diagnosis-treatment-treatment 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laffan-2020-von-willebrand-disease-diagnosis-treatment-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laffan-2020-von-willebrand-disease-diagnosis-treatment-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laffan-2020-von-willebrand-disease-diagnosis-treatment-treatment 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/weyand-2021-von-willebrand-disease-current-status-diagnosis 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/weyand-2021-von-willebrand-disease-current-status-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/weyand-2021-von-willebrand-disease-current-status-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/weyand-2021-von-willebrand-disease-current-status-diagnosis 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pacheco-2023-von-willebrand-disease-hemophilia-other-inherited 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pacheco-2023-von-willebrand-disease-hemophilia-other-inherited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pacheco-2023-von-willebrand-disease-hemophilia-other-inherited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pacheco-2023-von-willebrand-disease-hemophilia-other-inherited 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/daniel-2024-type-2n-von-willebrand-disease-genotype 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/daniel-2024-type-2n-von-willebrand-disease-genotype 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/daniel-2024-type-2n-von-willebrand-disease-genotype 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/daniel-2024-type-2n-von-willebrand-disease-genotype 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/functional-properties-of-a-recombinant-chimeric-zhang-2004 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/functional-properties-of-a-recombinant-chimeric-zhang-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/functional-properties-of-a-recombinant-chimeric-zhang-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/functional-properties-of-a-recombinant-chimeric-zhang-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-design-and-characterization-of-recombinant-bai-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-design-and-characterization-of-recombinant-bai-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-design-and-characterization-of-recombinant-bai-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-design-and-characterization-of-recombinant-bai-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/chemical-synthesis-of-the-rgd-protein-frare-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/chemical-synthesis-of-the-rgd-protein-frare-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/chemical-synthesis-of-the-rgd-protein-frare-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/chemical-synthesis-of-the-rgd-protein-frare-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/three-dimensional-culture-of-leech-and-babington-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/three-dimensional-culture-of-leech-and-babington-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/three-dimensional-culture-of-leech-and-babington-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/three-dimensional-culture-of-leech-and-babington-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/selective-factor-xa-inhibition-by-recombinant-schaffer-1992 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/selective-factor-xa-inhibition-by-recombinant-schaffer-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/selective-factor-xa-inhibition-by-recombinant-schaffer-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/selective-factor-xa-inhibition-by-recombinant-schaffer-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulant-efficacy-and-immunogenicity-of-the-dunwiddie-1992 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulant-efficacy-and-immunogenicity-of-the-dunwiddie-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulant-efficacy-and-immunogenicity-of-the-dunwiddie-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulant-efficacy-and-immunogenicity-of-the-dunwiddie-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-region-of-the-thrombin-receptor-liu-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-region-of-the-thrombin-receptor-liu-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-region-of-the-thrombin-receptor-liu-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-region-of-the-thrombin-receptor-liu-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mechanism-of-thrombosis-physiopathology-role-of-hamon-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mechanism-of-thrombosis-physiopathology-role-of-hamon-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mechanism-of-thrombosis-physiopathology-role-of-hamon-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mechanism-of-thrombosis-physiopathology-role-of-hamon-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/emerging-anticoagulants-mechanism-of-action-and-klement-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/emerging-anticoagulants-mechanism-of-action-and-klement-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/emerging-anticoagulants-mechanism-of-action-and-klement-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/emerging-anticoagulants-mechanism-of-action-and-klement-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/promotion-of-proinflammatory-interactions-between-platelets-harding-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/promotion-of-proinflammatory-interactions-between-platelets-harding-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/promotion-of-proinflammatory-interactions-between-platelets-harding-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/promotion-of-proinflammatory-interactions-between-platelets-harding-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/preparation-of-monoclonal-antibodies-to-hirudin-schlaeppi-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/preparation-of-monoclonal-antibodies-to-hirudin-schlaeppi-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/preparation-of-monoclonal-antibodies-to-hirudin-schlaeppi-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/preparation-of-monoclonal-antibodies-to-hirudin-schlaeppi-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/expression-of-surface-glycoproteins-early-in-mcglade-mcculloh-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/expression-of-surface-glycoproteins-early-in-mcglade-mcculloh-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/expression-of-surface-glycoproteins-early-in-mcglade-mcculloh-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/expression-of-surface-glycoproteins-early-in-mcglade-mcculloh-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/effects-of-unfractionated-heparin-and-glycoprotein-li-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/effects-of-unfractionated-heparin-and-glycoprotein-li-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/effects-of-unfractionated-heparin-and-glycoprotein-li-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/effects-of-unfractionated-heparin-and-glycoprotein-li-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-antithrombins-mechanisms-trials-and-role-wong-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-antithrombins-mechanisms-trials-and-role-wong-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-antithrombins-mechanisms-trials-and-role-wong-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-antithrombins-mechanisms-trials-and-role-wong-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hirudin-and-platelets-glusa-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hirudin-and-platelets-glusa-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hirudin-and-platelets-glusa-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hirudin-and-platelets-glusa-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/toxicology-of-hirudin-kl-xf6-cking-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/toxicology-of-hirudin-kl-xf6-cking-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/toxicology-of-hirudin-kl-xf6-cking-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/toxicology-of-hirudin-kl-xf6-cking-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-of-thrombin-inhibitor-from-the-electricwala-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-of-thrombin-inhibitor-from-the-electricwala-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-of-thrombin-inhibitor-from-the-electricwala-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-of-thrombin-inhibitor-from-the-electricwala-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-novel-allosteric-pathway-of-thrombin-henry-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-novel-allosteric-pathway-of-thrombin-henry-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-novel-allosteric-pathway-of-thrombin-henry-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-novel-allosteric-pathway-of-thrombin-henry-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/physicians-and-leeches-and-traces-in-naess-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/physicians-and-leeches-and-traces-in-naess-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/physicians-and-leeches-and-traces-in-naess-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/physicians-and-leeches-and-traces-in-naess-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/atypical-embryonic-synapses-fail-to-regenerate-kloos-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/atypical-embryonic-synapses-fail-to-regenerate-kloos-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/atypical-embryonic-synapses-fail-to-regenerate-kloos-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/atypical-embryonic-synapses-fail-to-regenerate-kloos-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-of-a-human-coagulation-factor-faure-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-of-a-human-coagulation-factor-faure-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-of-a-human-coagulation-factor-faure-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-of-a-human-coagulation-factor-faure-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/computational-study-of-the-putative-active-chandrasekaran-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/computational-study-of-the-putative-active-chandrasekaran-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/computational-study-of-the-putative-active-chandrasekaran-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/computational-study-of-the-putative-active-chandrasekaran-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fragment-based-approach-to-drug-lead-fattori-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fragment-based-approach-to-drug-lead-fattori-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fragment-based-approach-to-drug-lead-fattori-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fragment-based-approach-to-drug-lead-fattori-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-dimer-of-fragment-d-from-zavalova-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-dimer-of-fragment-d-from-zavalova-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-dimer-of-fragment-d-from-zavalova-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-dimer-of-fragment-d-from-zavalova-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-decreases-no-bioavailability-by-vascular-rudolph-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-decreases-no-bioavailability-by-vascular-rudolph-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-decreases-no-bioavailability-by-vascular-rudolph-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-decreases-no-bioavailability-by-vascular-rudolph-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/on-designing-non-saccharide-allosteric-activators-raghuraman-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/on-designing-non-saccharide-allosteric-activators-raghuraman-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/on-designing-non-saccharide-allosteric-activators-raghuraman-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/on-designing-non-saccharide-allosteric-activators-raghuraman-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hirudin-and-nitrates-inhibit-the-thrombin-boulanger-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hirudin-and-nitrates-inhibit-the-thrombin-boulanger-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hirudin-and-nitrates-inhibit-the-thrombin-boulanger-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hirudin-and-nitrates-inhibit-the-thrombin-boulanger-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/transcriptomic-analysis-of-the-entomopathogenic-nematode-bai-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/transcriptomic-analysis-of-the-entomopathogenic-nematode-bai-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/transcriptomic-analysis-of-the-entomopathogenic-nematode-bai-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/transcriptomic-analysis-of-the-entomopathogenic-nematode-bai-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/use-of-scanning-ion-conductance-microscopy-pellegrino-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/use-of-scanning-ion-conductance-microscopy-pellegrino-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/use-of-scanning-ion-conductance-microscopy-pellegrino-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/use-of-scanning-ion-conductance-microscopy-pellegrino-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-of-an-i-type-lysozyme-cong-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-of-an-i-type-lysozyme-cong-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-of-an-i-type-lysozyme-cong-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-of-an-i-type-lysozyme-cong-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sulfated-low-molecular-weight-lignins-inhibit-henry-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sulfated-low-molecular-weight-lignins-inhibit-henry-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sulfated-low-molecular-weight-lignins-inhibit-henry-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sulfated-low-molecular-weight-lignins-inhibit-henry-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/effect-of-recombinant-hirudin-a-specific-hoffmann-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/effect-of-recombinant-hirudin-a-specific-hoffmann-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/effect-of-recombinant-hirudin-a-specific-hoffmann-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/effect-of-recombinant-hirudin-a-specific-hoffmann-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/production-properties-and-thrombin-inhibitory-mechanism-chang-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/production-properties-and-thrombin-inhibitory-mechanism-chang-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/production-properties-and-thrombin-inhibitory-mechanism-chang-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/production-properties-and-thrombin-inhibitory-mechanism-chang-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/potent-direct-inhibitors-of-factor-xa-al-horani-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/potent-direct-inhibitors-of-factor-xa-al-horani-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/potent-direct-inhibitors-of-factor-xa-al-horani-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/potent-direct-inhibitors-of-factor-xa-al-horani-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antiplatelet-and-antithrombin-strategies-in-acute-showkathali-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antiplatelet-and-antithrombin-strategies-in-acute-showkathali-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antiplatelet-and-antithrombin-strategies-in-acute-showkathali-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antiplatelet-and-antithrombin-strategies-in-acute-showkathali-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/involvement-of-nitric-oxide-through-endocannabinoids-arafah-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/involvement-of-nitric-oxide-through-endocannabinoids-arafah-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/involvement-of-nitric-oxide-through-endocannabinoids-arafah-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/involvement-of-nitric-oxide-through-endocannabinoids-arafah-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-thrombin-and-platelets-clinical-implications-becker-2003 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-thrombin-and-platelets-clinical-implications-becker-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-thrombin-and-platelets-clinical-implications-becker-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-thrombin-and-platelets-clinical-implications-becker-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/age-dependent-expression-of-stress-and-husmann-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/age-dependent-expression-of-stress-and-husmann-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/age-dependent-expression-of-stress-and-husmann-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/age-dependent-expression-of-stress-and-husmann-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-cooh-terminal-domain-of-hirudin-naski-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-cooh-terminal-domain-of-hirudin-naski-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-cooh-terminal-domain-of-hirudin-naski-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-cooh-terminal-domain-of-hirudin-naski-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fusion-of-the-c-terminal-triskaidecapeptide-roddick-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fusion-of-the-c-terminal-triskaidecapeptide-roddick-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fusion-of-the-c-terminal-triskaidecapeptide-roddick-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fusion-of-the-c-terminal-triskaidecapeptide-roddick-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/polyphenol-compounds-belonging-to-flavonoids-inhibit-bijak-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/polyphenol-compounds-belonging-to-flavonoids-inhibit-bijak-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/polyphenol-compounds-belonging-to-flavonoids-inhibit-bijak-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/polyphenol-compounds-belonging-to-flavonoids-inhibit-bijak-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-novel-toll-like-receptor-with-ren-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-novel-toll-like-receptor-with-ren-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-novel-toll-like-receptor-with-ren-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-novel-toll-like-receptor-with-ren-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/differences-in-the-gene-expression-profiles-zahoor-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/differences-in-the-gene-expression-profiles-zahoor-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/differences-in-the-gene-expression-profiles-zahoor-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/differences-in-the-gene-expression-profiles-zahoor-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/designing-allosteric-inhibitors-of-factor-xia-al-horani-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/designing-allosteric-inhibitors-of-factor-xia-al-horani-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/designing-allosteric-inhibitors-of-factor-xia-al-horani-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/designing-allosteric-inhibitors-of-factor-xia-al-horani-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sulfated-low-molecular-weight-lignins-allosteric-henry-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sulfated-low-molecular-weight-lignins-allosteric-henry-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sulfated-low-molecular-weight-lignins-allosteric-henry-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sulfated-low-molecular-weight-lignins-allosteric-henry-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-simple-general-approach-of-allosteric-sidhu-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-simple-general-approach-of-allosteric-sidhu-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-simple-general-approach-of-allosteric-sidhu-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-simple-general-approach-of-allosteric-sidhu-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/multiple-inhibitory-kinetics-reveal-an-allosteric-zavyalova-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/multiple-inhibitory-kinetics-reveal-an-allosteric-zavyalova-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/multiple-inhibitory-kinetics-reveal-an-allosteric-zavyalova-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/multiple-inhibitory-kinetics-reveal-an-allosteric-zavyalova-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/plasmin-regulation-through-allosteric-sulfated-small-al-horani-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/plasmin-regulation-through-allosteric-sulfated-small-al-horani-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/plasmin-regulation-through-allosteric-sulfated-small-al-horani-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/plasmin-regulation-through-allosteric-sulfated-small-al-horani-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparing-sixteen-scoring-functions-for-predicting-xu-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparing-sixteen-scoring-functions-for-predicting-xu-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparing-sixteen-scoring-functions-for-predicting-xu-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparing-sixteen-scoring-functions-for-predicting-xu-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hm-myd88-and-hm-sarm-two-rodet-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hm-myd88-and-hm-sarm-two-rodet-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hm-myd88-and-hm-sarm-two-rodet-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hm-myd88-and-hm-sarm-two-rodet-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/contribution-of-the-n-terminal-region-wallace-1989 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/contribution-of-the-n-terminal-region-wallace-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/contribution-of-the-n-terminal-region-wallace-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/contribution-of-the-n-terminal-region-wallace-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/factor-v-leiden-van-cott-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/factor-v-leiden-van-cott-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/factor-v-leiden-van-cott-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/factor-v-leiden-van-cott-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/active-versus-passive-anchoring-vascular-closure-baker-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/active-versus-passive-anchoring-vascular-closure-baker-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/active-versus-passive-anchoring-vascular-closure-baker-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/active-versus-passive-anchoring-vascular-closure-baker-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-mitogenomics-of-leeches-annelida-clitellata-oceguera-figueroa-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-mitogenomics-of-leeches-annelida-clitellata-oceguera-figueroa-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-mitogenomics-of-leeches-annelida-clitellata-oceguera-figueroa-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-mitogenomics-of-leeches-annelida-clitellata-oceguera-figueroa-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/g-quadruplex-aptamers-to-human-thrombin-zavyalova-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/g-quadruplex-aptamers-to-human-thrombin-zavyalova-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/g-quadruplex-aptamers-to-human-thrombin-zavyalova-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/g-quadruplex-aptamers-to-human-thrombin-zavyalova-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antistasin-an-inhibitor-of-coagulation-and-holt-1989 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antistasin-an-inhibitor-of-coagulation-and-holt-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antistasin-an-inhibitor-of-coagulation-and-holt-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antistasin-an-inhibitor-of-coagulation-and-holt-1989 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allosteric-inhibition-of-factor-xiiia-non-al-horani-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allosteric-inhibition-of-factor-xiiia-non-al-horani-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allosteric-inhibition-of-factor-xiiia-non-al-horani-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allosteric-inhibition-of-factor-xiiia-non-al-horani-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/structural-and-functional-aspects-of-decorsin-lao-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/structural-and-functional-aspects-of-decorsin-lao-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/structural-and-functional-aspects-of-decorsin-lao-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/structural-and-functional-aspects-of-decorsin-lao-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-thrombin-inhibitor-resistance-and-possible-cardinale-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-thrombin-inhibitor-resistance-and-possible-cardinale-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-thrombin-inhibitor-resistance-and-possible-cardinale-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-thrombin-inhibitor-resistance-and-possible-cardinale-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mechanically-oriented-3d-collagen-hydrogel-for-antman-passig-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mechanically-oriented-3d-collagen-hydrogel-for-antman-passig-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mechanically-oriented-3d-collagen-hydrogel-for-antman-passig-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mechanically-oriented-3d-collagen-hydrogel-for-antman-passig-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/recent-advances-in-the-discovery-and-al-horani-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/recent-advances-in-the-discovery-and-al-horani-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/recent-advances-in-the-discovery-and-al-horani-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/recent-advances-in-the-discovery-and-al-horani-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antiplatelet-and-anticoagulant-activities-of-two-fatah-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antiplatelet-and-anticoagulant-activities-of-two-fatah-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antiplatelet-and-anticoagulant-activities-of-two-fatah-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antiplatelet-and-anticoagulant-activities-of-two-fatah-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tranexamic-acid-blocks-the-thrombin-mediated-nakanishi-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tranexamic-acid-blocks-the-thrombin-mediated-nakanishi-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tranexamic-acid-blocks-the-thrombin-mediated-nakanishi-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tranexamic-acid-blocks-the-thrombin-mediated-nakanishi-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-cloning-and-functional-characterization-of-huang-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-cloning-and-functional-characterization-of-huang-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-cloning-and-functional-characterization-of-huang-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-cloning-and-functional-characterization-of-huang-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-use-of-the-specific-thrombin-walsmann-1988 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-use-of-the-specific-thrombin-walsmann-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-use-of-the-specific-thrombin-walsmann-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-use-of-the-specific-thrombin-walsmann-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/enhanced-potency-of-prasugrel-on-protease-kimmelstiel-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/enhanced-potency-of-prasugrel-on-protease-kimmelstiel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/enhanced-potency-of-prasugrel-on-protease-kimmelstiel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/enhanced-potency-of-prasugrel-on-protease-kimmelstiel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crystal-structures-of-the-recombinant-factor-pathak-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crystal-structures-of-the-recombinant-factor-pathak-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crystal-structures-of-the-recombinant-factor-pathak-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crystal-structures-of-the-recombinant-factor-pathak-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulant-decapeptide-interacts-with-thrombin-at-liu-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulant-decapeptide-interacts-with-thrombin-at-liu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulant-decapeptide-interacts-with-thrombin-at-liu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulant-decapeptide-interacts-with-thrombin-at-liu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/impact-of-posttranslational-modifications-on-atomistic-sovov-xe1-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/impact-of-posttranslational-modifications-on-atomistic-sovov-xe1-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/impact-of-posttranslational-modifications-on-atomistic-sovov-xe1-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/impact-of-posttranslational-modifications-on-atomistic-sovov-xe1-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/interaction-of-hirudin-with-thrombin-identification-mao-1988 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/interaction-of-hirudin-with-thrombin-identification-mao-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/interaction-of-hirudin-with-thrombin-identification-mao-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/interaction-of-hirudin-with-thrombin-identification-mao-1988 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-leech-or-hirudo-medicinalis-zandbergen-1987 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-leech-or-hirudo-medicinalis-zandbergen-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-leech-or-hirudo-medicinalis-zandbergen-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-leech-or-hirudo-medicinalis-zandbergen-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-of-a-novel-toll-like-yin-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-of-a-novel-toll-like-yin-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-of-a-novel-toll-like-yin-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-of-a-novel-toll-like-yin-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/two-nf-b-subunits-are-associated-zhu-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/two-nf-b-subunits-are-associated-zhu-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/two-nf-b-subunits-are-associated-zhu-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/two-nf-b-subunits-are-associated-zhu-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombin-cleaves-il-33-and-modulates-huang-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombin-cleaves-il-33-and-modulates-huang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombin-cleaves-il-33-and-modulates-huang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombin-cleaves-il-33-and-modulates-huang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/screening-of-the-promising-direct-thrombin-kostromina-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/screening-of-the-promising-direct-thrombin-kostromina-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/screening-of-the-promising-direct-thrombin-kostromina-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/screening-of-the-promising-direct-thrombin-kostromina-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rna-seq-transcriptome-analysis-and-identification-amparyup-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rna-seq-transcriptome-analysis-and-identification-amparyup-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rna-seq-transcriptome-analysis-and-identification-amparyup-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rna-seq-transcriptome-analysis-and-identification-amparyup-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/arrestin-interacts-with-traf6-to-negatively-jian-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/arrestin-interacts-with-traf6-to-negatively-jian-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/arrestin-interacts-with-traf6-to-negatively-jian-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/arrestin-interacts-with-traf6-to-negatively-jian-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rapid-purification-and-revised-amino-terminal-mao-1987 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rapid-purification-and-revised-amino-terminal-mao-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rapid-purification-and-revised-amino-terminal-mao-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rapid-purification-and-revised-amino-terminal-mao-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/regeneration-of-afferent-axons-into-discrete-peinado-1987 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/regeneration-of-afferent-axons-into-discrete-peinado-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/regeneration-of-afferent-axons-into-discrete-peinado-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/regeneration-of-afferent-axons-into-discrete-peinado-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/proline-rich-region-ii-prr2-plays-murray-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/proline-rich-region-ii-prr2-plays-murray-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/proline-rich-region-ii-prr2-plays-murray-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/proline-rich-region-ii-prr2-plays-murray-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-complete-mitochondrial-genome-of-annelida-zhu-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-complete-mitochondrial-genome-of-annelida-zhu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-complete-mitochondrial-genome-of-annelida-zhu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-complete-mitochondrial-genome-of-annelida-zhu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alpha-thrombin-induced-pulmonary-vasoconstriction-horgan-1987 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alpha-thrombin-induced-pulmonary-vasoconstriction-horgan-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alpha-thrombin-induced-pulmonary-vasoconstriction-horgan-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alpha-thrombin-induced-pulmonary-vasoconstriction-horgan-1987 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/in-silico-and-in-vitro-evaluation-hassan-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/in-silico-and-in-vitro-evaluation-hassan-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/in-silico-and-in-vitro-evaluation-hassan-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/in-silico-and-in-vitro-evaluation-hassan-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-hydrogel-coatings-of-polyvinyl-chloride-gao-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-hydrogel-coatings-of-polyvinyl-chloride-gao-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-hydrogel-coatings-of-polyvinyl-chloride-gao-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-hydrogel-coatings-of-polyvinyl-chloride-gao-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/diterpenes-isolated-from-three-differentspecies-and-g-xe1-borov-xe1-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/diterpenes-isolated-from-three-differentspecies-and-g-xe1-borov-xe1-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/diterpenes-isolated-from-three-differentspecies-and-g-xe1-borov-xe1-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/diterpenes-isolated-from-three-differentspecies-and-g-xe1-borov-xe1-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/use-of-protease-substrate-specificity-screening-mahoney-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/use-of-protease-substrate-specificity-screening-mahoney-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/use-of-protease-substrate-specificity-screening-mahoney-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/use-of-protease-substrate-specificity-screening-mahoney-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-characterization-and-immunological-functions-of-hu-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-characterization-and-immunological-functions-of-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-characterization-and-immunological-functions-of-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-characterization-and-immunological-functions-of-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rapid-clearance-of-achiral-small-molecule-chen-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rapid-clearance-of-achiral-small-molecule-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rapid-clearance-of-achiral-small-molecule-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rapid-clearance-of-achiral-small-molecule-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/targeting-thrombin-with-hirudin-alleviates-paraquat-hu-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/targeting-thrombin-with-hirudin-alleviates-paraquat-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/targeting-thrombin-with-hirudin-alleviates-paraquat-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/targeting-thrombin-with-hirudin-alleviates-paraquat-hu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-nacre-protein-hcperlucin-provides-antibacterial-tan-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-nacre-protein-hcperlucin-provides-antibacterial-tan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-nacre-protein-hcperlucin-provides-antibacterial-tan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-nacre-protein-hcperlucin-provides-antibacterial-tan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulation-and-hemostasis-in-the-extracorporeal-saura-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulation-and-hemostasis-in-the-extracorporeal-saura-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulation-and-hemostasis-in-the-extracorporeal-saura-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulation-and-hemostasis-in-the-extracorporeal-saura-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombin-generation-and-the-pharmacodynamics-of-shaw-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombin-generation-and-the-pharmacodynamics-of-shaw-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombin-generation-and-the-pharmacodynamics-of-shaw-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombin-generation-and-the-pharmacodynamics-of-shaw-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hementin-anticoagulant-protease-from-the-salivary-malinconico-1984 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hementin-anticoagulant-protease-from-the-salivary-malinconico-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hementin-anticoagulant-protease-from-the-salivary-malinconico-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hementin-anticoagulant-protease-from-the-salivary-malinconico-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-functional-domain-of-hirudin-a-chang-1983 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-functional-domain-of-hirudin-a-chang-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-functional-domain-of-hirudin-a-chang-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-functional-domain-of-hirudin-a-chang-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/microglial-movement-to-sites-of-nerve-morgese-1983 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/microglial-movement-to-sites-of-nerve-morgese-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/microglial-movement-to-sites-of-nerve-morgese-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/microglial-movement-to-sites-of-nerve-morgese-1983 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/inhibition-of-the-thrombin-platelet-reaction-hoffmann-1984 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/inhibition-of-the-thrombin-platelet-reaction-hoffmann-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/inhibition-of-the-thrombin-platelet-reaction-hoffmann-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/inhibition-of-the-thrombin-platelet-reaction-hoffmann-1984 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/regeneration-of-axons-and-nerve-cell-hulsebosch-1981 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/regeneration-of-axons-and-nerve-cell-hulsebosch-1981 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/regeneration-of-axons-and-nerve-cell-hulsebosch-1981 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/regeneration-of-axons-and-nerve-cell-hulsebosch-1981 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/decolorization-and-isolation-of-recombinant-hirudin-zhou-2001 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/decolorization-and-isolation-of-recombinant-hirudin-zhou-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/decolorization-and-isolation-of-recombinant-hirudin-zhou-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/decolorization-and-isolation-of-recombinant-hirudin-zhou-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/external-decontamination-of-wild-leeches-with-aydin-2004 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/external-decontamination-of-wild-leeches-with-aydin-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/external-decontamination-of-wild-leeches-with-aydin-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/external-decontamination-of-wild-leeches-with-aydin-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/primary-structure-and-function-of-novel-steiner-1992 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/primary-structure-and-function-of-novel-steiner-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/primary-structure-and-function-of-novel-steiner-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/primary-structure-and-function-of-novel-steiner-1992 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/purification-and-identification-of-recombinant-hirudin-zhou-2004 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/purification-and-identification-of-recombinant-hirudin-zhou-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/purification-and-identification-of-recombinant-hirudin-zhou-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/purification-and-identification-of-recombinant-hirudin-zhou-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/structure-function-relationships-of-the-c-krstenansky-1991 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/structure-function-relationships-of-the-c-krstenansky-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/structure-function-relationships-of-the-c-krstenansky-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/structure-function-relationships-of-the-c-krstenansky-1991 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/trichoplax-the-simplest-known-animal-contains-baker-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/trichoplax-the-simplest-known-animal-contains-baker-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/trichoplax-the-simplest-known-animal-contains-baker-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/trichoplax-the-simplest-known-animal-contains-baker-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-antithrombotic-effect-of-a-novel-lu-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-antithrombotic-effect-of-a-novel-lu-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-antithrombotic-effect-of-a-novel-lu-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-antithrombotic-effect-of-a-novel-lu-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-and-purification-of-novel-hirudins-steiner-1990 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-and-purification-of-novel-hirudins-steiner-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-and-purification-of-novel-hirudins-steiner-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-and-purification-of-novel-hirudins-steiner-1990 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ecdysone-receptor-homologs-from-mollusks-leeches-laguerre-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ecdysone-receptor-homologs-from-mollusks-leeches-laguerre-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ecdysone-receptor-homologs-from-mollusks-leeches-laguerre-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ecdysone-receptor-homologs-from-mollusks-leeches-laguerre-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/neuropeptide-evolution-neurohormones-and-neuropeptides-predicted-veenstra-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/neuropeptide-evolution-neurohormones-and-neuropeptides-predicted-veenstra-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/neuropeptide-evolution-neurohormones-and-neuropeptides-predicted-veenstra-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/neuropeptide-evolution-neurohormones-and-neuropeptides-predicted-veenstra-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/annelid-distal-less-dlx-duplications-reveal-mcdougall-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/annelid-distal-less-dlx-duplications-reveal-mcdougall-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/annelid-distal-less-dlx-duplications-reveal-mcdougall-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/annelid-distal-less-dlx-duplications-reveal-mcdougall-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phylogenomics-of-reichenowia-parasitica-an-alphaproteobacterial-kvist-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phylogenomics-of-reichenowia-parasitica-an-alphaproteobacterial-kvist-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phylogenomics-of-reichenowia-parasitica-an-alphaproteobacterial-kvist-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phylogenomics-of-reichenowia-parasitica-an-alphaproteobacterial-kvist-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/identification-of-3-utr-sequence-elements-farooq-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/identification-of-3-utr-sequence-elements-farooq-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/identification-of-3-utr-sequence-elements-farooq-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/identification-of-3-utr-sequence-elements-farooq-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/insights-into-bilaterian-evolution-from-three-simakov-2012 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/insights-into-bilaterian-evolution-from-three-simakov-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/insights-into-bilaterian-evolution-from-three-simakov-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/insights-into-bilaterian-evolution-from-three-simakov-2012 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/are-leeches-effective-in-local-regional-welshhans-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/are-leeches-effective-in-local-regional-welshhans-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/are-leeches-effective-in-local-regional-welshhans-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/are-leeches-effective-in-local-regional-welshhans-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/short-tail-stories-the-hirudin-like-m-xfc-ller-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/short-tail-stories-the-hirudin-like-m-xfc-ller-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/short-tail-stories-the-hirudin-like-m-xfc-ller-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/short-tail-stories-the-hirudin-like-m-xfc-ller-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/wpk5-a-novel-kunitz-type-peptide-zheng-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/wpk5-a-novel-kunitz-type-peptide-zheng-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/wpk5-a-novel-kunitz-type-peptide-zheng-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/wpk5-a-novel-kunitz-type-peptide-zheng-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/letter-to-the-editor-1-year-rajab-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/letter-to-the-editor-1-year-rajab-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/letter-to-the-editor-1-year-rajab-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/letter-to-the-editor-1-year-rajab-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/is-bivalirudin-ready-for-a-comeback-stone-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/is-bivalirudin-ready-for-a-comeback-stone-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/is-bivalirudin-ready-for-a-comeback-stone-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/is-bivalirudin-ready-for-a-comeback-stone-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/enhancing-ventricular-remodeling-and-cardiac-function-luo-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/enhancing-ventricular-remodeling-and-cardiac-function-luo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/enhancing-ventricular-remodeling-and-cardiac-function-luo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/enhancing-ventricular-remodeling-and-cardiac-function-luo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/peak-procedural-act-is-associated-with-sampath-kumar-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/peak-procedural-act-is-associated-with-sampath-kumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/peak-procedural-act-is-associated-with-sampath-kumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/peak-procedural-act-is-associated-with-sampath-kumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evaluation-of-the-reduction-of-thrombus-galo-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evaluation-of-the-reduction-of-thrombus-galo-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evaluation-of-the-reduction-of-thrombus-galo-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evaluation-of-the-reduction-of-thrombus-galo-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-for-anticoagulation-in-elderly-acute-cheng-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-for-anticoagulation-in-elderly-acute-cheng-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-for-anticoagulation-in-elderly-acute-cheng-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-for-anticoagulation-in-elderly-acute-cheng-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/autoimmune-heparin-induced-thrombocytopenia-following-cardiac-st-bernard-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/autoimmune-heparin-induced-thrombocytopenia-following-cardiac-st-bernard-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/autoimmune-heparin-induced-thrombocytopenia-following-cardiac-st-bernard-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/autoimmune-heparin-induced-thrombocytopenia-following-cardiac-st-bernard-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/diversity-and-expression-pattern-of-novel-park-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/diversity-and-expression-pattern-of-novel-park-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/diversity-and-expression-pattern-of-novel-park-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/diversity-and-expression-pattern-of-novel-park-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/don-t-hit-me-one-more-kerstjens-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/don-t-hit-me-one-more-kerstjens-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/don-t-hit-me-one-more-kerstjens-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/don-t-hit-me-one-more-kerstjens-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nafamostat-mesilate-as-an-anticoagulation-strategy-mei-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nafamostat-mesilate-as-an-anticoagulation-strategy-mei-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nafamostat-mesilate-as-an-anticoagulation-strategy-mei-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nafamostat-mesilate-as-an-anticoagulation-strategy-mei-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vlx-1005-but-not-argatroban-prevents-yamaguchi-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vlx-1005-but-not-argatroban-prevents-yamaguchi-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vlx-1005-but-not-argatroban-prevents-yamaguchi-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vlx-1005-but-not-argatroban-prevents-yamaguchi-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-challenges-in-profound-thrombocytopenia-associated-coe-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-challenges-in-profound-thrombocytopenia-associated-coe-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-challenges-in-profound-thrombocytopenia-associated-coe-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-challenges-in-profound-thrombocytopenia-associated-coe-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-effectiveness-of-parenteral-anticoagulants-fondaparinux-rehman-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-effectiveness-of-parenteral-anticoagulants-fondaparinux-rehman-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-effectiveness-of-parenteral-anticoagulants-fondaparinux-rehman-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-effectiveness-of-parenteral-anticoagulants-fondaparinux-rehman-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/extending-inferences-from-a-randomized-trial-young-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/extending-inferences-from-a-randomized-trial-young-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/extending-inferences-from-a-randomized-trial-young-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/extending-inferences-from-a-randomized-trial-young-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/review-of-the-current-issues-surrounding-guy-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/review-of-the-current-issues-surrounding-guy-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/review-of-the-current-issues-surrounding-guy-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/review-of-the-current-issues-surrounding-guy-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cancer-associated-stroke-complicated-by-heparin-okada-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cancer-associated-stroke-complicated-by-heparin-okada-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cancer-associated-stroke-complicated-by-heparin-okada-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cancer-associated-stroke-complicated-by-heparin-okada-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/use-of-argatroban-as-anticoagulation-for-faggioli-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/use-of-argatroban-as-anticoagulation-for-faggioli-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/use-of-argatroban-as-anticoagulation-for-faggioli-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/use-of-argatroban-as-anticoagulation-for-faggioli-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fondaparinux-versus-argatroban-for-the-management-alfehaid-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fondaparinux-versus-argatroban-for-the-management-alfehaid-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fondaparinux-versus-argatroban-for-the-management-alfehaid-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fondaparinux-versus-argatroban-for-the-management-alfehaid-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/core-domain-of-hirudin-from-the-de-filippis-1995 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/core-domain-of-hirudin-from-the-de-filippis-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/core-domain-of-hirudin-from-the-de-filippis-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/core-domain-of-hirudin-from-the-de-filippis-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/novel-hirudin-variants-from-the-leech-scacheri-1993 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/novel-hirudin-variants-from-the-leech-scacheri-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/novel-hirudin-variants-from-the-leech-scacheri-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/novel-hirudin-variants-from-the-leech-scacheri-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/probing-the-structure-of-hirudin-from-vindigni-1994 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/probing-the-structure-of-hirudin-from-vindigni-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/probing-the-structure-of-hirudin-from-vindigni-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/probing-the-structure-of-hirudin-from-vindigni-1994 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/structures-of-thrombin-complexes-with-a-qiu-1993 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/structures-of-thrombin-complexes-with-a-qiu-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/structures-of-thrombin-complexes-with-a-qiu-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/structures-of-thrombin-complexes-with-a-qiu-1993 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/high-level-secretion-of-hirudin-by-weydemann-1995 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/high-level-secretion-of-hirudin-by-weydemann-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/high-level-secretion-of-hirudin-by-weydemann-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/high-level-secretion-of-hirudin-by-weydemann-1995 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/peptides-as-inhibitors-of-thrombin-coagulation-pastorova-1999 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/peptides-as-inhibitors-of-thrombin-coagulation-pastorova-1999 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/peptides-as-inhibitors-of-thrombin-coagulation-pastorova-1999 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/peptides-as-inhibitors-of-thrombin-coagulation-pastorova-1999 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/penthalaris-a-novel-recombinant-five-kunitz-francischetti-2004 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/penthalaris-a-novel-recombinant-five-kunitz-francischetti-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/penthalaris-a-novel-recombinant-five-kunitz-francischetti-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/penthalaris-a-novel-recombinant-five-kunitz-francischetti-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rational-design-and-selection-of-bivalent-su-2004 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rational-design-and-selection-of-bivalent-su-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rational-design-and-selection-of-bivalent-su-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rational-design-and-selection-of-bivalent-su-2004 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hirudin-binding-reveals-key-determinants-of-mengwasser-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hirudin-binding-reveals-key-determinants-of-mengwasser-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hirudin-binding-reveals-key-determinants-of-mengwasser-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hirudin-binding-reveals-key-determinants-of-mengwasser-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/directing-thrombin-lane-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/directing-thrombin-lane-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/directing-thrombin-lane-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/directing-thrombin-lane-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/studies-on-the-basis-for-the-siebenlist-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/studies-on-the-basis-for-the-siebenlist-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/studies-on-the-basis-for-the-siebenlist-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/studies-on-the-basis-for-the-siebenlist-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombin-cofactor-interactions-structural-insights-into-adams-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombin-cofactor-interactions-structural-insights-into-adams-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombin-cofactor-interactions-structural-insights-into-adams-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombin-cofactor-interactions-structural-insights-into-adams-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ecotin-modulates-thrombin-activity-through-exosite-castro-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ecotin-modulates-thrombin-activity-through-exosite-castro-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ecotin-modulates-thrombin-activity-through-exosite-castro-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ecotin-modulates-thrombin-activity-through-exosite-castro-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/crystal-structures-of-murine-thrombin-in-bah-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/crystal-structures-of-murine-thrombin-in-bah-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/crystal-structures-of-murine-thrombin-in-bah-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/crystal-structures-of-murine-thrombin-in-bah-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/sodium-ions-as-the-effector-of-kolodze-x12d-skaia-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/sodium-ions-as-the-effector-of-kolodze-x12d-skaia-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/sodium-ions-as-the-effector-of-kolodze-x12d-skaia-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/sodium-ions-as-the-effector-of-kolodze-x12d-skaia-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/structural-insight-into-distinct-mechanisms-of-wu-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/structural-insight-into-distinct-mechanisms-of-wu-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/structural-insight-into-distinct-mechanisms-of-wu-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/structural-insight-into-distinct-mechanisms-of-wu-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/structural-identification-of-the-pathway-of-gandhi-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/structural-identification-of-the-pathway-of-gandhi-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/structural-identification-of-the-pathway-of-gandhi-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/structural-identification-of-the-pathway-of-gandhi-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/update-on-atrial-fibrillation-part-i-savelieva-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/update-on-atrial-fibrillation-part-i-savelieva-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/update-on-atrial-fibrillation-part-i-savelieva-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/update-on-atrial-fibrillation-part-i-savelieva-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombin-di-cera-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombin-di-cera-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombin-di-cera-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombin-di-cera-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fibrinogen-elongated-gamma-chain-inhibits-thrombin-lancellotti-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fibrinogen-elongated-gamma-chain-inhibits-thrombin-lancellotti-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fibrinogen-elongated-gamma-chain-inhibits-thrombin-lancellotti-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fibrinogen-elongated-gamma-chain-inhibits-thrombin-lancellotti-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/new-oral-anticoagulants-molecular-characteristics-mechanisms-marco-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/new-oral-anticoagulants-molecular-characteristics-mechanisms-marco-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/new-oral-anticoagulants-molecular-characteristics-mechanisms-marco-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/new-oral-anticoagulants-molecular-characteristics-mechanisms-marco-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mechanism-of-the-anticoagulant-activity-of-gandhi-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mechanism-of-the-anticoagulant-activity-of-gandhi-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mechanism-of-the-anticoagulant-activity-of-gandhi-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mechanism-of-the-anticoagulant-activity-of-gandhi-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/long-range-communication-between-exosites-1-petrera-2009 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/long-range-communication-between-exosites-1-petrera-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/long-range-communication-between-exosites-1-petrera-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/long-range-communication-between-exosites-1-petrera-2009 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ligand-binding-shuttles-thrombin-along-a-kamath-2010 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ligand-binding-shuttles-thrombin-along-a-kamath-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ligand-binding-shuttles-thrombin-along-a-kamath-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ligand-binding-shuttles-thrombin-along-a-kamath-2010 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/binding-of-alpha-thrombin-to-surface-zarpellon-2011 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/binding-of-alpha-thrombin-to-surface-zarpellon-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/binding-of-alpha-thrombin-to-surface-zarpellon-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/binding-of-alpha-thrombin-to-surface-zarpellon-2011 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/designing-allosteric-regulators-of-thrombin-exosite-sidhu-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/designing-allosteric-regulators-of-thrombin-exosite-sidhu-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/designing-allosteric-regulators-of-thrombin-exosite-sidhu-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/designing-allosteric-regulators-of-thrombin-exosite-sidhu-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/laboratory-monitoring-of-anticoagulant-medications-focus-baruch-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/laboratory-monitoring-of-anticoagulant-medications-focus-baruch-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/laboratory-monitoring-of-anticoagulant-medications-focus-baruch-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/laboratory-monitoring-of-anticoagulant-medications-focus-baruch-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ensemble-refinement-shows-conformational-flexibility-in-forneris-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ensemble-refinement-shows-conformational-flexibility-in-forneris-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ensemble-refinement-shows-conformational-flexibility-in-forneris-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ensemble-refinement-shows-conformational-flexibility-in-forneris-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/targeting-the-gpib-binding-site-of-mehta-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/targeting-the-gpib-binding-site-of-mehta-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/targeting-the-gpib-binding-site-of-mehta-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/targeting-the-gpib-binding-site-of-mehta-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulation-in-atrial-fibrillation-steinberg-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulation-in-atrial-fibrillation-steinberg-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulation-in-atrial-fibrillation-steinberg-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulation-in-atrial-fibrillation-steinberg-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/emergency-reversal-of-anticoagulation-novel-agents-levine-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/emergency-reversal-of-anticoagulation-novel-agents-levine-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/emergency-reversal-of-anticoagulation-novel-agents-levine-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/emergency-reversal-of-anticoagulation-novel-agents-levine-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/erpobdellid-leeches-annelida-clitellata-hirudinida-from-ben-ahmed-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/erpobdellid-leeches-annelida-clitellata-hirudinida-from-ben-ahmed-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/erpobdellid-leeches-annelida-clitellata-hirudinida-from-ben-ahmed-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/erpobdellid-leeches-annelida-clitellata-hirudinida-from-ben-ahmed-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/managing-bleeding-and-emergency-reversal-of-peacock-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/managing-bleeding-and-emergency-reversal-of-peacock-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/managing-bleeding-and-emergency-reversal-of-peacock-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/managing-bleeding-and-emergency-reversal-of-peacock-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/selective-disruption-of-heparin-and-antithrombin-westmark-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/selective-disruption-of-heparin-and-antithrombin-westmark-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/selective-disruption-of-heparin-and-antithrombin-westmark-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/selective-disruption-of-heparin-and-antithrombin-westmark-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bleeding-risk-management-and-outcome-in-werth-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bleeding-risk-management-and-outcome-in-werth-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bleeding-risk-management-and-outcome-in-werth-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bleeding-risk-management-and-outcome-in-werth-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/conserved-amblyomma-americanum-tick-serpin19-an-kim-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/conserved-amblyomma-americanum-tick-serpin19-an-kim-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/conserved-amblyomma-americanum-tick-serpin19-an-kim-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/conserved-amblyomma-americanum-tick-serpin19-an-kim-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/intracranial-bleedings-in-patients-on-long-x141-ukasik-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/intracranial-bleedings-in-patients-on-long-x141-ukasik-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/intracranial-bleedings-in-patients-on-long-x141-ukasik-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/intracranial-bleedings-in-patients-on-long-x141-ukasik-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allosterism-based-simultaneous-dual-anticoagulant-and-mehta-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allosterism-based-simultaneous-dual-anticoagulant-and-mehta-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allosterism-based-simultaneous-dual-anticoagulant-and-mehta-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allosterism-based-simultaneous-dual-anticoagulant-and-mehta-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-overview-taking-a-patient-with-alturki-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-overview-taking-a-patient-with-alturki-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-overview-taking-a-patient-with-alturki-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-overview-taking-a-patient-with-alturki-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allosteric-partial-inhibition-of-monomeric-proteases-verespy-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allosteric-partial-inhibition-of-monomeric-proteases-verespy-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allosteric-partial-inhibition-of-monomeric-proteases-verespy-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allosteric-partial-inhibition-of-monomeric-proteases-verespy-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/managing-reversal-of-direct-oral-anticoagulants-ageno-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/managing-reversal-of-direct-oral-anticoagulants-ageno-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/managing-reversal-of-direct-oral-anticoagulants-ageno-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/managing-reversal-of-direct-oral-anticoagulants-ageno-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/warfarin-and-newer-agents-what-the-steed-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/warfarin-and-newer-agents-what-the-steed-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/warfarin-and-newer-agents-what-the-steed-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/warfarin-and-newer-agents-what-the-steed-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andexanet-alfa-a-recombinant-mimetic-of-escolar-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andexanet-alfa-a-recombinant-mimetic-of-escolar-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andexanet-alfa-a-recombinant-mimetic-of-escolar-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andexanet-alfa-a-recombinant-mimetic-of-escolar-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/h-n-andc-resonance-assignments-of-de-paula-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/h-n-andc-resonance-assignments-of-de-paula-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/h-n-andc-resonance-assignments-of-de-paula-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/h-n-andc-resonance-assignments-of-de-paula-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antiphospholipid-syndrome-committee-of-the-brazilian-balbi-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antiphospholipid-syndrome-committee-of-the-brazilian-balbi-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antiphospholipid-syndrome-committee-of-the-brazilian-balbi-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antiphospholipid-syndrome-committee-of-the-brazilian-balbi-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-new-species-of-buffalo-leech-jeratthitikul-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-new-species-of-buffalo-leech-jeratthitikul-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-new-species-of-buffalo-leech-jeratthitikul-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-new-species-of-buffalo-leech-jeratthitikul-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/regulation-of-thrombin-activity-with-ultrasmall-lira-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/regulation-of-thrombin-activity-with-ultrasmall-lira-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/regulation-of-thrombin-activity-with-ultrasmall-lira-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/regulation-of-thrombin-activity-with-ultrasmall-lira-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whole-genome-sequence-ofcvm861-isolated-from-poole-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whole-genome-sequence-ofcvm861-isolated-from-poole-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whole-genome-sequence-ofcvm861-isolated-from-poole-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whole-genome-sequence-ofcvm861-isolated-from-poole-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/use-of-bacteriophage-to-control-experimentalinfection-phumkhachorn-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/use-of-bacteriophage-to-control-experimentalinfection-phumkhachorn-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/use-of-bacteriophage-to-control-experimentalinfection-phumkhachorn-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/use-of-bacteriophage-to-control-experimentalinfection-phumkhachorn-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-characterization-and-genomic-analysis-of-pallavi-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-characterization-and-genomic-analysis-of-pallavi-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-characterization-and-genomic-analysis-of-pallavi-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-characterization-and-genomic-analysis-of-pallavi-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mirna-seq-analysis-of-spleen-and-zhou-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mirna-seq-analysis-of-spleen-and-zhou-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mirna-seq-analysis-of-spleen-and-zhou-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mirna-seq-analysis-of-spleen-and-zhou-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prediction-and-analysisof-genomic-islands-in-da-silva-filho-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prediction-and-analysisof-genomic-islands-in-da-silva-filho-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prediction-and-analysisof-genomic-islands-in-da-silva-filho-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prediction-and-analysisof-genomic-islands-in-da-silva-filho-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/vash-contributes-to-virulence-ofand-is-li-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/vash-contributes-to-virulence-ofand-is-li-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/vash-contributes-to-virulence-ofand-is-li-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/vash-contributes-to-virulence-ofand-is-li-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antimicrobial-activity-of-an-artificially-designed-bhat-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antimicrobial-activity-of-an-artificially-designed-bhat-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antimicrobial-activity-of-an-artificially-designed-bhat-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antimicrobial-activity-of-an-artificially-designed-bhat-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fate-of-resistome-components-and-characteristics-liu-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fate-of-resistome-components-and-characteristics-liu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fate-of-resistome-components-and-characteristics-liu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fate-of-resistome-components-and-characteristics-liu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clonal-dissemination-ofwith-binary-carriage-of-xu-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clonal-dissemination-ofwith-binary-carriage-of-xu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clonal-dissemination-ofwith-binary-carriage-of-xu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clonal-dissemination-ofwith-binary-carriage-of-xu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lytic-bacteriophage-pzl-ah152-as-biocontrol-feng-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lytic-bacteriophage-pzl-ah152-as-biocontrol-feng-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lytic-bacteriophage-pzl-ah152-as-biocontrol-feng-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lytic-bacteriophage-pzl-ah152-as-biocontrol-feng-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-transcriptome-combined-with-morphophysiological-analyses-dong-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-transcriptome-combined-with-morphophysiological-analyses-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-transcriptome-combined-with-morphophysiological-analyses-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-transcriptome-combined-with-morphophysiological-analyses-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/first-record-of-the-rare-speciesfrom-fern-xe1-ndez-bravo-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/first-record-of-the-rare-speciesfrom-fern-xe1-ndez-bravo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/first-record-of-the-rare-speciesfrom-fern-xe1-ndez-bravo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/first-record-of-the-rare-speciesfrom-fern-xe1-ndez-bravo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-of-virulence-and-antimicrobial-resistance-dubey-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-of-virulence-and-antimicrobial-resistance-dubey-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-of-virulence-and-antimicrobial-resistance-dubey-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-of-virulence-and-antimicrobial-resistance-dubey-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/proteomics-analysis-reveals-that-cira-in-song-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/proteomics-analysis-reveals-that-cira-in-song-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/proteomics-analysis-reveals-that-cira-in-song-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/proteomics-analysis-reveals-that-cira-in-song-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-doacs-from-the-margeti-x107-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-doacs-from-the-margeti-x107-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-doacs-from-the-margeti-x107-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-doacs-from-the-margeti-x107-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hiding-in-plain-sight-characterization-ofspecies-canellas-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hiding-in-plain-sight-characterization-ofspecies-canellas-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hiding-in-plain-sight-characterization-ofspecies-canellas-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hiding-in-plain-sight-characterization-ofspecies-canellas-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whole-genome-sequence-of-a-novel-cebeci-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whole-genome-sequence-of-a-novel-cebeci-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whole-genome-sequence-of-a-novel-cebeci-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whole-genome-sequence-of-a-novel-cebeci-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/allosteric-modulation-of-thrombin-by-thrombomodulin-wu-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/allosteric-modulation-of-thrombin-by-thrombomodulin-wu-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/allosteric-modulation-of-thrombin-by-thrombomodulin-wu-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/allosteric-modulation-of-thrombin-by-thrombomodulin-wu-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/novel-lytic-bacteriophage-ahfm11-as-an-muliya-sankappa-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/novel-lytic-bacteriophage-ahfm11-as-an-muliya-sankappa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/novel-lytic-bacteriophage-ahfm11-as-an-muliya-sankappa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/novel-lytic-bacteriophage-ahfm11-as-an-muliya-sankappa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/investigating-protein-nucleic-acid-binding-interactions-kirsch-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/investigating-protein-nucleic-acid-binding-interactions-kirsch-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/investigating-protein-nucleic-acid-binding-interactions-kirsch-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/investigating-protein-nucleic-acid-binding-interactions-kirsch-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-and-genome-analyses-of-the-nagar-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-and-genome-analyses-of-the-nagar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-and-genome-analyses-of-the-nagar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-and-genome-analyses-of-the-nagar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/temporal-dynamics-of-extended-spectrum-lactamase-tanabe-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/temporal-dynamics-of-extended-spectrum-lactamase-tanabe-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/temporal-dynamics-of-extended-spectrum-lactamase-tanabe-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/temporal-dynamics-of-extended-spectrum-lactamase-tanabe-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/transcriptomic-and-proteomic-analyses-of-the-ge-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/transcriptomic-and-proteomic-analyses-of-the-ge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/transcriptomic-and-proteomic-analyses-of-the-ge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/transcriptomic-and-proteomic-analyses-of-the-ge-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/infection-status-etiological-analysis-ofspp-in-lou-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/infection-status-etiological-analysis-ofspp-in-lou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/infection-status-etiological-analysis-ofspp-in-lou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/infection-status-etiological-analysis-ofspp-in-lou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-novel-in-silico-approach-to-sobhzahedi-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-novel-in-silico-approach-to-sobhzahedi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-novel-in-silico-approach-to-sobhzahedi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-novel-in-silico-approach-to-sobhzahedi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/synonymization-of-placobdella-picta-verrill-1872-phillips-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/synonymization-of-placobdella-picta-verrill-1872-phillips-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/synonymization-of-placobdella-picta-verrill-1872-phillips-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/synonymization-of-placobdella-picta-verrill-1872-phillips-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/first-report-of-natural-co-infections-pinto-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/first-report-of-natural-co-infections-pinto-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/first-report-of-natural-co-infections-pinto-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/first-report-of-natural-co-infections-pinto-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/proteomics-reveals-the-role-of-the-xu-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/proteomics-reveals-the-role-of-the-xu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/proteomics-reveals-the-role-of-the-xu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/proteomics-reveals-the-role-of-the-xu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/identification-of-anstrain-as-a-new-wehbe-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/identification-of-anstrain-as-a-new-wehbe-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/identification-of-anstrain-as-a-new-wehbe-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/identification-of-anstrain-as-a-new-wehbe-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/genomic-insights-determination-of-quorum-quenching-ghosh-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/genomic-insights-determination-of-quorum-quenching-ghosh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/genomic-insights-determination-of-quorum-quenching-ghosh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/genomic-insights-determination-of-quorum-quenching-ghosh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-and-genomic-analysis-of-phage-han-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-and-genomic-analysis-of-phage-han-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-and-genomic-analysis-of-phage-han-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-and-genomic-analysis-of-phage-han-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-effects-of-heparin-binding-and-balogh-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-effects-of-heparin-binding-and-balogh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-effects-of-heparin-binding-and-balogh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-effects-of-heparin-binding-and-balogh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-novel-bacteriophage-paeh1-for-controlling-jiang-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-novel-bacteriophage-paeh1-for-controlling-jiang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-novel-bacteriophage-paeh1-for-controlling-jiang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-novel-bacteriophage-paeh1-for-controlling-jiang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comprehensive-investigation-of-a-novel-and-choi-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comprehensive-investigation-of-a-novel-and-choi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comprehensive-investigation-of-a-novel-and-choi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comprehensive-investigation-of-a-novel-and-choi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-characterization-and-evaluation-of-a-zhang-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-characterization-and-evaluation-of-a-zhang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-characterization-and-evaluation-of-a-zhang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-characterization-and-evaluation-of-a-zhang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/probiotic-properties-in-vitro-offjat-57093-chen-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/probiotic-properties-in-vitro-offjat-57093-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/probiotic-properties-in-vitro-offjat-57093-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/probiotic-properties-in-vitro-offjat-57093-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/distribution-characteristics-of-integrons-and-correlation-yang-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/distribution-characteristics-of-integrons-and-correlation-yang-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/distribution-characteristics-of-integrons-and-correlation-yang-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/distribution-characteristics-of-integrons-and-correlation-yang-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/argatroban-a-direct-thrombin-inhibitor-for-chen-2001 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/argatroban-a-direct-thrombin-inhibitor-for-chen-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/argatroban-a-direct-thrombin-inhibitor-for-chen-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/argatroban-a-direct-thrombin-inhibitor-for-chen-2001 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/alternative-parenteral-anticoagulation-with-argatroban-a-lamonte-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/alternative-parenteral-anticoagulation-with-argatroban-a-lamonte-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/alternative-parenteral-anticoagulation-with-argatroban-a-lamonte-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/alternative-parenteral-anticoagulation-with-argatroban-a-lamonte-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/argatroban-update-yeh-2006 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/argatroban-update-yeh-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/argatroban-update-yeh-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/argatroban-update-yeh-2006 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/dabigatran-etexilate-an-oral-direct-thrombin-baetz-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/dabigatran-etexilate-an-oral-direct-thrombin-baetz-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/dabigatran-etexilate-an-oral-direct-thrombin-baetz-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/dabigatran-etexilate-an-oral-direct-thrombin-baetz-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/the-direct-thrombin-inhibitor-argatroban-a-koster-2007 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/the-direct-thrombin-inhibitor-argatroban-a-koster-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/the-direct-thrombin-inhibitor-argatroban-a-koster-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/the-direct-thrombin-inhibitor-argatroban-a-koster-2007 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/randomized-multicenter-trial-of-artss-2-barreto-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/randomized-multicenter-trial-of-artss-2-barreto-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/randomized-multicenter-trial-of-artss-2-barreto-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/randomized-multicenter-trial-of-artss-2-barreto-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-versus-heparin-in-percutaneous-coronary-anantha-narayanan-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-versus-heparin-in-percutaneous-coronary-anantha-narayanan-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-versus-heparin-in-percutaneous-coronary-anantha-narayanan-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-versus-heparin-in-percutaneous-coronary-anantha-narayanan-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-versus-heparin-monotherapy-in-non-erlinge-2018 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-versus-heparin-monotherapy-in-non-erlinge-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-versus-heparin-monotherapy-in-non-erlinge-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-versus-heparin-monotherapy-in-non-erlinge-2018 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/optimal-antithrombotic-therapy-for-patients-with-tu-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/optimal-antithrombotic-therapy-for-patients-with-tu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/optimal-antithrombotic-therapy-for-patients-with-tu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/optimal-antithrombotic-therapy-for-patients-with-tu-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/impact-of-baseline-anemia-in-patients-wester-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/impact-of-baseline-anemia-in-patients-wester-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/impact-of-baseline-anemia-in-patients-wester-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/impact-of-baseline-anemia-in-patients-wester-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ecg-analysis-in-patients-with-acute-gragnano-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ecg-analysis-in-patients-with-acute-gragnano-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ecg-analysis-in-patients-with-acute-gragnano-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ecg-analysis-in-patients-with-acute-gragnano-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bivalirudin-versus-heparin-during-percutaneous-coronary-patel-2019 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bivalirudin-versus-heparin-during-percutaneous-coronary-patel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bivalirudin-versus-heparin-during-percutaneous-coronary-patel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bivalirudin-versus-heparin-during-percutaneous-coronary-patel-2019 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-outcomes-of-bivalirudin-versus-heparin-meng-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-outcomes-of-bivalirudin-versus-heparin-meng-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-outcomes-of-bivalirudin-versus-heparin-meng-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-outcomes-of-bivalirudin-versus-heparin-meng-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/radial-access-first-for-pci-in-marbach-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/radial-access-first-for-pci-in-marbach-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/radial-access-first-for-pci-in-marbach-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/radial-access-first-for-pci-in-marbach-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/current-practice-of-percutaneous-coronary-intervention-el-khoury-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/current-practice-of-percutaneous-coronary-intervention-el-khoury-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/current-practice-of-percutaneous-coronary-intervention-el-khoury-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/current-practice-of-percutaneous-coronary-intervention-el-khoury-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-and-safety-of-bivalirudin-bridging-guo-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-and-safety-of-bivalirudin-bridging-guo-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-and-safety-of-bivalirudin-bridging-guo-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-and-safety-of-bivalirudin-bridging-guo-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evidence-based-management-of-major-bleeding-al-aseri-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evidence-based-management-of-major-bleeding-al-aseri-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evidence-based-management-of-major-bleeding-al-aseri-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evidence-based-management-of-major-bleeding-al-aseri-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reversing-dabigatran-effect-with-idarucizumab-to-w-x142-odarczyk-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reversing-dabigatran-effect-with-idarucizumab-to-w-x142-odarczyk-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reversing-dabigatran-effect-with-idarucizumab-to-w-x142-odarczyk-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reversing-dabigatran-effect-with-idarucizumab-to-w-x142-odarczyk-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/one-case-of-recurrent-st-segment-qiu-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/one-case-of-recurrent-st-segment-qiu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/one-case-of-recurrent-st-segment-qiu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/one-case-of-recurrent-st-segment-qiu-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulation-reversal-vitamin-k-prothrombin-complex-bekka-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulation-reversal-vitamin-k-prothrombin-complex-bekka-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulation-reversal-vitamin-k-prothrombin-complex-bekka-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulation-reversal-vitamin-k-prothrombin-complex-bekka-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulation-and-antiplatelet-regimen-in-cardiac-groba-marco-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulation-and-antiplatelet-regimen-in-cardiac-groba-marco-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulation-and-antiplatelet-regimen-in-cardiac-groba-marco-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulation-and-antiplatelet-regimen-in-cardiac-groba-marco-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-presentation-and-outcomes-following-infection-campbell-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-presentation-and-outcomes-following-infection-campbell-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-presentation-and-outcomes-following-infection-campbell-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-presentation-and-outcomes-following-infection-campbell-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-genomics-of-incq1-plasmids-carrying-conte-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-genomics-of-incq1-plasmids-carrying-conte-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-genomics-of-incq1-plasmids-carrying-conte-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-genomics-of-incq1-plasmids-carrying-conte-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/changing-epidemiological-trend-of-aeromonas-species-mohanty-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/changing-epidemiological-trend-of-aeromonas-species-mohanty-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/changing-epidemiological-trend-of-aeromonas-species-mohanty-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/changing-epidemiological-trend-of-aeromonas-species-mohanty-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antibiotic-resistant-bacteria-contaminating-leafy-vegetables-elsafi-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antibiotic-resistant-bacteria-contaminating-leafy-vegetables-elsafi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antibiotic-resistant-bacteria-contaminating-leafy-vegetables-elsafi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antibiotic-resistant-bacteria-contaminating-leafy-vegetables-elsafi-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antimicrobial-susceptibility-profile-of-bacteria-of-fraz-xe3-o-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antimicrobial-susceptibility-profile-of-bacteria-of-fraz-xe3-o-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antimicrobial-susceptibility-profile-of-bacteria-of-fraz-xe3-o-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antimicrobial-susceptibility-profile-of-bacteria-of-fraz-xe3-o-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombolysis-for-ischemic-stroke-despite-recent-meinel-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombolysis-for-ischemic-stroke-despite-recent-meinel-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombolysis-for-ischemic-stroke-despite-recent-meinel-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombolysis-for-ischemic-stroke-despite-recent-meinel-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombolysis-after-dabigatran-reversal-for-acute-theodorou-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombolysis-after-dabigatran-reversal-for-acute-theodorou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombolysis-after-dabigatran-reversal-for-acute-theodorou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombolysis-after-dabigatran-reversal-for-acute-theodorou-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/in-vitro-efficacy-of-aquaculture-antimicrobials-gopakumar-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/in-vitro-efficacy-of-aquaculture-antimicrobials-gopakumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/in-vitro-efficacy-of-aquaculture-antimicrobials-gopakumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/in-vitro-efficacy-of-aquaculture-antimicrobials-gopakumar-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-identification-histopathology-and-antibiotic-susceptibility-bari-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-identification-histopathology-and-antibiotic-susceptibility-bari-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-identification-histopathology-and-antibiotic-susceptibility-bari-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-identification-histopathology-and-antibiotic-susceptibility-bari-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/reversal-of-dabigatran-and-apixaban-induced-morando-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/reversal-of-dabigatran-and-apixaban-induced-morando-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/reversal-of-dabigatran-and-apixaban-induced-morando-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/reversal-of-dabigatran-and-apixaban-induced-morando-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/intravenous-thrombolysis-for-patients-with-acute-roberts-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/intravenous-thrombolysis-for-patients-with-acute-roberts-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/intravenous-thrombolysis-for-patients-with-acute-roberts-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/intravenous-thrombolysis-for-patients-with-acute-roberts-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/correction-of-the-effect-of-direct-baranich-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/correction-of-the-effect-of-direct-baranich-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/correction-of-the-effect-of-direct-baranich-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/correction-of-the-effect-of-direct-baranich-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phenotypic-and-genotypic-characterization-of-aeromonas-abo-shama-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phenotypic-and-genotypic-characterization-of-aeromonas-abo-shama-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phenotypic-and-genotypic-characterization-of-aeromonas-abo-shama-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phenotypic-and-genotypic-characterization-of-aeromonas-abo-shama-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whole-genome-sequencing-based-species-classification-lu-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whole-genome-sequencing-based-species-classification-lu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whole-genome-sequencing-based-species-classification-lu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whole-genome-sequencing-based-species-classification-lu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/an-evaluation-of-the-modified-carbapenem-uechi-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/an-evaluation-of-the-modified-carbapenem-uechi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/an-evaluation-of-the-modified-carbapenem-uechi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/an-evaluation-of-the-modified-carbapenem-uechi-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comprehensive-genomic-analysis-of-antimicrobial-resistance-chen-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comprehensive-genomic-analysis-of-antimicrobial-resistance-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comprehensive-genomic-analysis-of-antimicrobial-resistance-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comprehensive-genomic-analysis-of-antimicrobial-resistance-chen-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/susceptibility-ofsubsp-bacteria-from-french-farmed-rostang-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/susceptibility-ofsubsp-bacteria-from-french-farmed-rostang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/susceptibility-ofsubsp-bacteria-from-french-farmed-rostang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/susceptibility-ofsubsp-bacteria-from-french-farmed-rostang-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andexanet-alfa-in-urgent-cardiac-surgery-al-mawed-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andexanet-alfa-in-urgent-cardiac-surgery-al-mawed-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andexanet-alfa-in-urgent-cardiac-surgery-al-mawed-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andexanet-alfa-in-urgent-cardiac-surgery-al-mawed-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bacterial-flora-and-antibiogram-sensitivity-in-konak-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bacterial-flora-and-antibiogram-sensitivity-in-konak-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bacterial-flora-and-antibiogram-sensitivity-in-konak-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bacterial-flora-and-antibiogram-sensitivity-in-konak-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/epidemiology-and-drug-resistance-of-salmonella-gao-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/epidemiology-and-drug-resistance-of-salmonella-gao-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/epidemiology-and-drug-resistance-of-salmonella-gao-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/epidemiology-and-drug-resistance-of-salmonella-gao-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antimicrobial-resistance-in-the-aconcagua-river-gonz-xe1-lez-rojas-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antimicrobial-resistance-in-the-aconcagua-river-gonz-xe1-lez-rojas-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antimicrobial-resistance-in-the-aconcagua-river-gonz-xe1-lez-rojas-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antimicrobial-resistance-in-the-aconcagua-river-gonz-xe1-lez-rojas-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/whole-genome-sequencing-analysis-of-the-xie-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/whole-genome-sequencing-analysis-of-the-xie-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/whole-genome-sequencing-analysis-of-the-xie-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/whole-genome-sequencing-analysis-of-the-xie-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-unique-case-of-aeromonas-salmonicida-romero-feregrino-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-unique-case-of-aeromonas-salmonicida-romero-feregrino-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-unique-case-of-aeromonas-salmonicida-romero-feregrino-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-unique-case-of-aeromonas-salmonicida-romero-feregrino-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/urban-wastewater-overflows-as-hotspots-for-ruiz-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/urban-wastewater-overflows-as-hotspots-for-ruiz-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/urban-wastewater-overflows-as-hotspots-for-ruiz-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/urban-wastewater-overflows-as-hotspots-for-ruiz-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/susceptibility-profile-ofspp-from-clinical-strains-sainte-rose-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/susceptibility-profile-ofspp-from-clinical-strains-sainte-rose-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/susceptibility-profile-ofspp-from-clinical-strains-sainte-rose-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/susceptibility-profile-ofspp-from-clinical-strains-sainte-rose-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/feasibility-of-setting-epidemiological-cut-off-smith-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/feasibility-of-setting-epidemiological-cut-off-smith-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/feasibility-of-setting-epidemiological-cut-off-smith-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/feasibility-of-setting-epidemiological-cut-off-smith-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/elucidating-environmental-reservoir-of-antimicrobial-resistance-orhan-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/elucidating-environmental-reservoir-of-antimicrobial-resistance-orhan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/elucidating-environmental-reservoir-of-antimicrobial-resistance-orhan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/elucidating-environmental-reservoir-of-antimicrobial-resistance-orhan-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-and-antibiogram-of-bacterial-isolates-hassan-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-and-antibiogram-of-bacterial-isolates-hassan-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-and-antibiogram-of-bacterial-isolates-hassan-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-and-antibiogram-of-bacterial-isolates-hassan-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/isolation-of-proteus-sp-closely-related-lim-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/isolation-of-proteus-sp-closely-related-lim-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/isolation-of-proteus-sp-closely-related-lim-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/isolation-of-proteus-sp-closely-related-lim-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pathogenic-aeromonas-hydrophila-in-ornamental-neocaridina-guz-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pathogenic-aeromonas-hydrophila-in-ornamental-neocaridina-guz-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pathogenic-aeromonas-hydrophila-in-ornamental-neocaridina-guz-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pathogenic-aeromonas-hydrophila-in-ornamental-neocaridina-guz-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/genome-resolved-co-infection-byandsp-in-tasci-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/genome-resolved-co-infection-byandsp-in-tasci-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/genome-resolved-co-infection-byandsp-in-tasci-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/genome-resolved-co-infection-byandsp-in-tasci-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/occurrence-of-antibiotic-resistant-aeromonas-species-adah-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/occurrence-of-antibiotic-resistant-aeromonas-species-adah-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/occurrence-of-antibiotic-resistant-aeromonas-species-adah-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/occurrence-of-antibiotic-resistant-aeromonas-species-adah-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bloody-diarrhea-associated-with-cytotoxic-aeromonas-ohno-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bloody-diarrhea-associated-with-cytotoxic-aeromonas-ohno-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bloody-diarrhea-associated-with-cytotoxic-aeromonas-ohno-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bloody-diarrhea-associated-with-cytotoxic-aeromonas-ohno-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/epidemiology-and-antimicrobial-resistance-patterns-of-boattini-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/epidemiology-and-antimicrobial-resistance-patterns-of-boattini-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/epidemiology-and-antimicrobial-resistance-patterns-of-boattini-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/epidemiology-and-antimicrobial-resistance-patterns-of-boattini-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/gastrointestinal-infection-caused-by-five-different-recio-com-xed-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/gastrointestinal-infection-caused-by-five-different-recio-com-xed-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/gastrointestinal-infection-caused-by-five-different-recio-com-xed-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/gastrointestinal-infection-caused-by-five-different-recio-com-xed-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/soft-tissue-infections-during-a-climate-amaya-franco-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/soft-tissue-infections-during-a-climate-amaya-franco-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/soft-tissue-infections-during-a-climate-amaya-franco-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/soft-tissue-infections-during-a-climate-amaya-franco-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/translated-article-soft-tissue-infections-during-amaya-franco-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/translated-article-soft-tissue-infections-during-amaya-franco-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/translated-article-soft-tissue-infections-during-amaya-franco-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/translated-article-soft-tissue-infections-during-amaya-franco-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/culture-qpcr-and-genome-based-surveillance-cortez-astorga-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/culture-qpcr-and-genome-based-surveillance-cortez-astorga-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/culture-qpcr-and-genome-based-surveillance-cortez-astorga-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/culture-qpcr-and-genome-based-surveillance-cortez-astorga-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pancreaticobiliary-cancers-and-aeromonas-isolates-carrying-chen-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pancreaticobiliary-cancers-and-aeromonas-isolates-carrying-chen-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pancreaticobiliary-cancers-and-aeromonas-isolates-carrying-chen-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pancreaticobiliary-cancers-and-aeromonas-isolates-carrying-chen-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/virulence-determinants-and-plasmid-mediated-colistin-tartor-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/virulence-determinants-and-plasmid-mediated-colistin-tartor-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/virulence-determinants-and-plasmid-mediated-colistin-tartor-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/virulence-determinants-and-plasmid-mediated-colistin-tartor-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/emergence-of-a-highly-colistin-resistant-komeda-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/emergence-of-a-highly-colistin-resistant-komeda-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/emergence-of-a-highly-colistin-resistant-komeda-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/emergence-of-a-highly-colistin-resistant-komeda-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/establishment-of-epidemiological-cut-off-values-woo-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/establishment-of-epidemiological-cut-off-values-woo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/establishment-of-epidemiological-cut-off-values-woo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/establishment-of-epidemiological-cut-off-values-woo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/multidrug-resistant-gram-negative-bacteria-and-veloo-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/multidrug-resistant-gram-negative-bacteria-and-veloo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/multidrug-resistant-gram-negative-bacteria-and-veloo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/multidrug-resistant-gram-negative-bacteria-and-veloo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/harboring-aeromonas-veronii-from-the-hospital-yang-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/harboring-aeromonas-veronii-from-the-hospital-yang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/harboring-aeromonas-veronii-from-the-hospital-yang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/harboring-aeromonas-veronii-from-the-hospital-yang-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/a-high-level-of-antibiotic-resistance-salamandane-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/a-high-level-of-antibiotic-resistance-salamandane-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/a-high-level-of-antibiotic-resistance-salamandane-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/a-high-level-of-antibiotic-resistance-salamandane-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/plasmid-mediated-fluoroquinolone-resistance-genes-in-kosikowska-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/plasmid-mediated-fluoroquinolone-resistance-genes-in-kosikowska-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/plasmid-mediated-fluoroquinolone-resistance-genes-in-kosikowska-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/plasmid-mediated-fluoroquinolone-resistance-genes-in-kosikowska-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/characterization-of-bacterial-resistance-in-treated-canan-rochenbach-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/characterization-of-bacterial-resistance-in-treated-canan-rochenbach-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/characterization-of-bacterial-resistance-in-treated-canan-rochenbach-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/characterization-of-bacterial-resistance-in-treated-canan-rochenbach-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prevalence-of-antimicrobial-resistance-in-select-tate-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prevalence-of-antimicrobial-resistance-in-select-tate-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prevalence-of-antimicrobial-resistance-in-select-tate-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prevalence-of-antimicrobial-resistance-in-select-tate-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-isolates-with-high-carbapenem-resistance-puah-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-isolates-with-high-carbapenem-resistance-puah-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-isolates-with-high-carbapenem-resistance-puah-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-isolates-with-high-carbapenem-resistance-puah-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/incidence-evaluation-of-detection-and-identification-teodoro-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/incidence-evaluation-of-detection-and-identification-teodoro-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/incidence-evaluation-of-detection-and-identification-teodoro-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/incidence-evaluation-of-detection-and-identification-teodoro-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/epidemiological-cutoff-values-for-standard-broth-gieseker-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/epidemiological-cutoff-values-for-standard-broth-gieseker-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/epidemiological-cutoff-values-for-standard-broth-gieseker-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/epidemiological-cutoff-values-for-standard-broth-gieseker-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antibiotic-resistance-and-virulence-factor-gene-goudarztalejerdi-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antibiotic-resistance-and-virulence-factor-gene-goudarztalejerdi-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antibiotic-resistance-and-virulence-factor-gene-goudarztalejerdi-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antibiotic-resistance-and-virulence-factor-gene-goudarztalejerdi-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aerolysin-gene-characterization-and-antimicrobial-resistance-fikri-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aerolysin-gene-characterization-and-antimicrobial-resistance-fikri-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aerolysin-gene-characterization-and-antimicrobial-resistance-fikri-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aerolysin-gene-characterization-and-antimicrobial-resistance-fikri-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/genetic-diversity-antibiotic-resistance-and-pathogenicity-qu-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/genetic-diversity-antibiotic-resistance-and-pathogenicity-qu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/genetic-diversity-antibiotic-resistance-and-pathogenicity-qu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/genetic-diversity-antibiotic-resistance-and-pathogenicity-qu-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/distribution-and-spread-of-the-mobilised-dong-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/distribution-and-spread-of-the-mobilised-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/distribution-and-spread-of-the-mobilised-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/distribution-and-spread-of-the-mobilised-dong-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/maldi-tof-ms-for-rapid-analysis-anwer-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/maldi-tof-ms-for-rapid-analysis-anwer-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/maldi-tof-ms-for-rapid-analysis-anwer-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/maldi-tof-ms-for-rapid-analysis-anwer-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/diversity-and-antibiograms-of-bacteria-isolated-yeboaa-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/diversity-and-antibiograms-of-bacteria-isolated-yeboaa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/diversity-and-antibiograms-of-bacteria-isolated-yeboaa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/diversity-and-antibiograms-of-bacteria-isolated-yeboaa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/requiring-reconsideration-of-differences-ofinfections-between-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/requiring-reconsideration-of-differences-ofinfections-between-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/requiring-reconsideration-of-differences-ofinfections-between-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/requiring-reconsideration-of-differences-ofinfections-between-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bacteriological-profile-of-hospital-acquired-infection-farzin-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bacteriological-profile-of-hospital-acquired-infection-farzin-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bacteriological-profile-of-hospital-acquired-infection-farzin-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bacteriological-profile-of-hospital-acquired-infection-farzin-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/first-report-ofas-an-emerging-bacterial-dos-santos-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/first-report-ofas-an-emerging-bacterial-dos-santos-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/first-report-ofas-an-emerging-bacterial-dos-santos-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/first-report-ofas-an-emerging-bacterial-dos-santos-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/identification-and-characterization-of-a-novel-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/identification-and-characterization-of-a-novel-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/identification-and-characterization-of-a-novel-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/identification-and-characterization-of-a-novel-zhang-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/showing-the-limitations-of-available-phenotypic-orababa-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/showing-the-limitations-of-available-phenotypic-orababa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/showing-the-limitations-of-available-phenotypic-orababa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/showing-the-limitations-of-available-phenotypic-orababa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/identification-and-characterization-of-motile-aeromonas-legario-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/identification-and-characterization-of-motile-aeromonas-legario-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/identification-and-characterization-of-motile-aeromonas-legario-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/identification-and-characterization-of-motile-aeromonas-legario-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-features-genome-epidemiology-and-antimicrobial-sakurai-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-features-genome-epidemiology-and-antimicrobial-sakurai-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-features-genome-epidemiology-and-antimicrobial-sakurai-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-features-genome-epidemiology-and-antimicrobial-sakurai-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-characterization-and-antibiotics-resistance-of-adah-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-characterization-and-antibiotics-resistance-of-adah-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-characterization-and-antibiotics-resistance-of-adah-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-characterization-and-antibiotics-resistance-of-adah-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prevalence-and-antimicrobial-resistance-of-bacterial-maraki-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prevalence-and-antimicrobial-resistance-of-bacterial-maraki-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prevalence-and-antimicrobial-resistance-of-bacterial-maraki-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prevalence-and-antimicrobial-resistance-of-bacterial-maraki-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cross-sectional-analysis-of-risk-factors-attia-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cross-sectional-analysis-of-risk-factors-attia-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cross-sectional-analysis-of-risk-factors-attia-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cross-sectional-analysis-of-risk-factors-attia-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-in-trauma-patients-sch-xf6-chl-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-in-trauma-patients-sch-xf6-chl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-in-trauma-patients-sch-xf6-chl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-in-trauma-patients-sch-xf6-chl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/real-world-experience-of-direct-oral-valenti-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/real-world-experience-of-direct-oral-valenti-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/real-world-experience-of-direct-oral-valenti-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/real-world-experience-of-direct-oral-valenti-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/exploring-aeromonas-dhakensis-in-aldabra-giant-zhao-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/exploring-aeromonas-dhakensis-in-aldabra-giant-zhao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/exploring-aeromonas-dhakensis-in-aldabra-giant-zhao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/exploring-aeromonas-dhakensis-in-aldabra-giant-zhao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lymphatic-uptake-of-a-highly-lipophilic-xie-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lymphatic-uptake-of-a-highly-lipophilic-xie-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lymphatic-uptake-of-a-highly-lipophilic-xie-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lymphatic-uptake-of-a-highly-lipophilic-xie-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/challenges-to-laboratory-monitoring-of-direct-qiao-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/challenges-to-laboratory-monitoring-of-direct-qiao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/challenges-to-laboratory-monitoring-of-direct-qiao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/challenges-to-laboratory-monitoring-of-direct-qiao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/interactions-betweenandisolated-from-a-case-of-fern-xe1-ndez-bravo-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/interactions-betweenandisolated-from-a-case-of-fern-xe1-ndez-bravo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/interactions-betweenandisolated-from-a-case-of-fern-xe1-ndez-bravo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/interactions-betweenandisolated-from-a-case-of-fern-xe1-ndez-bravo-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/phenotypic-and-genotypic-analysis-of-antimicrobial-sagas-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/phenotypic-and-genotypic-analysis-of-antimicrobial-sagas-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/phenotypic-and-genotypic-analysis-of-antimicrobial-sagas-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/phenotypic-and-genotypic-analysis-of-antimicrobial-sagas-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-and-safety-of-antithrombotic-therapy-gao-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-and-safety-of-antithrombotic-therapy-gao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-and-safety-of-antithrombotic-therapy-gao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-and-safety-of-antithrombotic-therapy-gao-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/molecular-epidemiological-characteristics-of-carbapenem-resistantfrom-zhang-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/molecular-epidemiological-characteristics-of-carbapenem-resistantfrom-zhang-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/molecular-epidemiological-characteristics-of-carbapenem-resistantfrom-zhang-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/molecular-epidemiological-characteristics-of-carbapenem-resistantfrom-zhang-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/overdosing-of-direct-oral-anticoagulants-neumann-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/overdosing-of-direct-oral-anticoagulants-neumann-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/overdosing-of-direct-oral-anticoagulants-neumann-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/overdosing-of-direct-oral-anticoagulants-neumann-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/beyond-anticoagulation-a-comprehensive-review-of-jannati-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/beyond-anticoagulation-a-comprehensive-review-of-jannati-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/beyond-anticoagulation-a-comprehensive-review-of-jannati-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/beyond-anticoagulation-a-comprehensive-review-of-jannati-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/innovative-techniques-preventing-salvaging-neurovascular-pedicle-flaps-zgonist-2008 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/innovative-techniques-preventing-salvaging-neurovascular-pedicle-flaps-zgonist-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/innovative-techniques-preventing-salvaging-neurovascular-pedicle-flaps-zgonist-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/innovative-techniques-preventing-salvaging-neurovascular-pedicle-flaps-zgonist-2008 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/effect-medicinal-leech-salivary-gland-secretion-state-baskovaip-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/effect-medicinal-leech-salivary-gland-secretion-state-baskovaip-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/effect-medicinal-leech-salivary-gland-secretion-state-baskovaip-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/effect-medicinal-leech-salivary-gland-secretion-state-baskovaip-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/binding-hirudin-meizothrombin-fischerbe-1998 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/binding-hirudin-meizothrombin-fischerbe-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/binding-hirudin-meizothrombin-fischerbe-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/binding-hirudin-meizothrombin-fischerbe-1998 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ddavp-reduces-bleeding-continued-hirudin-administration-rabbit-bovecm-1996 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ddavp-reduces-bleeding-continued-hirudin-administration-rabbit-bovecm-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ddavp-reduces-bleeding-continued-hirudin-administration-rabbit-bovecm-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ddavp-reduces-bleeding-continued-hirudin-administration-rabbit-bovecm-1996 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/secondary-prevention-venous-thromboembolism-oral-direct-thrombin-schulmans-2003 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/secondary-prevention-venous-thromboembolism-oral-direct-thrombin-schulmans-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/secondary-prevention-venous-thromboembolism-oral-direct-thrombin-schulmans-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/secondary-prevention-venous-thromboembolism-oral-direct-thrombin-schulmans-2003 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/duration-anticoagulation-following-venous-thromboembolism-meta-analysis-ostd-2005 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/duration-anticoagulation-following-venous-thromboembolism-meta-analysis-ostd-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/duration-anticoagulation-following-venous-thromboembolism-meta-analysis-ostd-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/duration-anticoagulation-following-venous-thromboembolism-meta-analysis-ostd-2005 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/diagnosis-treatment-superficial-vein-thrombosis-bauersachsrm-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/diagnosis-treatment-superficial-vein-thrombosis-bauersachsrm-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/diagnosis-treatment-superficial-vein-thrombosis-bauersachsrm-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/diagnosis-treatment-superficial-vein-thrombosis-bauersachsrm-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-relevance-symptomatic-superficial-vein-thrombosis-extension-lessons-leizorovicza-2013 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-relevance-symptomatic-superficial-vein-thrombosis-extension-lessons-leizorovicza-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-relevance-symptomatic-superficial-vein-thrombosis-extension-lessons-leizorovicza-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-relevance-symptomatic-superficial-vein-thrombosis-extension-lessons-leizorovicza-2013 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/major-bleeding-secondary-prevention-venous-thromboembolism-patients-castelluccila-2014 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/major-bleeding-secondary-prevention-venous-thromboembolism-patients-castelluccila-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/major-bleeding-secondary-prevention-venous-thromboembolism-patients-castelluccila-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/major-bleeding-secondary-prevention-venous-thromboembolism-patients-castelluccila-2014 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-superficial-vein-thrombosis-cosmib-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-superficial-vein-thrombosis-cosmib-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-superficial-vein-thrombosis-cosmib-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-superficial-vein-thrombosis-cosmib-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/extended-anticoagulant-aspirin-treatment-secondary-prevention-thromboembolic-marikpe-2015 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/extended-anticoagulant-aspirin-treatment-secondary-prevention-thromboembolic-marikpe-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/extended-anticoagulant-aspirin-treatment-secondary-prevention-thromboembolic-marikpe-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/extended-anticoagulant-aspirin-treatment-secondary-prevention-thromboembolic-marikpe-2015 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/superficial-vein-thrombosis-treated-45-xa0-days-werths-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/superficial-vein-thrombosis-treated-45-xa0-days-werths-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/superficial-vein-thrombosis-treated-45-xa0-days-werths-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/superficial-vein-thrombosis-treated-45-xa0-days-werths-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/extended-duration-anticoagulation-edoxaban-patients-venous-thromboembolism-raskobg-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/extended-duration-anticoagulation-edoxaban-patients-venous-thromboembolism-raskobg-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/extended-duration-anticoagulation-edoxaban-patients-venous-thromboembolism-raskobg-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/extended-duration-anticoagulation-edoxaban-patients-venous-thromboembolism-raskobg-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/safety-fondaparinux-sodium-treatment-venous-thromboembolism-mastroiacovod-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/safety-fondaparinux-sodium-treatment-venous-thromboembolism-mastroiacovod-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/safety-fondaparinux-sodium-treatment-venous-thromboembolism-mastroiacovod-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/safety-fondaparinux-sodium-treatment-venous-thromboembolism-mastroiacovod-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pentasaccharides-prevention-venous-thromboembolism-dongk-2016 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pentasaccharides-prevention-venous-thromboembolism-dongk-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pentasaccharides-prevention-venous-thromboembolism-dongk-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pentasaccharides-prevention-venous-thromboembolism-dongk-2016 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prevention-thromboembolic-complications-patients-superficial-vein-thrombosis-given-beyerwestendorfj-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prevention-thromboembolic-complications-patients-superficial-vein-thrombosis-given-beyerwestendorfj-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prevention-thromboembolic-complications-patients-superficial-vein-thrombosis-given-beyerwestendorfj-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prevention-thromboembolic-complications-patients-superficial-vein-thrombosis-given-beyerwestendorfj-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rivaroxaban-aspirin-extended-treatment-venous-thromboembolism-weitzji-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rivaroxaban-aspirin-extended-treatment-venous-thromboembolism-weitzji-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rivaroxaban-aspirin-extended-treatment-venous-thromboembolism-weitzji-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rivaroxaban-aspirin-extended-treatment-venous-thromboembolism-weitzji-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-outcomes-high-prevalence-abnormalities-comprehensive-arterial-limst-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-outcomes-high-prevalence-abnormalities-comprehensive-arterial-limst-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-outcomes-high-prevalence-abnormalities-comprehensive-arterial-limst-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-outcomes-high-prevalence-abnormalities-comprehensive-arterial-limst-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/association-between-thrombophilic-genes-polymorphisms-recurrent-pregnancy-kamalim-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/association-between-thrombophilic-genes-polymorphisms-recurrent-pregnancy-kamalim-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/association-between-thrombophilic-genes-polymorphisms-recurrent-pregnancy-kamalim-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/association-between-thrombophilic-genes-polymorphisms-recurrent-pregnancy-kamalim-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/long-term-outcomes-patent-foramen-ovale-closure-medical-saverjl-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/long-term-outcomes-patent-foramen-ovale-closure-medical-saverjl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/long-term-outcomes-patent-foramen-ovale-closure-medical-saverjl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/long-term-outcomes-patent-foramen-ovale-closure-medical-saverjl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/recurrent-thrombosis-case-hereditary-thromboembolism-giofrxe8mc-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/recurrent-thrombosis-case-hereditary-thromboembolism-giofrxe8mc-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/recurrent-thrombosis-case-hereditary-thromboembolism-giofrxe8mc-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/recurrent-thrombosis-case-hereditary-thromboembolism-giofrxe8mc-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/medical-management-acute-superficial-vein-thrombosis-saphenous-scovellsd-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/medical-management-acute-superficial-vein-thrombosis-saphenous-scovellsd-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/medical-management-acute-superficial-vein-thrombosis-saphenous-scovellsd-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/medical-management-acute-superficial-vein-thrombosis-saphenous-scovellsd-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/secondary-prevention-recurrent-venous-thromboembolism-initial-oral-robertsonl-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/secondary-prevention-recurrent-venous-thromboembolism-initial-oral-robertsonl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/secondary-prevention-recurrent-venous-thromboembolism-initial-oral-robertsonl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/secondary-prevention-recurrent-venous-thromboembolism-initial-oral-robertsonl-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/before-after-electronic-order-set-reversal-vitamin-k-vittjr-2017 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/before-after-electronic-order-set-reversal-vitamin-k-vittjr-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/before-after-electronic-order-set-reversal-vitamin-k-vittjr-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/before-after-electronic-order-set-reversal-vitamin-k-vittjr-2017 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-bivalirudin-anticoagulation-therapy-extracorporeal-membrane-oxygenation-zhongh-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-bivalirudin-anticoagulation-therapy-extracorporeal-membrane-oxygenation-zhongh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-bivalirudin-anticoagulation-therapy-extracorporeal-membrane-oxygenation-zhongh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-bivalirudin-anticoagulation-therapy-extracorporeal-membrane-oxygenation-zhongh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/off-label-direct-oral-anticoagulants-valvular-atrial-fibrillation-brokmeierh-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/off-label-direct-oral-anticoagulants-valvular-atrial-fibrillation-brokmeierh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/off-label-direct-oral-anticoagulants-valvular-atrial-fibrillation-brokmeierh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/off-label-direct-oral-anticoagulants-valvular-atrial-fibrillation-brokmeierh-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-antiphospholipid-syndrome-meta-analysis-randomized-dufrostv-2020 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-antiphospholipid-syndrome-meta-analysis-randomized-dufrostv-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-antiphospholipid-syndrome-meta-analysis-randomized-dufrostv-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-antiphospholipid-syndrome-meta-analysis-randomized-dufrostv-2020 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/outcomes-patients-nontriple-antiphospholipid-syndrome-aps-anticoagulated-htuttw-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/outcomes-patients-nontriple-antiphospholipid-syndrome-aps-anticoagulated-htuttw-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/outcomes-patients-nontriple-antiphospholipid-syndrome-aps-anticoagulated-htuttw-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/outcomes-patients-nontriple-antiphospholipid-syndrome-aps-anticoagulated-htuttw-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/hereditary-thrombophilia-recurrent-pregnancy-loss-systematic-review-liux-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/hereditary-thrombophilia-recurrent-pregnancy-loss-systematic-review-liux-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/hereditary-thrombophilia-recurrent-pregnancy-loss-systematic-review-liux-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/hereditary-thrombophilia-recurrent-pregnancy-loss-systematic-review-liux-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antiphospholipid-antibody-syndrome-associated-renal-thrombotic-microangiopathy-improved-horitas-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antiphospholipid-antibody-syndrome-associated-renal-thrombotic-microangiopathy-improved-horitas-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antiphospholipid-antibody-syndrome-associated-renal-thrombotic-microangiopathy-improved-horitas-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antiphospholipid-antibody-syndrome-associated-renal-thrombotic-microangiopathy-improved-horitas-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/activated-prothrombin-complex-concentrate-induced-atypical-hemolytic-uremic-tsaihhc-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/activated-prothrombin-complex-concentrate-induced-atypical-hemolytic-uremic-tsaihhc-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/activated-prothrombin-complex-concentrate-induced-atypical-hemolytic-uremic-tsaihhc-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/activated-prothrombin-complex-concentrate-induced-atypical-hemolytic-uremic-tsaihhc-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/coagulopathy-hospitalised-covid-19-pragmatic-randomised-controlled-therapeutic-sholzbergm-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/coagulopathy-hospitalised-covid-19-pragmatic-randomised-controlled-therapeutic-sholzbergm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/coagulopathy-hospitalised-covid-19-pragmatic-randomised-controlled-therapeutic-sholzbergm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/coagulopathy-hospitalised-covid-19-pragmatic-randomised-controlled-therapeutic-sholzbergm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulation-transfusion-management-neonatal-pediatric-extracorporeal-membrane-ozmentcp-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulation-transfusion-management-neonatal-pediatric-extracorporeal-membrane-ozmentcp-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulation-transfusion-management-neonatal-pediatric-extracorporeal-membrane-ozmentcp-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulation-transfusion-management-neonatal-pediatric-extracorporeal-membrane-ozmentcp-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/observational-evaluate-effectiveness-rivaroxaban-management-cerebral-venous-fatimam-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/observational-evaluate-effectiveness-rivaroxaban-management-cerebral-venous-fatimam-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/observational-evaluate-effectiveness-rivaroxaban-management-cerebral-venous-fatimam-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/observational-evaluate-effectiveness-rivaroxaban-management-cerebral-venous-fatimam-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evaluation-fixed-variable-dosing-4-factor-prothrombin-complex-stoeckerz-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evaluation-fixed-variable-dosing-4-factor-prothrombin-complex-stoeckerz-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evaluation-fixed-variable-dosing-4-factor-prothrombin-complex-stoeckerz-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evaluation-fixed-variable-dosing-4-factor-prothrombin-complex-stoeckerz-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-patients-antiphospholipid-syndrome-systematic-pastorid-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-patients-antiphospholipid-syndrome-systematic-pastorid-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-patients-antiphospholipid-syndrome-systematic-pastorid-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-patients-antiphospholipid-syndrome-systematic-pastorid-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/risk-factors-gastrointestinal-bleeding-patients-gastrointestinal-cancer-boschftm-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/risk-factors-gastrointestinal-bleeding-patients-gastrointestinal-cancer-boschftm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/risk-factors-gastrointestinal-bleeding-patients-gastrointestinal-cancer-boschftm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/risk-factors-gastrointestinal-bleeding-patients-gastrointestinal-cancer-boschftm-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-doacs-drawbacks-bleeding-reversal-karciogluo-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-doacs-drawbacks-bleeding-reversal-karciogluo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-doacs-drawbacks-bleeding-reversal-karciogluo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-doacs-drawbacks-bleeding-reversal-karciogluo-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/estimating-bleeding-risk-patients-cancer-associated-thrombosis-evaluation-dewinterma-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/estimating-bleeding-risk-patients-cancer-associated-thrombosis-evaluation-dewinterma-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/estimating-bleeding-risk-patients-cancer-associated-thrombosis-evaluation-dewinterma-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/estimating-bleeding-risk-patients-cancer-associated-thrombosis-evaluation-dewinterma-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/roles-four-factor-prothrombin-complex-concentrate-management-critical-tanakaka-2021 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/roles-four-factor-prothrombin-complex-concentrate-management-critical-tanakaka-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/roles-four-factor-prothrombin-complex-concentrate-management-critical-tanakaka-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/roles-four-factor-prothrombin-complex-concentrate-management-critical-tanakaka-2021 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/eastern-association-surgery-trauma-multicenter-comparison-pre-injury-yorkgitisbk-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/eastern-association-surgery-trauma-multicenter-comparison-pre-injury-yorkgitisbk-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/eastern-association-surgery-trauma-multicenter-comparison-pre-injury-yorkgitisbk-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/eastern-association-surgery-trauma-multicenter-comparison-pre-injury-yorkgitisbk-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antithrombotic-therapy-secondary-prevention-unprovoked-venous-thromboembolism-lid-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antithrombotic-therapy-secondary-prevention-unprovoked-venous-thromboembolism-lid-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antithrombotic-therapy-secondary-prevention-unprovoked-venous-thromboembolism-lid-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antithrombotic-therapy-secondary-prevention-unprovoked-venous-thromboembolism-lid-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/eculizumab-refractory-thrombosis-antiphospholipid-syndrome-hussainh-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/eculizumab-refractory-thrombosis-antiphospholipid-syndrome-hussainh-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/eculizumab-refractory-thrombosis-antiphospholipid-syndrome-hussainh-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/eculizumab-refractory-thrombosis-antiphospholipid-syndrome-hussainh-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/riete-registry-patients-upper-extremity-deep-vein-rosav-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/riete-registry-patients-upper-extremity-deep-vein-rosav-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/riete-registry-patients-upper-extremity-deep-vein-rosav-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/riete-registry-patients-upper-extremity-deep-vein-rosav-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-oral-anticoagulants-warfarin-patients-single-antibody-positive-liua-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-oral-anticoagulants-warfarin-patients-single-antibody-positive-liua-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-oral-anticoagulants-warfarin-patients-single-antibody-positive-liua-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-oral-anticoagulants-warfarin-patients-single-antibody-positive-liua-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/lupus-anticoagulant-testing-anticoagulation-including-direct-oral-favaloroej-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/lupus-anticoagulant-testing-anticoagulation-including-direct-oral-favaloroej-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/lupus-anticoagulant-testing-anticoagulation-including-direct-oral-favaloroej-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/lupus-anticoagulant-testing-anticoagulation-including-direct-oral-favaloroej-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/prothrombin-g20210a-gene-mutation-induced-recurrent-deep-vein-elkattawys-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/prothrombin-g20210a-gene-mutation-induced-recurrent-deep-vein-elkattawys-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/prothrombin-g20210a-gene-mutation-induced-recurrent-deep-vein-elkattawys-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/prothrombin-g20210a-gene-mutation-induced-recurrent-deep-vein-elkattawys-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-hemostatic-efficacy-4f-pcc-patients-intracranial-hemorrhage-heathm-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-hemostatic-efficacy-4f-pcc-patients-intracranial-hemorrhage-heathm-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-hemostatic-efficacy-4f-pcc-patients-intracranial-hemorrhage-heathm-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-hemostatic-efficacy-4f-pcc-patients-intracranial-hemorrhage-heathm-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/preoperative-thrombolysis-associated-improved-vein-patency-functional-chuntt-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/preoperative-thrombolysis-associated-improved-vein-patency-functional-chuntt-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/preoperative-thrombolysis-associated-improved-vein-patency-functional-chuntt-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/preoperative-thrombolysis-associated-improved-vein-patency-functional-chuntt-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-safety-considerations-dose-reduced-direct-oral-anticoagulants-bikdelib-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-safety-considerations-dose-reduced-direct-oral-anticoagulants-bikdelib-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-safety-considerations-dose-reduced-direct-oral-anticoagulants-bikdelib-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-safety-considerations-dose-reduced-direct-oral-anticoagulants-bikdelib-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cost-effectiveness-direct-oral-anticoagulants-compared-low-molecular-weight-heparins-treatment-muxf1oza-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cost-effectiveness-direct-oral-anticoagulants-compared-low-molecular-weight-heparins-treatment-muxf1oza-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cost-effectiveness-direct-oral-anticoagulants-compared-low-molecular-weight-heparins-treatment-muxf1oza-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cost-effectiveness-direct-oral-anticoagulants-compared-low-molecular-weight-heparins-treatment-muxf1oza-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/atypical-presentation-paget-schroetter-syndrome-case-report-management-desaij-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/atypical-presentation-paget-schroetter-syndrome-case-report-management-desaij-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/atypical-presentation-paget-schroetter-syndrome-case-report-management-desaij-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/atypical-presentation-paget-schroetter-syndrome-case-report-management-desaij-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/surgical-decompression-among-paget-schroetter-patients-subacute-chronic-chengmj-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/surgical-decompression-among-paget-schroetter-patients-subacute-chronic-chengmj-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/surgical-decompression-among-paget-schroetter-patients-subacute-chronic-chengmj-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/surgical-decompression-among-paget-schroetter-patients-subacute-chronic-chengmj-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/long-term-outcomes-nonoperative-surgical-management-paget-schroetter-syndrome-hoexumf-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/long-term-outcomes-nonoperative-surgical-management-paget-schroetter-syndrome-hoexumf-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/long-term-outcomes-nonoperative-surgical-management-paget-schroetter-syndrome-hoexumf-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/long-term-outcomes-nonoperative-surgical-management-paget-schroetter-syndrome-hoexumf-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-safety-direct-oral-anticoagulants-patients-antiphospholipid-gullapallik-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-safety-direct-oral-anticoagulants-patients-antiphospholipid-gullapallik-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-safety-direct-oral-anticoagulants-patients-antiphospholipid-gullapallik-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-safety-direct-oral-anticoagulants-patients-antiphospholipid-gullapallik-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evaluation-direct-oral-anticoagulant-reversal-agents-intracranial-chaudharyr-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evaluation-direct-oral-anticoagulant-reversal-agents-intracranial-chaudharyr-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evaluation-direct-oral-anticoagulant-reversal-agents-intracranial-chaudharyr-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evaluation-direct-oral-anticoagulant-reversal-agents-intracranial-chaudharyr-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/performance-status-long-term-outcomes-cancer-associated-pulmonary-embolism-farmakisit-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/performance-status-long-term-outcomes-cancer-associated-pulmonary-embolism-farmakisit-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/performance-status-long-term-outcomes-cancer-associated-pulmonary-embolism-farmakisit-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/performance-status-long-term-outcomes-cancer-associated-pulmonary-embolism-farmakisit-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/redefining-clinical-venous-thromboembolism-phenotypes-xa0-approach-dewinterma-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/redefining-clinical-venous-thromboembolism-phenotypes-xa0-approach-dewinterma-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/redefining-clinical-venous-thromboembolism-phenotypes-xa0-approach-dewinterma-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/redefining-clinical-venous-thromboembolism-phenotypes-xa0-approach-dewinterma-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/surgical-pharmaceutical-treatment-superficial-vein-thrombosis-lower-papageorgopoulouc-2022 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/surgical-pharmaceutical-treatment-superficial-vein-thrombosis-lower-papageorgopoulouc-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/surgical-pharmaceutical-treatment-superficial-vein-thrombosis-lower-papageorgopoulouc-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/surgical-pharmaceutical-treatment-superficial-vein-thrombosis-lower-papageorgopoulouc-2022 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/oral-anticoagulation-patients-chronic-liver-disease-costachers-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/oral-anticoagulation-patients-chronic-liver-disease-costachers-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/oral-anticoagulation-patients-chronic-liver-disease-costachers-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/oral-anticoagulation-patients-chronic-liver-disease-costachers-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/ten-year-experience-surgical-management-paget-schroetter-syndrome-devezee-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/ten-year-experience-surgical-management-paget-schroetter-syndrome-devezee-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/ten-year-experience-surgical-management-paget-schroetter-syndrome-devezee-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/ten-year-experience-surgical-management-paget-schroetter-syndrome-devezee-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/choosing-safe-effective-anticoagulation-treat-idiopathic-ovarian-yiie-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/choosing-safe-effective-anticoagulation-treat-idiopathic-ovarian-yiie-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/choosing-safe-effective-anticoagulation-treat-idiopathic-ovarian-yiie-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/choosing-safe-effective-anticoagulation-treat-idiopathic-ovarian-yiie-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/direct-acting-oral-anticoagulants-antiphospholipid-syndrome-systematic-review-girxf3nortegaja-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/direct-acting-oral-anticoagulants-antiphospholipid-syndrome-systematic-review-girxf3nortegaja-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/direct-acting-oral-anticoagulants-antiphospholipid-syndrome-systematic-review-girxf3nortegaja-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/direct-acting-oral-anticoagulants-antiphospholipid-syndrome-systematic-review-girxf3nortegaja-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/exploratory-next-generation-sequencing-identify-prothrombotic-variants-patients-kramerra-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/exploratory-next-generation-sequencing-identify-prothrombotic-variants-patients-kramerra-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/exploratory-next-generation-sequencing-identify-prothrombotic-variants-patients-kramerra-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/exploratory-next-generation-sequencing-identify-prothrombotic-variants-patients-kramerra-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/results-flexible-patient-centered-approach-timing-thoracic-outlet-seni-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/results-flexible-patient-centered-approach-timing-thoracic-outlet-seni-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/results-flexible-patient-centered-approach-timing-thoracic-outlet-seni-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/results-flexible-patient-centered-approach-timing-thoracic-outlet-seni-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/recurrent-miscarriagegreen-top-guideline-no-17-reganl-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/recurrent-miscarriagegreen-top-guideline-no-17-reganl-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/recurrent-miscarriagegreen-top-guideline-no-17-reganl-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/recurrent-miscarriagegreen-top-guideline-no-17-reganl-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pneumatic-compression-combined-standard-treatment-total-hip-carnevalepellinov-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pneumatic-compression-combined-standard-treatment-total-hip-carnevalepellinov-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pneumatic-compression-combined-standard-treatment-total-hip-carnevalepellinov-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pneumatic-compression-combined-standard-treatment-total-hip-carnevalepellinov-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/common-practice-treatment-superficial-vein-thrombosis-involving-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/common-practice-treatment-superficial-vein-thrombosis-involving-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/common-practice-treatment-superficial-vein-thrombosis-involving-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/common-practice-treatment-superficial-vein-thrombosis-involving-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/risk-venous-thromboembolism-thromboprophylaxis-between-aspirin-low-nxfaxf1ezjh-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/risk-venous-thromboembolism-thromboprophylaxis-between-aspirin-low-nxfaxf1ezjh-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/risk-venous-thromboembolism-thromboprophylaxis-between-aspirin-low-nxfaxf1ezjh-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/risk-venous-thromboembolism-thromboprophylaxis-between-aspirin-low-nxfaxf1ezjh-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pulmonary-embolism-following-undiagnosed-paget-schroetter-syndrome-case-negrxe3opantalexe3oa-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pulmonary-embolism-following-undiagnosed-paget-schroetter-syndrome-case-negrxe3opantalexe3oa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pulmonary-embolism-following-undiagnosed-paget-schroetter-syndrome-case-negrxe3opantalexe3oa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pulmonary-embolism-following-undiagnosed-paget-schroetter-syndrome-case-negrxe3opantalexe3oa-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-paget-schroetter-syndrome-systematic-review-meta-analysis-hoexumf-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-paget-schroetter-syndrome-systematic-review-meta-analysis-hoexumf-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-paget-schroetter-syndrome-systematic-review-meta-analysis-hoexumf-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-paget-schroetter-syndrome-systematic-review-meta-analysis-hoexumf-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/real-world-data-emulating-randomized-controlled-trials-non-vitamin-yoond-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/real-world-data-emulating-randomized-controlled-trials-non-vitamin-yoond-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/real-world-data-emulating-randomized-controlled-trials-non-vitamin-yoond-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/real-world-data-emulating-randomized-controlled-trials-non-vitamin-yoond-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/persistent-underuse-extended-venous-thromboembolism-prophylaxis-patients-herbjn-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/persistent-underuse-extended-venous-thromboembolism-prophylaxis-patients-herbjn-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/persistent-underuse-extended-venous-thromboembolism-prophylaxis-patients-herbjn-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/persistent-underuse-extended-venous-thromboembolism-prophylaxis-patients-herbjn-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mesoglycan-secondary-prevention-superficial-vein-thrombosis-randomized-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mesoglycan-secondary-prevention-superficial-vein-thrombosis-randomized-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mesoglycan-secondary-prevention-superficial-vein-thrombosis-randomized-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mesoglycan-secondary-prevention-superficial-vein-thrombosis-randomized-camporeseg-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/effect-different-application-duration-venous-foot-pump-gus-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/effect-different-application-duration-venous-foot-pump-gus-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/effect-different-application-duration-venous-foot-pump-gus-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/effect-different-application-duration-venous-foot-pump-gus-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/relevance-prothrombotic-genetic-variants-women-who-experienced-cernerag-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/relevance-prothrombotic-genetic-variants-women-who-experienced-cernerag-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/relevance-prothrombotic-genetic-variants-women-who-experienced-cernerag-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/relevance-prothrombotic-genetic-variants-women-who-experienced-cernerag-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/test-not-test-routine-thrombophilia-diagnostic-screening-wysockau-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/test-not-test-routine-thrombophilia-diagnostic-screening-wysockau-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/test-not-test-routine-thrombophilia-diagnostic-screening-wysockau-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/test-not-test-routine-thrombophilia-diagnostic-screening-wysockau-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evaluation-bivalirudin-adult-extracorporeal-membrane-oxygenation-retrospective-lopeznd-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evaluation-bivalirudin-adult-extracorporeal-membrane-oxygenation-retrospective-lopeznd-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evaluation-bivalirudin-adult-extracorporeal-membrane-oxygenation-retrospective-lopeznd-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evaluation-bivalirudin-adult-extracorporeal-membrane-oxygenation-retrospective-lopeznd-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparison-efficacy-safety-between-aspirin-oral-anticoagulants-zhengx-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparison-efficacy-safety-between-aspirin-oral-anticoagulants-zhengx-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparison-efficacy-safety-between-aspirin-oral-anticoagulants-zhengx-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparison-efficacy-safety-between-aspirin-oral-anticoagulants-zhengx-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/jugular-subclavian-junction-venous-drainage-brain-singha-2023 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/jugular-subclavian-junction-venous-drainage-brain-singha-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/jugular-subclavian-junction-venous-drainage-brain-singha-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/jugular-subclavian-junction-venous-drainage-brain-singha-2023 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/translated-article-risk-venous-thromboembolism-thromboprophylaxis-between-nxfaxf1ezjh-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/translated-article-risk-venous-thromboembolism-thromboprophylaxis-between-nxfaxf1ezjh-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/translated-article-risk-venous-thromboembolism-thromboprophylaxis-between-nxfaxf1ezjh-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/translated-article-risk-venous-thromboembolism-thromboprophylaxis-between-nxfaxf1ezjh-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fixed-variable-dose-prothrombin-complex-concentrate-emergent-reversal-alwakeala-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fixed-variable-dose-prothrombin-complex-concentrate-emergent-reversal-alwakeala-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fixed-variable-dose-prothrombin-complex-concentrate-emergent-reversal-alwakeala-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fixed-variable-dose-prothrombin-complex-concentrate-emergent-reversal-alwakeala-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/safety-efficacy-noacs-lmwh-thromboprophylaxis-tha-tka-dingk-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/safety-efficacy-noacs-lmwh-thromboprophylaxis-tha-tka-dingk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/safety-efficacy-noacs-lmwh-thromboprophylaxis-tha-tka-dingk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/safety-efficacy-noacs-lmwh-thromboprophylaxis-tha-tka-dingk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/real-world-data-treatment-patterns-bleeding-cancer-associated-thrombosis-zaborasz-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/real-world-data-treatment-patterns-bleeding-cancer-associated-thrombosis-zaborasz-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/real-world-data-treatment-patterns-bleeding-cancer-associated-thrombosis-zaborasz-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/real-world-data-treatment-patterns-bleeding-cancer-associated-thrombosis-zaborasz-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulants-treatment-isolated-lower-limb-superficial-vein-bontinisa-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulants-treatment-isolated-lower-limb-superficial-vein-bontinisa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulants-treatment-isolated-lower-limb-superficial-vein-bontinisa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulants-treatment-isolated-lower-limb-superficial-vein-bontinisa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-safety-aspirin-venous-thromboembolism-prevention-total-jiangw-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-safety-aspirin-venous-thromboembolism-prevention-total-jiangw-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-safety-aspirin-venous-thromboembolism-prevention-total-jiangw-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-safety-aspirin-venous-thromboembolism-prevention-total-jiangw-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/apixaban-low-molecular-weight-heparin-patients-cancer-associated-amina-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/apixaban-low-molecular-weight-heparin-patients-cancer-associated-amina-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/apixaban-low-molecular-weight-heparin-patients-cancer-associated-amina-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/apixaban-low-molecular-weight-heparin-patients-cancer-associated-amina-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-efficacy-aspirin-direct-oral-anticoagulants-venous-syedfa-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-efficacy-aspirin-direct-oral-anticoagulants-venous-syedfa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-efficacy-aspirin-direct-oral-anticoagulants-venous-syedfa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-efficacy-aspirin-direct-oral-anticoagulants-venous-syedfa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-aspirin-low-molecular-weight-heparin-venous-thromboembolism-prophylaxis-salmanla-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-aspirin-low-molecular-weight-heparin-venous-thromboembolism-prophylaxis-salmanla-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-aspirin-low-molecular-weight-heparin-venous-thromboembolism-prophylaxis-salmanla-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-aspirin-low-molecular-weight-heparin-venous-thromboembolism-prophylaxis-salmanla-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antithrombotic-efficacy-bleeding-risks-vaccine-induced-immune-thrombotic-leunghhl-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antithrombotic-efficacy-bleeding-risks-vaccine-induced-immune-thrombotic-leunghhl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antithrombotic-efficacy-bleeding-risks-vaccine-induced-immune-thrombotic-leunghhl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antithrombotic-efficacy-bleeding-risks-vaccine-induced-immune-thrombotic-leunghhl-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/risk-recurrent-venous-thromboembolism-patients-cancer-individual-lantingvr-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/risk-recurrent-venous-thromboembolism-patients-cancer-individual-lantingvr-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/risk-recurrent-venous-thromboembolism-patients-cancer-individual-lantingvr-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/risk-recurrent-venous-thromboembolism-patients-cancer-individual-lantingvr-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/when-anticoagulation-backfires-heparin-induced-thrombocytopenia-acute-kumara-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/when-anticoagulation-backfires-heparin-induced-thrombocytopenia-acute-kumara-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/when-anticoagulation-backfires-heparin-induced-thrombocytopenia-acute-kumara-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/when-anticoagulation-backfires-heparin-induced-thrombocytopenia-acute-kumara-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/primary-prevention-cancer-associated-thrombosis-current-perspectives-hartc-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/primary-prevention-cancer-associated-thrombosis-current-perspectives-hartc-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/primary-prevention-cancer-associated-thrombosis-current-perspectives-hartc-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/primary-prevention-cancer-associated-thrombosis-current-perspectives-hartc-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/current-evidence-effectiveness-safety-oral-anticoagulants-superficial-damayva-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/current-evidence-effectiveness-safety-oral-anticoagulants-superficial-damayva-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/current-evidence-effectiveness-safety-oral-anticoagulants-superficial-damayva-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/current-evidence-effectiveness-safety-oral-anticoagulants-superficial-damayva-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fragility-statistical-significance-aspirin-prevention-venous-thromboembolism-williamsontk-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fragility-statistical-significance-aspirin-prevention-venous-thromboembolism-williamsontk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fragility-statistical-significance-aspirin-prevention-venous-thromboembolism-williamsontk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fragility-statistical-significance-aspirin-prevention-venous-thromboembolism-williamsontk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/12-year-review-upper-extremity-deep-vein-thrombosis-are-leungp-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/12-year-review-upper-extremity-deep-vein-thrombosis-are-leungp-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/12-year-review-upper-extremity-deep-vein-thrombosis-are-leungp-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/12-year-review-upper-extremity-deep-vein-thrombosis-are-leungp-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/mechanical-thrombectomy-clottriever-system-upper-extremity-deep-patelpj-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/mechanical-thrombectomy-clottriever-system-upper-extremity-deep-patelpj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/mechanical-thrombectomy-clottriever-system-upper-extremity-deep-patelpj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/mechanical-thrombectomy-clottriever-system-upper-extremity-deep-patelpj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cluster-pediatric-vaccine-induced-immune-thrombotic-thrombocytopenia-like-cases-dimopouloud-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cluster-pediatric-vaccine-induced-immune-thrombotic-thrombocytopenia-like-cases-dimopouloud-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cluster-pediatric-vaccine-induced-immune-thrombotic-thrombocytopenia-like-cases-dimopouloud-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cluster-pediatric-vaccine-induced-immune-thrombotic-thrombocytopenia-like-cases-dimopouloud-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/standard-extended-duration-anticoagulation-primary-venous-thromboembolism-prophylaxis-kolkailahaa-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/standard-extended-duration-anticoagulation-primary-venous-thromboembolism-prophylaxis-kolkailahaa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/standard-extended-duration-anticoagulation-primary-venous-thromboembolism-prophylaxis-kolkailahaa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/standard-extended-duration-anticoagulation-primary-venous-thromboembolism-prophylaxis-kolkailahaa-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/upper-arm-deep-vein-thrombosis-patient-active-hassaneinmfk-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/upper-arm-deep-vein-thrombosis-patient-active-hassaneinmfk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/upper-arm-deep-vein-thrombosis-patient-active-hassaneinmfk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/upper-arm-deep-vein-thrombosis-patient-active-hassaneinmfk-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/aspirin-prophylaxis-vte-patients-hip-knee-replacement-maddukurirk-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/aspirin-prophylaxis-vte-patients-hip-knee-replacement-maddukurirk-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/aspirin-prophylaxis-vte-patients-hip-knee-replacement-maddukurirk-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/aspirin-prophylaxis-vte-patients-hip-knee-replacement-maddukurirk-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-safety-extended-duration-postoperative-thromboprophylaxis-low-girardil-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-safety-extended-duration-postoperative-thromboprophylaxis-low-girardil-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-safety-extended-duration-postoperative-thromboprophylaxis-low-girardil-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-safety-extended-duration-postoperative-thromboprophylaxis-low-girardil-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/extended-treatment-venous-thromboembolism-reduced-dose-full-dose-direct-couturaudf-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/extended-treatment-venous-thromboembolism-reduced-dose-full-dose-direct-couturaudf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/extended-treatment-venous-thromboembolism-reduced-dose-full-dose-direct-couturaudf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/extended-treatment-venous-thromboembolism-reduced-dose-full-dose-direct-couturaudf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/treatment-outcomes-on-treatment-recurrent-venous-thromboembolism-patients-lantingvr-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/treatment-outcomes-on-treatment-recurrent-venous-thromboembolism-patients-lantingvr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/treatment-outcomes-on-treatment-recurrent-venous-thromboembolism-patients-lantingvr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/treatment-outcomes-on-treatment-recurrent-venous-thromboembolism-patients-lantingvr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/nonbacterial-thrombotic-endocarditis-mitral-prosthesis-warfarin-enoxaparin-nevina-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/nonbacterial-thrombotic-endocarditis-mitral-prosthesis-warfarin-enoxaparin-nevina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/nonbacterial-thrombotic-endocarditis-mitral-prosthesis-warfarin-enoxaparin-nevina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/nonbacterial-thrombotic-endocarditis-mitral-prosthesis-warfarin-enoxaparin-nevina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/antiphospholipid-syndrome-presenting-isolated-renal-vein-thrombosis-mooranikn-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/antiphospholipid-syndrome-presenting-isolated-renal-vein-thrombosis-mooranikn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/antiphospholipid-syndrome-presenting-isolated-renal-vein-thrombosis-mooranikn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/antiphospholipid-syndrome-presenting-isolated-renal-vein-thrombosis-mooranikn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparing-fondaparinux-low-molecular-weight-heparin-thromboprophylaxis-waseemmh-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparing-fondaparinux-low-molecular-weight-heparin-thromboprophylaxis-waseemmh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparing-fondaparinux-low-molecular-weight-heparin-thromboprophylaxis-waseemmh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparing-fondaparinux-low-molecular-weight-heparin-thromboprophylaxis-waseemmh-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/extended-reduced-dose-apixaban-cancer-associated-venous-thromboembolism-mahxe9i-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/extended-reduced-dose-apixaban-cancer-associated-venous-thromboembolism-mahxe9i-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/extended-reduced-dose-apixaban-cancer-associated-venous-thromboembolism-mahxe9i-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/extended-reduced-dose-apixaban-cancer-associated-venous-thromboembolism-mahxe9i-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/twenty-years-four-factor-prothrombin-complex-concentrate-octaplex-karkoutik-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/twenty-years-four-factor-prothrombin-complex-concentrate-octaplex-karkoutik-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/twenty-years-four-factor-prothrombin-complex-concentrate-octaplex-karkoutik-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/twenty-years-four-factor-prothrombin-complex-concentrate-octaplex-karkoutik-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/unraveling-clot-miscarriage-nexus-mechanisms-management-future-directions-husseina-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/unraveling-clot-miscarriage-nexus-mechanisms-management-future-directions-husseina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/unraveling-clot-miscarriage-nexus-mechanisms-management-future-directions-husseina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/unraveling-clot-miscarriage-nexus-mechanisms-management-future-directions-husseina-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/superficial-vein-thrombosis-state-art-review-cortesef-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/superficial-vein-thrombosis-state-art-review-cortesef-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/superficial-vein-thrombosis-state-art-review-cortesef-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/superficial-vein-thrombosis-state-art-review-cortesef-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/safety-comparisons-among-different-subcutaneous-anticoagulants-venous-lubw-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/safety-comparisons-among-different-subcutaneous-anticoagulants-venous-lubw-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/safety-comparisons-among-different-subcutaneous-anticoagulants-venous-lubw-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/safety-comparisons-among-different-subcutaneous-anticoagulants-venous-lubw-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-heparin-induced-thrombocytopenia-due-therapeutic-plasmapheresis-heparin-lvc-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-heparin-induced-thrombocytopenia-due-therapeutic-plasmapheresis-heparin-lvc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-heparin-induced-thrombocytopenia-due-therapeutic-plasmapheresis-heparin-lvc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-heparin-induced-thrombocytopenia-due-therapeutic-plasmapheresis-heparin-lvc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/risk-factors-management-cancer-associated-thrombosis-ongoing-battle-vrotniakaitebajercienek-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/risk-factors-management-cancer-associated-thrombosis-ongoing-battle-vrotniakaitebajercienek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/risk-factors-management-cancer-associated-thrombosis-ongoing-battle-vrotniakaitebajercienek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/risk-factors-management-cancer-associated-thrombosis-ongoing-battle-vrotniakaitebajercienek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/cerebral-venous-sinus-thrombosis-complication-heparin-induced-thrombocytopenia-abualrobma-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/cerebral-venous-sinus-thrombosis-complication-heparin-induced-thrombocytopenia-abualrobma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/cerebral-venous-sinus-thrombosis-complication-heparin-induced-thrombocytopenia-abualrobma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/cerebral-venous-sinus-thrombosis-complication-heparin-induced-thrombocytopenia-abualrobma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/strategies-anticoagulation-patients-thrombocytopenia-cancer-associated-thrombosis-start-wangtf-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/strategies-anticoagulation-patients-thrombocytopenia-cancer-associated-thrombosis-start-wangtf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/strategies-anticoagulation-patients-thrombocytopenia-cancer-associated-thrombosis-start-wangtf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/strategies-anticoagulation-patients-thrombocytopenia-cancer-associated-thrombosis-start-wangtf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fondaparinux-failure-heparin-induced-thrombocytopenia-acute-limb-ischemia-bowena-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fondaparinux-failure-heparin-induced-thrombocytopenia-acute-limb-ischemia-bowena-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fondaparinux-failure-heparin-induced-thrombocytopenia-acute-limb-ischemia-bowena-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fondaparinux-failure-heparin-induced-thrombocytopenia-acute-limb-ischemia-bowena-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/optimizing-blood-management-arthroplasty-meta-analysis-carbazochrome-sodium-alsaiedma-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/optimizing-blood-management-arthroplasty-meta-analysis-carbazochrome-sodium-alsaiedma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/optimizing-blood-management-arthroplasty-meta-analysis-carbazochrome-sodium-alsaiedma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/optimizing-blood-management-arthroplasty-meta-analysis-carbazochrome-sodium-alsaiedma-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/treatment-heparin-induced-thrombocytopenia-hit-fondaparinux-patient-liver-deliss-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/treatment-heparin-induced-thrombocytopenia-hit-fondaparinux-patient-liver-deliss-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/treatment-heparin-induced-thrombocytopenia-hit-fondaparinux-patient-liver-deliss-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/treatment-heparin-induced-thrombocytopenia-hit-fondaparinux-patient-liver-deliss-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/interventional-procedures-deep-venous-thrombosis-treatment-review-kacax142aa-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/interventional-procedures-deep-venous-thrombosis-treatment-review-kacax142aa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/interventional-procedures-deep-venous-thrombosis-treatment-review-kacax142aa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/interventional-procedures-deep-venous-thrombosis-treatment-review-kacax142aa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/time-hemostatic-agent-administration-increases-mortality-veterans-markovicn-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/time-hemostatic-agent-administration-increases-mortality-veterans-markovicn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/time-hemostatic-agent-administration-increases-mortality-veterans-markovicn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/time-hemostatic-agent-administration-increases-mortality-veterans-markovicn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/efficacy-factor-xa-inhibitors-placebo-thromboprophylaxis-cancer-associated-kamila-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/efficacy-factor-xa-inhibitors-placebo-thromboprophylaxis-cancer-associated-kamila-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/efficacy-factor-xa-inhibitors-placebo-thromboprophylaxis-cancer-associated-kamila-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/efficacy-factor-xa-inhibitors-placebo-thromboprophylaxis-cancer-associated-kamila-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/case-paget-schroetter-syndrome-young-healthy-woman-maj-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/case-paget-schroetter-syndrome-young-healthy-woman-maj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/case-paget-schroetter-syndrome-young-healthy-woman-maj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/case-paget-schroetter-syndrome-young-healthy-woman-maj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/safety-efficacy-fondaparinux-hemodialysis-patients-heparin-induced-thrombocytopenia-stojadinovicm-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/safety-efficacy-fondaparinux-hemodialysis-patients-heparin-induced-thrombocytopenia-stojadinovicm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/safety-efficacy-fondaparinux-hemodialysis-patients-heparin-induced-thrombocytopenia-stojadinovicm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/safety-efficacy-fondaparinux-hemodialysis-patients-heparin-induced-thrombocytopenia-stojadinovicm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/managing-anticoagulation-peripartum-langeral-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/managing-anticoagulation-peripartum-langeral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/managing-anticoagulation-peripartum-langeral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/managing-anticoagulation-peripartum-langeral-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/thrombectomy-high-risk-pulmonary-embolism-device-thrombolysis-stengerwje-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/thrombectomy-high-risk-pulmonary-embolism-device-thrombolysis-stengerwje-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/thrombectomy-high-risk-pulmonary-embolism-device-thrombolysis-stengerwje-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/thrombectomy-high-risk-pulmonary-embolism-device-thrombolysis-stengerwje-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/protocol-distinct-individual-targeted-thrombosis-prophylaxis-standard-kokry-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/protocol-distinct-individual-targeted-thrombosis-prophylaxis-standard-kokry-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/protocol-distinct-individual-targeted-thrombosis-prophylaxis-standard-kokry-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/protocol-distinct-individual-targeted-thrombosis-prophylaxis-standard-kokry-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/supercharged-hypercoagulability-case-heparin-induced-thrombocytopenia-thrombosis-patient-okabey-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/supercharged-hypercoagulability-case-heparin-induced-thrombocytopenia-thrombosis-patient-okabey-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/supercharged-hypercoagulability-case-heparin-induced-thrombocytopenia-thrombosis-patient-okabey-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/supercharged-hypercoagulability-case-heparin-induced-thrombocytopenia-thrombosis-patient-okabey-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/effect-prophylactic-fibrinogen-concentrate-scoliosis-surgery-efiss-hudecj-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/effect-prophylactic-fibrinogen-concentrate-scoliosis-surgery-efiss-hudecj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/effect-prophylactic-fibrinogen-concentrate-scoliosis-surgery-efiss-hudecj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/effect-prophylactic-fibrinogen-concentrate-scoliosis-surgery-efiss-hudecj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/anticoagulant-management-antithrombin-deficient-pregnant-woman-history-venous-kozakm-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/anticoagulant-management-antithrombin-deficient-pregnant-woman-history-venous-kozakm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/anticoagulant-management-antithrombin-deficient-pregnant-woman-history-venous-kozakm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/anticoagulant-management-antithrombin-deficient-pregnant-woman-history-venous-kozakm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/evaluation-catheter-directed-thrombolysis-device-type-dosing-treatment-gonsalvescf-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/evaluation-catheter-directed-thrombolysis-device-type-dosing-treatment-gonsalvescf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/evaluation-catheter-directed-thrombolysis-device-type-dosing-treatment-gonsalvescf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/evaluation-catheter-directed-thrombolysis-device-type-dosing-treatment-gonsalvescf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/association-between-thrombophilic-gene-variants-thrombosis-iranian-safdarism-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/association-between-thrombophilic-gene-variants-thrombosis-iranian-safdarism-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/association-between-thrombophilic-gene-variants-thrombosis-iranian-safdarism-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/association-between-thrombophilic-gene-variants-thrombosis-iranian-safdarism-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/has-systemic-thrombolysis-run-course-systematic-review-avielg-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/has-systemic-thrombolysis-run-course-systematic-review-avielg-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/has-systemic-thrombolysis-run-course-systematic-review-avielg-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/has-systemic-thrombolysis-run-course-systematic-review-avielg-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/procoagulant-off-target-effect-direct-oral-anticoagulant-reversal-hoornstraims-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/procoagulant-off-target-effect-direct-oral-anticoagulant-reversal-hoornstraims-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/procoagulant-off-target-effect-direct-oral-anticoagulant-reversal-hoornstraims-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/procoagulant-off-target-effect-direct-oral-anticoagulant-reversal-hoornstraims-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bleeding-risk-prediction-non-valvular-atrial-fibrillation-comparing-almalbisca-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bleeding-risk-prediction-non-valvular-atrial-fibrillation-comparing-almalbisca-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bleeding-risk-prediction-non-valvular-atrial-fibrillation-comparing-almalbisca-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bleeding-risk-prediction-non-valvular-atrial-fibrillation-comparing-almalbisca-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/volume-location-intracerebral-hemorrhage-appropriate-andexanet-alfa-umemurat-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/volume-location-intracerebral-hemorrhage-appropriate-andexanet-alfa-umemurat-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/volume-location-intracerebral-hemorrhage-appropriate-andexanet-alfa-umemurat-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/volume-location-intracerebral-hemorrhage-appropriate-andexanet-alfa-umemurat-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-characteristics-prognostic-deep-venous-thrombosis-pediatric-renj-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-characteristics-prognostic-deep-venous-thrombosis-pediatric-renj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-characteristics-prognostic-deep-venous-thrombosis-pediatric-renj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-characteristics-prognostic-deep-venous-thrombosis-pediatric-renj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andexanet-alfa-induced-heparin-resistance-percutaneous-coronary-intervention-sasakis-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andexanet-alfa-induced-heparin-resistance-percutaneous-coronary-intervention-sasakis-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andexanet-alfa-induced-heparin-resistance-percutaneous-coronary-intervention-sasakis-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andexanet-alfa-induced-heparin-resistance-percutaneous-coronary-intervention-sasakis-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/policy-adherence-antithrombotic-therapy-prophylactic-anticoagulation-multisystem-clouseraa-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/policy-adherence-antithrombotic-therapy-prophylactic-anticoagulation-multisystem-clouseraa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/policy-adherence-antithrombotic-therapy-prophylactic-anticoagulation-multisystem-clouseraa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/policy-adherence-antithrombotic-therapy-prophylactic-anticoagulation-multisystem-clouseraa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparison-limus-paclitaxel-drug-coated-balloons-second-generation-newer-kiyoharay-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparison-limus-paclitaxel-drug-coated-balloons-second-generation-newer-kiyoharay-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparison-limus-paclitaxel-drug-coated-balloons-second-generation-newer-kiyoharay-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparison-limus-paclitaxel-drug-coated-balloons-second-generation-newer-kiyoharay-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/heparin-induced-thrombocytopenia-following-tinzaparin-administration-case-report-khallafl-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/heparin-induced-thrombocytopenia-following-tinzaparin-administration-case-report-khallafl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/heparin-induced-thrombocytopenia-following-tinzaparin-administration-case-report-khallafl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/heparin-induced-thrombocytopenia-following-tinzaparin-administration-case-report-khallafl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/development-validation-dynamic-prediction-model-thromboembolic-bleeding-heokn-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/development-validation-dynamic-prediction-model-thromboembolic-bleeding-heokn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/development-validation-dynamic-prediction-model-thromboembolic-bleeding-heokn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/development-validation-dynamic-prediction-model-thromboembolic-bleeding-heokn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/fine-balance-anticoagulation-non-valvular-atrial-fibrillation-cerebral-turnerd-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/fine-balance-anticoagulation-non-valvular-atrial-fibrillation-cerebral-turnerd-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/fine-balance-anticoagulation-non-valvular-atrial-fibrillation-cerebral-turnerd-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/fine-balance-anticoagulation-non-valvular-atrial-fibrillation-cerebral-turnerd-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/frequency-prognostic-factors-residual-thrombosis-complete-veno-occlusion-bhatr-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/frequency-prognostic-factors-residual-thrombosis-complete-veno-occlusion-bhatr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/frequency-prognostic-factors-residual-thrombosis-complete-veno-occlusion-bhatr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/frequency-prognostic-factors-residual-thrombosis-complete-veno-occlusion-bhatr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/pharmacokinetic-prediction-dosage-adjustment-enoxaparin-administration-pregnant-guog-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/pharmacokinetic-prediction-dosage-adjustment-enoxaparin-administration-pregnant-guog-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/pharmacokinetic-prediction-dosage-adjustment-enoxaparin-administration-pregnant-guog-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/pharmacokinetic-prediction-dosage-adjustment-enoxaparin-administration-pregnant-guog-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/bleeding-thrombotic-events-patients-heparin-induced-thrombocytopenia-two-decade-chantarawichiany-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/bleeding-thrombotic-events-patients-heparin-induced-thrombocytopenia-two-decade-chantarawichiany-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/bleeding-thrombotic-events-patients-heparin-induced-thrombocytopenia-two-decade-chantarawichiany-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/bleeding-thrombotic-events-patients-heparin-induced-thrombocytopenia-two-decade-chantarawichiany-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/enoxaparin-dalteparin-venous-thromboembolism-prophylaxis-hip-knee-hajio-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/enoxaparin-dalteparin-venous-thromboembolism-prophylaxis-hip-knee-hajio-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/enoxaparin-dalteparin-venous-thromboembolism-prophylaxis-hip-knee-hajio-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/enoxaparin-dalteparin-venous-thromboembolism-prophylaxis-hip-knee-hajio-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andexanet-alfa-standard-care-factor-xa-inhibitor-induced-xiangaj-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andexanet-alfa-standard-care-factor-xa-inhibitor-induced-xiangaj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andexanet-alfa-standard-care-factor-xa-inhibitor-induced-xiangaj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andexanet-alfa-standard-care-factor-xa-inhibitor-induced-xiangaj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/enhanced-efficiency-contemporaneous-control-recapture-parallel-cohort-rct-sochetaa-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/enhanced-efficiency-contemporaneous-control-recapture-parallel-cohort-rct-sochetaa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/enhanced-efficiency-contemporaneous-control-recapture-parallel-cohort-rct-sochetaa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/enhanced-efficiency-contemporaneous-control-recapture-parallel-cohort-rct-sochetaa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/survey-current-practice-thrombophilia-testing-phenotype-genotype-vanlaerc-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/survey-current-practice-thrombophilia-testing-phenotype-genotype-vanlaerc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/survey-current-practice-thrombophilia-testing-phenotype-genotype-vanlaerc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/survey-current-practice-thrombophilia-testing-phenotype-genotype-vanlaerc-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/predicting-clinically-relevant-bleeding-new-onset-atrial-fibrillation-vanderhorstsfb-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/predicting-clinically-relevant-bleeding-new-onset-atrial-fibrillation-vanderhorstsfb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/predicting-clinically-relevant-bleeding-new-onset-atrial-fibrillation-vanderhorstsfb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/predicting-clinically-relevant-bleeding-new-onset-atrial-fibrillation-vanderhorstsfb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/predictors-hematoma-expansion-intracerebral-hemorrhage-associated-factor-komatsuy-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/predictors-hematoma-expansion-intracerebral-hemorrhage-associated-factor-komatsuy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/predictors-hematoma-expansion-intracerebral-hemorrhage-associated-factor-komatsuy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/predictors-hematoma-expansion-intracerebral-hemorrhage-associated-factor-komatsuy-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/tinzaparin-prevention-thromboembolic-events-ambulatory-patients-metastatic-salgadom-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/tinzaparin-prevention-thromboembolic-events-ambulatory-patients-metastatic-salgadom-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/tinzaparin-prevention-thromboembolic-events-ambulatory-patients-metastatic-salgadom-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/tinzaparin-prevention-thromboembolic-events-ambulatory-patients-metastatic-salgadom-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/clinical-laboratory-testing-blood-patients-presenting-emergency-wuahb-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/clinical-laboratory-testing-blood-patients-presenting-emergency-wuahb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/clinical-laboratory-testing-blood-patients-presenting-emergency-wuahb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/clinical-laboratory-testing-blood-patients-presenting-emergency-wuahb-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/andexanet-alfa-emergency-cranial-neurosurgical-procedures-bicentric-hounchonouhf-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/andexanet-alfa-emergency-cranial-neurosurgical-procedures-bicentric-hounchonouhf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/andexanet-alfa-emergency-cranial-neurosurgical-procedures-bicentric-hounchonouhf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/andexanet-alfa-emergency-cranial-neurosurgical-procedures-bicentric-hounchonouhf-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/optimizing-venous-thromboembolism-prophylaxis-achilles-tendon-rupture-hashemm-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/optimizing-venous-thromboembolism-prophylaxis-achilles-tendon-rupture-hashemm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/optimizing-venous-thromboembolism-prophylaxis-achilles-tendon-rupture-hashemm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/optimizing-venous-thromboembolism-prophylaxis-achilles-tendon-rupture-hashemm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/research-progress-bleeding-risk-assessment-models-anticoagulant-senl-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/research-progress-bleeding-risk-assessment-models-anticoagulant-senl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/research-progress-bleeding-risk-assessment-models-anticoagulant-senl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/research-progress-bleeding-risk-assessment-models-anticoagulant-senl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/venous-thromboembolism-obese-hormonal-contraceptive-users-large-citlasridhard-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/venous-thromboembolism-obese-hormonal-contraceptive-users-large-citlasridhard-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/venous-thromboembolism-obese-hormonal-contraceptive-users-large-citlasridhard-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/venous-thromboembolism-obese-hormonal-contraceptive-users-large-citlasridhard-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/treatment-catheter-related-thrombosis-systematic-review-meta-analysis-oomenla-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/treatment-catheter-related-thrombosis-systematic-review-meta-analysis-oomenla-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/treatment-catheter-related-thrombosis-systematic-review-meta-analysis-oomenla-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/treatment-catheter-related-thrombosis-systematic-review-meta-analysis-oomenla-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-pregnancies-history-venous-thromboembolism-low-dose-low-molecular-weight-beksacms-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-pregnancies-history-venous-thromboembolism-low-dose-low-molecular-weight-beksacms-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-pregnancies-history-venous-thromboembolism-low-dose-low-molecular-weight-beksacms-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-pregnancies-history-venous-thromboembolism-low-dose-low-molecular-weight-beksacms-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/impact-extended-duration-pharmacological-thromboprophylaxis-venous-thromboembolism-gurunathanu-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/impact-extended-duration-pharmacological-thromboprophylaxis-venous-thromboembolism-gurunathanu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/impact-extended-duration-pharmacological-thromboprophylaxis-venous-thromboembolism-gurunathanu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/impact-extended-duration-pharmacological-thromboprophylaxis-venous-thromboembolism-gurunathanu-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/preferences-among-expert-physicians-areas-uncertainty-venous-diminnoa-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/preferences-among-expert-physicians-areas-uncertainty-venous-diminnoa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/preferences-among-expert-physicians-areas-uncertainty-venous-diminnoa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/preferences-among-expert-physicians-areas-uncertainty-venous-diminnoa-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/trends-variation-andexanet-alfa-reversal-direct-oral-fisherl-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/trends-variation-andexanet-alfa-reversal-direct-oral-fisherl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/trends-variation-andexanet-alfa-reversal-direct-oral-fisherl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/trends-variation-andexanet-alfa-reversal-direct-oral-fisherl-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-performance-machine-learning-traditional-risk-scores-nicolasj-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-performance-machine-learning-traditional-risk-scores-nicolasj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-performance-machine-learning-traditional-risk-scores-nicolasj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-performance-machine-learning-traditional-risk-scores-nicolasj-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/estrogen-upregulates-lactoferrin-induce-hypercoagulability-hemostatic-protection-chengr-2026 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/estrogen-upregulates-lactoferrin-induce-hypercoagulability-hemostatic-protection-chengr-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/estrogen-upregulates-lactoferrin-induce-hypercoagulability-hemostatic-protection-chengr-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/estrogen-upregulates-lactoferrin-induce-hypercoagulability-hemostatic-protection-chengr-2026 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/win-ratio-evaluating-edoxaban-dalteparin-cancer-associated-venous-vanesn-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/win-ratio-evaluating-edoxaban-dalteparin-cancer-associated-venous-vanesn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/win-ratio-evaluating-edoxaban-dalteparin-cancer-associated-venous-vanesn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/win-ratio-evaluating-edoxaban-dalteparin-cancer-associated-venous-vanesn-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/low-molecular-weight-heparin-dosing-regimens-total-shangj-2024 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/low-molecular-weight-heparin-dosing-regimens-total-shangj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/low-molecular-weight-heparin-dosing-regimens-total-shangj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/low-molecular-weight-heparin-dosing-regimens-total-shangj-2024 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/management-upper-extremity-dvt-zanek-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/management-upper-extremity-dvt-zanek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/management-upper-extremity-dvt-zanek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/management-upper-extremity-dvt-zanek-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/large-bore-mechanical-thrombectomy-standard-care-acute-high-risk-chopardr-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/large-bore-mechanical-thrombectomy-standard-care-acute-high-risk-chopardr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/large-bore-mechanical-thrombectomy-standard-care-acute-high-risk-chopardr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/large-bore-mechanical-thrombectomy-standard-care-acute-high-risk-chopardr-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/rethinking-thrombophilia-testing-pediatric-vte-decade-real-world-aslehm-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/rethinking-thrombophilia-testing-pediatric-vte-decade-real-world-aslehm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/rethinking-thrombophilia-testing-pediatric-vte-decade-real-world-aslehm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/rethinking-thrombophilia-testing-pediatric-vte-decade-real-world-aslehm-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/en/research/comparative-outcomes-apixaban-acenocoumarol-advanced-chronic-kidney-sulimanil-2025 2026-03-18T00:00:00.000Z monthly 0.6 https://www.hirudotherapysociety.org/ru/research/comparative-outcomes-apixaban-acenocoumarol-advanced-chronic-kidney-sulimanil-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/es/research/comparative-outcomes-apixaban-acenocoumarol-advanced-chronic-kidney-sulimanil-2025 2026-03-18T00:00:00.000Z monthly 0.54 https://www.hirudotherapysociety.org/de/research/comparative-outcomes-apixaban-acenocoumarol-advanced-chronic-kidney-sulimanil-2025 2026-03-18T00:00:00.000Z monthly 0.54